Small|O cell|O carcinoma|O of|O the|O gallbladder|O :|O a|O clinicopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O pathology|O study|O of|O 12|O cases|O .|O 
Small|O cell|O carcinomas|O of|O the|O gallbladder|O are|O unusual|O neoplasms|O that|O have|O been|O characterized|O only|O recently|O .|O 
The|O authors|O describe|O the|O clinical|O ,|O histopathologic|O ,|O immunohistochemical|O ,|O and|O molecular|O features|O of|O 12|O small|O cell|O carcinomas|O of|O the|O gallbladder|O .|O 
The|O mean|O age|O at|O diagnosis|O was|O 69|O years|O ,|O and|O the|O male|O -|O to|O -|O female|O ratio|O was|O 5|O :|O 7|O .|O 
The|O neoplasms|O had|O an|O average|O size|O of|O 3|O cm|O ,|O and|O 90|O %|O showed|O invasion|O of|O the|O muscularis|O propria|O and|O perimuscular|O connective|O tissue|O .|O 
Seventy-five|O percent|O of|O the|O carcinomas|O had|O metastasized|O or|O extended|O locally|O beyond|O the|O gallbladder|O at|O surgery|O .|O 
Survival|O was|O uniformly|O poor|O ,|O with|O a|O mean|O survival|O of|O 10.7|O months|O (|O range|O ,|O 3|O -|O 25|O months|O )|O .|O 
Half|O the|O small|O cell|O carcinomas|O were|O combined|O with|O other|O neoplasms|O .|O 
Four|O had|O foci|O of|O adenocarcinoma|O ,|O one|O contained|O areas|O of|O squamous|O differentiation|O ,|O and|O another|O had|O a|O component|O of|O carcinosarcoma|O .|O 
Immunohistochemical|O analysis|O showed|O focal|O reactivity|O for|O chromogranin|O (|O six|O of|O six|O cases|O )|O ,|O neuron|O -|O specific|O enolase|O (|O six|O of|O six|O cases|O )|O ,|O and|O Leu-7|O (|O three|O of|O three|O cases|O )|O .|O 
The|O molecular|O changes|O in|O small|O cell|O carcinomas|O were|O similar|O to|O those|O of|O adenocarcinomas|O occurring|O at|O this|O site|O ,|O with|O a|O high|O frequency|O of|O p53|O (|O 75|O %|O )|O and|O p16INK4a|O (|O 33|O %|O )|O abnormalities|O ,|O and|O a|O low|O frequency|O of|O deleted|O in|O pancreatic|O carcinoma-4|O inactivation|O (|O 0|O %|O )|O and|O K-ras|O codon|variation-location 12|variation-location mutations|O (|O 17|O %|O )|O .|O 
In|O contrast|O to|O pulmonary|O small|O cell|O carcinomas|O ,|O p16INK4a|O function|O appears|O to|O be|O abrogated|O more|O frequently|O in|O these|O carcinomas|O .|O 
Concurrent|O mutations|O of|O K-ras|O oncogene|O at|O codons|variation-location 12|variation-location and|O 22|variation-location in|O colon|O cancer|O .|O 
K-ras|O mutation|O is|O the|O most|O common|O oncogenic|O alteration|O in|O various|O human|O cancers|O including|O colorectal|O carcinomas|O .|O 
Point|variation-type mutations|variation-type have|O the|O potential|O to|O activate|O the|O K-ras|O gene|O if|O they|O occur|O in|O the|O critical|O coding|O sequences|O .|O 
Almost|O all|O of|O these|O mutations|variation-event have|O been|O localized|O in|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location .|O 
We|O report|O a|O case|O of|O colon|O cancer|O presenting|O point|variation-type mutations|variation-type at|O both|O codons|variation-location 12|variation-location and|O 22|variation-location of|O the|O K-ras|O gene|O .|O 
PCR|O -|O SSCP|O and|O subsequent|O sequencing|O revealed|O that|O GGT|variation-state-original (|O glycine|variation-state-original ,|O wild|O -|O type|O )|O to|O AGT|variation-state-altered (|O serine|variation-state-altered )|O substitution|variation-type at|O codon|variation-location 12|variation-location and|O CAG|variation-state-original (|O glutamine|variation-state-original ,|O wild|O -|O type|O )|O to|O CGG|variation-state-altered (|O arginine|variation-state-altered )|O substitution|variation-type at|O codon|variation-location 22|variation-location occurred|O in|O the|O same|O allele|O .|O 
Novel|O colon|O cancer|O cell|O lines|O leading|O to|O better|O understanding|O of|O the|O diversity|O of|O respective|O primary|O cancers|O .|O 
A|O major|O obstacle|O to|O obtaining|O more|O detailed|O insights|O into|O the|O diversity|O of|O phenotypic|O and|O molecular|O changes|O occurring|O in|O colon|O cancer|O cells|O is|O the|O lack|O of|O low|O -|O passage|O colon|O cancer|O cell|O lines|O ,|O which|O would|O still|O closely|O reflect|O the|O phenotype|O of|O the|O colon|O cancer|O cells|O in|O vivo|O .|O 
Here|O ,|O we|O characterize|O eight|O novel|O ,|O low|O passage|O number|O human|O colon|O carcinoma|O cell|O lines|O ,|O originating|O from|O colorectal|O cancers|O extensively|O characterized|O in|O the|O clinics|O .|O 
All|O cell|O lines|O closely|O resemble|O the|O original|O tumors|O with|O respect|O to|O phenotype|O ,|O markers|O and|O detectable|O genetic|O changes|O .|O 
Cell|O morphology|O and|O marker|O expression|O is|O highly|O variable|O ,|O ranging|O from|O fully|O polarized|O cells|O correctly|O expressing|O all|O basolateral|O epithelial|O markers|O ,|O to|O cells|O with|O mesenchymal|O characteristics|O and|O a|O complete|O loss|O of|O polarity|O due|O to|O delocalization|O or|O loss|O of|O junction|O complex|O proteins|O .|O 
The|O alterations|O in|O phenotype|O and|O epithelial|O marker|O expression|O correspond|O to|O changes|O already|O detectable|O in|O the|O primary|O tumor|O in|O vivo|O .|O 
Seven|O of|O the|O cell|O lines|O show|O chromosomal|O instability|O ,|O while|O one|O cell|O line|O is|O characterized|O by|O microsatellite|O instability|O .|O 
p53|O associated|O with|O K-ras|O mutations|O were|O detected|O in|O three|O cell|O lines|O .|O 
Hitherto|O non|O -|O described|O E-cadherin|O mutations|O were|O found|O at|O both|O alleles|O in|O one|O cell|O line|O whereas|O in|O another|O cell|O line|O the|O E-cadherin|O protein|O was|O down|O -|O regulated|O .|O 
A|O stabilizing|O beta-catenin|O mutation|O (|O S|variation-state-original 45|variation-location F|variation-state-altered )|O appears|O in|O the|O same|O cell|O line|O that|O carried|O the|O mutated|O E-cadherin|O gene|O .|O 
Six|O cell|O lines|O carried|O APC|O mutations|O ,|O which|O in|O five|O of|O the|O lines|O led|O to|O an|O activated|O beta-catenin|O /|O Tcf|O /|O LEF|O signaling|O pathway|O .|O 
In|O accordance|O with|O beta-catenin|O /|O Tcf|O /|O LEF|O activation|O ,|O the|O cell|O lines|O show|O increased|O migration|O and|O invasiveness|O .|O 
Our|O results|O show|O that|O the|O characterized|O ,|O low|O -|O passage|O cell|O lines|O mirror|O the|O diversity|O of|O the|O individual|O tumors|O from|O which|O they|O were|O derived|O .|O 
Through|O molecular|O analyses|O of|O these|O cell|O lines|O we|O demonstrate|O that|O tumorgenicity|O events|O are|O much|O more|O diverse|O in|O human|O colon|O cancer|O than|O expected|O ,|O despite|O the|O common|O origin|O of|O the|O tumors|O from|O a|O small|O patient|O group|O with|O similar|O tumor|O grading|O and|O clinical|O prognosis|O .|O 
Common|O occurrence|O of|O multiple|O K-RAS|O mutations|O in|O pancreatic|O cancers|O with|O associated|O precursor|O lesions|O and|O in|O biliary|O cancers|O .|O 
Recent|O studies|O on|O small|O series|O of|O pancreatic|O cancer|O (|O PC|O )|O with|O foci|O of|O pancreatic|O intraepithelial|O neoplasia|O (|O PanIN|O )|O ,|O a|O putative|O precursor|O lesion|O ,|O have|O shown|O that|O multiple|O K-RAS|O mutations|O may|O coexist|O in|O the|O same|O neoplastic|O pancreas|O .|O 
To|O see|O whether|O mutant|O -|O K-RAS|O polyclonality|O is|O a|O common|O and|O specific|O feature|O of|O pancreatic|O carcinogenesis|O ,|O we|O investigated|O a|O unselected|O series|O of|O periampullary|O cancers|O (|O 41|O pancreatic|O ,|O 13|O biliary|O and|O two|O ampullary|O adenocarcinomas|O )|O .|O 
After|O hemi|O -|O nested|O polymerase|O chain|O reaction|O (|O PCR|O )|O ,|O mutations|O identified|O with|O single|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O were|O confirmed|O by|O allele|O -|O specific|O PCR|O and|O sequencing|O .|O 
K-RAS|O codon|variation-location 12|variation-location was|O mutated|O in|O 34|O (|O 83|O %|O )|O pancreatic|O cancers|O and|O in|O 11|O (|O 85|O %|O )|O biliary|O cancers|O .|O 
Multiple|O distinct|O K-RAS|O mutations|O were|O found|O in|O 16|O PC|O (|O 39|O %|O of|O all|O cases|O ,|O 47|O %|O of|O those|O with|O mutated|O K-RAS|O )|O and|O in|O eight|O biliary|O cancers|O (|O 62|O and|O 72|O %|O ,|O respectively|O )|O .|O 
In|O PC|O ,|O multiple|O K-RAS|O mutations|O were|O more|O frequent|O (|O P|O <|O 0.001|O )|O in|O cancers|O with|O (|O nine|O of|O 12|O ,|O 75|O %|O )|O than|O in|O those|O without|O detectable|O PanIN|O (|O seven|O of|O 29|O ,|O 24|O %|O )|O .|O 
Individual|O precursor|O lesions|O of|O the|O same|O neoplastic|O pancreas|O were|O found|O to|O harbor|O distinct|O mutations|variation-event .|O 
Results|O show|O that|O multiple|O K-RAS|O mutations|O are|O frequent|O both|O in|O PC|O with|O associated|O PanIN|O and|O in|O biliary|O cancers|O ,|O and|O indicate|O that|O clonally|O distinct|O precursor|O lesions|O of|O PC|O might|O variably|O contribute|O to|O tumor|O development|O .|O 
Phase|O I|O clinical|O and|O pharmacologic|O study|O of|O chronic|O oral|O administration|O of|O the|O farnesyl|O protein|O transferase|O inhibitor|O R115777|O in|O advanced|O cancer|O .|O 
PURPOSE|O :|O 
To|O determine|O the|O maximum|O -|O tolerated|O dose|O ,|O toxicities|O ,|O and|O pharmacokinetics|O of|O R115777|O ,|O a|O farnesyl|O transferase|O inhibitor|O ,|O when|O administered|O continuously|O via|O the|O oral|O route|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
Patients|O with|O advanced|O solid|O malignancies|O were|O treated|O with|O R115777|O using|O an|O interpatient|O dose|O escalation|O scheme|O starting|O at|O 50|O mg|O bid|O .|O 
Pharmacokinetics|O were|O assessed|O on|O days|O 1|O ,|O 28|O ,|O and|O 56|O .|O 
RESULTS|O :|O 
Twenty-eight|O patients|O were|O entered|O onto|O the|O study|O and|O the|O median|O duration|O of|O treatment|O was|O 55|O days|O .|O 
The|O dose|O -|O limiting|O toxicities|O were|O myelosuppression|O and|O neurotoxicity|O .|O 
At|O a|O dose|O of|O 400|O mg|O bid|O ,|O grade|O 4|O leukocytopenia|O and|O neutropenia|O were|O seen|O in|O two|O of|O four|O patients|O .|O 
Neurotoxicity|O grade|O 3|O developed|O in|O one|O of|O five|O patients|O at|O 500|O mg|O bid|O and|O in|O one|O of|O 13|O at|O 300|O mg|O bid|O after|O 8|O weeks|O of|O treatment|O .|O 
Common|O nonhematologic|O toxicities|O were|O nausea|O ,|O vomiting|O ,|O and|O fatigue|O .|O 
The|O recommended|O dose|O for|O phase|O II|O /|O III|O testing|O in|O this|O scheme|O is|O 300|O mg|O bid|O .|O 
The|O pharmacokinetic|O studies|O indicated|O dose|O proportionality|O .|O 
Little|O accumulation|O occurred|O and|O steady|O -|O state|O levels|O were|O reached|O within|O 2|O to|O 3|O days|O .|O 
Analyses|O of|O historic|O tumor|O material|O showed|O that|O five|O of|O 15|O of|O patients|O had|O a|O K-ras|O mutation|O in|O codon|variation-location 12|variation-location .|O 
Three|O patients|O with|O pancreatic|O ,|O colon|O ,|O and|O cervix|O carcinomas|O had|O stable|O disease|O and|O one|O patient|O with|O a|O colon|O carcinoma|O had|O a|O minor|O response|O accompanied|O by|O a|O more|O than|O 50|O %|O decrease|O in|O carcinoembryonic|O antigen|O tumor|O marker|O .|O 
A|O fifth|O patient|O ,|O with|O platinum|O -|O refractory|O non|O -|O small|O -|O cell|O lung|O cancer|O ,|O showed|O a|O partial|O response|O that|O lasted|O for|O 5|O months|O .|O 
CONCLUSION|O :|O 
Continuous|O dosing|O of|O R115777|O is|O feasible|O with|O an|O acceptable|O toxicity|O profile|O at|O a|O dose|O of|O 300|O mg|O bid|O .|O 
APC|O /|O CTNNB1|O (|O beta-catenin|O )|O pathway|O alterations|O in|O human|O prostate|O cancers|O .|O 
Genetic|O alterations|O serve|O as|O beacons|O for|O the|O involvement|O of|O specific|O pathways|O in|O tumorigenesis|O .|O 
It|O was|O previously|O shown|O that|O 5|O %|O of|O prostate|O tumors|O harbor|O CTNNB1|O mutations|O ,|O suggesting|O that|O this|O tumor|O type|O may|O involve|O a|O deregulated|O APC|O /|O CTNNB1|O pathway|O .|O 
To|O explore|O this|O possibility|O further|O ,|O we|O searched|O for|O mutations|O in|O genes|O implicated|O in|O this|O pathway|O in|O 22|O samples|O that|O included|O cell|O lines|O ,|O xenografts|O ,|O and|O primary|O tumors|O .|O 
We|O identified|O seven|O alterations|O :|O two|O in|O CTNNB1|O ,|O three|O in|O APC|O ,|O and|O two|O in|O hTRCP1|O (|O also|O known|O as|O BTRC|O )|O which|O controls|O the|O degradation|O of|O CTNNB1|O .|O 
Alterations|O in|O the|O CTNNB1|O regulatory|O domain|O ,|O APC|O ,|O and|O hTRCP1|O were|O mutually|O exclusive|O ,|O consistent|O with|O their|O equivalent|O effects|O on|O CTNNB1|O stability|O .|O 
These|O results|O suggest|O that|O CTNNB1|O signaling|O plays|O a|O critical|O role|O in|O the|O development|O of|O a|O significant|O fraction|O of|O prostate|O cancers|O .|O 
Moreover|O ,|O they|O provide|O the|O first|O evidence|O that|O hTRCP1|O plays|O a|O role|O in|O human|O neoplasia|O .|O 
Secondary|O malignant|O giant|O -|O cell|O tumour|O of|O bone|O :|O molecular|O abnormalities|O of|O p53|O and|O H-ras|O gene|O correlated|O with|O malignant|O transformation|O .|O 
AIMS|O :|O 
We|O report|O two|O cases|O of|O secondary|O malignant|O giant|O -|O cell|O tumour|O occurring|O without|O irradiation|O therapy|O .|O 
To|O elucidate|O the|O mechanism|O of|O malignant|O transformation|O in|O this|O tumour|O ,|O we|O searched|O for|O the|O molecular|O abnormalities|O of|O p53|O ,|O MDM2|O and|O the|O H-ras|O genes|O .|O 
METHODS|O AND|O RESULTS|O :|O 
These|O cases|O were|O retrieved|O after|O a|O review|O of|O 103|O cases|O of|O primary|O giant|O -|O cell|O tumour|O of|O bone|O ,|O registered|O in|O our|O institute|O .|O 
One|O case|O occurred|O in|O the|O distal|O femur|O of|O a|O 42|O -|O year|O -|O old|O female|O after|O surgical|O curettage|O ,|O while|O the|O other|O arose|O in|O the|O acetabulum|O of|O a|O 25|O -|O year|O -|O old|O male|O after|O en|O bloc|O resection|O .|O 
Microscopically|O ,|O the|O malignant|O tumour|O in|O the|O distal|O femur|O was|O composed|O of|O a|O proliferation|O of|O ovoid|O or|O fusiform|O cells|O arranged|O in|O fascicles|O with|O high|O mitotic|O activities|O .|O 
The|O malignant|O transformed|O tumour|O in|O the|O acetabulum|O was|O made|O up|O of|O pleomorphic|O tumour|O cells|O with|O atypical|O mitoses|O .|O 
In|O the|O tumour|O of|O the|O distal|O femur|O ,|O both|O p53|O and|O H-ras|O mutations|O were|O detected|O .|O 
Abnormal|O nuclear|O accumulation|O of|O p53|O protein|O and|O c-myc|O expression|O were|O also|O revealed|O by|O immunohistochemistry|O .|O 
In|O both|O cases|O ,|O the|O recurrent|O malignant|O tumour|O over|O -|O expressed|O MMP-9|O and|O revealed|O a|O higher|O MIB-1|O -|O labelling|O index|O compared|O with|O the|O primary|O conventional|O giant|O -|O cell|O tumour|O .|O 
CONCLUSIONS|O :|O 
Our|O results|O suggest|O that|O multiple|O oncogene|O or|O tumour|O suppressor|O gene|O mutations|O may|O play|O an|O important|O role|O during|O malignant|O transformation|O in|O conventional|O giant|O -|O cell|O tumours|O .|O 
Cigarette|O smoking|O is|O strongly|O associated|O with|O mutation|O of|O the|O K-ras|O gene|O in|O patients|O with|O primary|O adenocarcinoma|O of|O the|O lung|O .|O 
BACKGROUND|O :|O 
The|O majority|O of|O lung|O carcinoma|O cases|O occur|O in|O current|O or|O former|O smokers|O .|O 
K-ras|O gene|O mutations|O are|O common|O in|O lung|O adenocarcinoma|O and|O have|O been|O associated|O with|O cigarette|O smoking|O ,|O asbestos|O exposure|O ,|O and|O female|O gender|O .|O 
METHODS|O :|O 
In|O the|O current|O study|O ,|O the|O authors|O examined|O the|O contribution|O of|O cigarette|O smoking|O to|O K-ras|O gene|O mutations|O in|O patients|O with|O primary|O lung|O adenocarcinoma|O .|O 
Smoking|O histories|O were|O obtained|O from|O 106|O prospectively|O enrolled|O patients|O with|O primary|O adenocarcinoma|O of|O the|O lung|O .|O 
RESULTS|O :|O 
K-ras|O mutations|O were|O detected|O in|O the|O primary|O tumor|O using|O an|O allele|O -|O specific|O ligation|O assay|O .|O 
Ninety-two|O of|O the|O 106|O patients|O (|O 87|O %|O )|O with|O lung|O adenocarcinoma|O were|O smokers|O .|O 
Nonsmokers|O with|O this|O tumor|O were|O more|O likely|O to|O be|O women|O (|O 11|O of|O 14|O ;|O 79|O %|O )|O ,|O whereas|O the|O majority|O of|O smokers|O (|O 57|O %|O )|O were|O men|O .|O 
K-ras|O mutations|O were|O detected|O in|O 40|O of|O 106|O tumors|O (|O 38|O %|O )|O and|O were|O significantly|O more|O common|O in|O smokers|O compared|O with|O nonsmokers|O (|O 43|O %|O vs.|O 0|O %|O ;|O P|O =|O 0.001|O )|O .|O 
CONCLUSIONS|O :|O 
The|O results|O of|O the|O current|O study|O confirm|O and|O extend|O previous|O observations|O that|O smokers|O with|O adenocarcinoma|O of|O the|O lung|O are|O more|O likely|O to|O have|O K-ras|O mutant|O tumors|O compared|O with|O nonsmokers|O .|O 
The|O strong|O link|O between|O cigarette|O smoking|O and|O K-ras|O mutations|O in|O adenocarcinoma|O of|O the|O lung|O supports|O the|O role|O of|O specific|O tobacco|O carcinogens|O in|O the|O etiology|O of|O this|O malignancy|O .|O 
beta-catenin|O expression|O in|O pilomatrixomas|O .|O 
Relationship|O with|O beta-catenin|O gene|O mutations|O and|O comparison|O with|O beta-catenin|O expression|O in|O normal|O hair|O follicles|O .|O 
BACKGROUND|O :|O 
beta-catenin|O functions|O in|O signal|O transduction|O in|O the|O Wnt|O signalling|O pathway|O ,|O which|O has|O recently|O been|O implicated|O in|O hair|O follicle|O (|O HF|O )|O morphogenesis|O .|O 
beta-catenin|O gene|O mutations|O affecting|O exon|variation-location 3|variation-location have|O been|O reported|O in|O a|O high|O percentage|O of|O human|O pilomatrixomas|O .|O 
However|O ,|O the|O expression|O pattern|O of|O beta-catenin|O in|O human|O HFs|O and|O pilomatrixomas|O has|O not|O been|O reported|O .|O 
OBJECTIVES|O :|O 
To|O analyse|O immunohistochemically|O the|O expression|O pattern|O of|O beta-catenin|O in|O normal|O anagen|O HFs|O and|O in|O 40|O human|O pilomatrixomas|O .|O 
METHODS|O :|O 
In|O 11|O of|O these|O tumours|O we|O also|O studied|O exon|variation-location 3|variation-location beta-catenin|O gene|O mutations|O by|O polymerase|O chain|O reaction|O and|O direct|O sequencing|O .|O 
As|O these|O mutations|O have|O been|O related|O to|O a|O replication|O error|O (|O RER|O )|O phenotype|O in|O other|O tumour|O types|O ,|O we|O explored|O whether|O or|O not|O this|O association|O also|O occurs|O in|O pilomatrixomas|O .|O 
RESULTS|O :|O 
beta-catenin|O was|O expressed|O in|O the|O cell|O membranes|O of|O the|O outer|O and|O inner|O root|O sheaths|O and|O in|O matrix|O cells|O located|O at|O the|O base|O and|O periphery|O of|O the|O HF|O bulb|O .|O 
However|O ,|O central|O matrix|O cells|O that|O differentiate|O into|O cortical|O cells|O ,|O cortical|O and|O cuticular|O cells|O expressed|O beta-catenin|O in|O the|O nucleus|O ,|O suggesting|O a|O role|O in|O signal|O transduction|O .|O 
In|O addition|O ,|O some|O fibroblasts|O of|O the|O dermal|O papilla|O also|O showed|O nuclear|O expression|O of|O beta-catenin|O .|O 
All|O 40|O analysed|O pilomatrixomas|O showed|O intense|O nuclear|O and|O cytoplasmic|O beta-catenin|O expression|O in|O proliferating|O matrix|O (|O basaloid|O )|O cells|O .|O 
In|O areas|O of|O maturation|O ,|O transitional|O cells|O mainly|O showed|O cytoplasmic|O and|O membranous|O expression|O of|O beta-catenin|O ,|O while|O only|O a|O few|O cells|O retained|O nuclear|O expression|O .|O 
Shadow|O or|O ghost|O cells|O did|O not|O show|O beta-catenin|O expression|O .|O 
Three|O of|O 11|O tumours|O (|O 26|O %|O )|O had|O beta-catenin|O mutations|O .|O 
All|O three|O had|O the|O same|O heterozygote|O mis|variation-type -|variation-type sense|variation-type mutation|variation-type :|O a|O G|variation-state-original to|O T|variation-state-altered change|O affecting|O the|O first|O nucleotide|O at|O codon|variation-location 32|variation-location (|O D|variation-state-original 32|variation-location Y|variation-state-altered )|O .|O 
None|O of|O the|O 11|O tumours|O studied|O had|O a|O positive|O RER|O phenotype|O .|O 
CONCLUSIONS|O :|O 
Present|O and|O previous|O studies|O suggest|O that|O the|O Wnt|O /|O beta-catenin|O /|O Tcf-Lef|O pathway|O is|O activated|O in|O normal|O matrix|O cells|O of|O the|O HF|O to|O induce|O differentiation|O to|O the|O hair|O shaft|O .|O 
Additionally|O ,|O the|O beta-catenin|O mutation|O in|O matrix|O cells|O of|O the|O HF|O stabilizes|O beta-catenin|O protein|O ,|O which|O translocates|O into|O the|O nucleus|O ,|O where|O it|O activates|O of|O gene|O transcription|O together|O with|O lymphoid|O enhancer|O factor-1|O producing|O pilomatrixoma|O .|O 
These|O mutations|variation-event occur|O without|O an|O underlying|O defect|O in|O DNA|O mismatch|O repair|O .|O 
Fibroblast|O growth|O factor|O receptor|O 3|O S|variation-state-original 249|variation-location C|variation-state-altered mutation|variation-event in|O virus|O associated|O squamous|O cell|O carcinomas|O .|O 
An|O S|variation-state-original 249|variation-location C|variation-state-altered mutation|variation-event in|O fibroblast|O growth|O factor|O receptor|O 3|O (|O FGFR3|O )|O gene|O was|O recently|O identified|O in|O patients|O with|O cervical|O carcinomas|O (|O CC|O )|O .|O 
However|O ,|O its|O importance|O in|O cervical|O tumorigenesis|O is|O still|O inconclusive|O .|O 
Apart|O from|O CC|O ,|O nasopharyngeal|O carcinoma|O (|O NPC|O )|O is|O the|O other|O major|O virus|O associated|O squamous|O cell|O carcinoma|O .|O 
We|O sought|O to|O clarify|O the|O frequency|O of|O the|O FGFR3|O S|variation-state-original 249|variation-location C|variation-state-altered mutation|variation-event in|O 75|O primary|O CC|O in|O the|O Thai|O population|O and|O to|O determine|O its|O prevalence|O in|O 69|O primary|O NPC|O by|O PCR|O and|O restriction|O enzyme|O digestion|O .|O 
None|O of|O the|O patients|O but|O one|O NPC|O showed|O the|O enzyme|O digestion|O pattern|O consistent|O with|O the|variation-event mutation|variation-event .|O 
This|O is|O the|O first|O report|O demonstrating|O the|O role|O of|O FGFR3|O in|O the|O development|O of|O human|O NPC|O .|O 
This|O study|O confirms|O the|O low|O frequency|O of|O the|O FGFR3|O S|variation-state-original 249|variation-location C|variation-state-altered mutation|variation-event in|O CC|O .|O 
Nevertheless|O ,|O the|O discovery|O of|O the|variation-event mutation|variation-event ,|O not|O only|O in|O CC|O as|O reported|O by|O previous|O studies|O ,|O but|O in|O NPC|O based|O on|O this|O report|O ,|O suggests|O that|O FGFR3|O may|O play|O a|O significant|O role|O in|O human|O CC|O and|O NPC|O development|O .|O 
Microsatellite|O instability|O and|O alternative|O genetic|O pathway|O in|O intrahepatic|O cholangiocarcinoma|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
Intrahepatic|O cholangiocarcinoma|O (|O ICC|O )|O arises|O from|O intrahepatic|O bile|O duct|O epithelium|O and|O is|O the|O second|O most|O prevalent|O among|O primary|O liver|O cancers|O .|O 
The|O aim|O of|O this|O study|O was|O to|O clarify|O the|O mechanism|O of|O cholangiocarcinogenesis|O .|O 
METHODS|O :|O 
We|O studied|O the|O incidence|O of|O microsatellite|O instability|O (|O MSI|O )|O involving|O eight|O highly|O polymorphic|O microsatellite|O markers|O and|O alternations|O of|O the|O K-ras|O ,|O p53|O and|O mdm-2|O genes|O in|O human|O ICC|O tissues|O .|O 
Overexpression|O of|O mdm-2|O oncoprotein|O was|O also|O immunohistochemically|O studied|O .|O 
RESULTS|O :|O 
Of|O all|O 65|O cases|O examined|O ,|O K-ras|O gene|O mutation|variation-event was|O found|O in|O three|O cases|O (|O 4.6|O %|O )|O at|O codon|variation-location 12|variation-location .|O 
Analysis|O of|O p53|O alterations|O was|O performed|O in|O 28|O cases|O including|O 22|O frozen|O samples|O and|O mutations|O were|O found|O in|O three|O cases|O (|O 10.7|O %|O )|O .|O 
Overexpression|O of|O mdm-2|O protein|O was|O observed|O in|O 25|O (|O 41.7|O %|O )|O out|O of|O 60|O cases|O analyzed|O .|O 
In|O 22|O frozen|O samples|O ,|O seven|O (|O 31.8|O %|O )|O cases|O showed|O mdm-2|O amplification|O and|O four|O (|O 18.2|O %|O )|O cases|O revealed|O MSI|O -|O positive|O phenotype|O .|O 
Among|O the|O cases|O analyzed|O ,|O all|O the|O tumors|O with|O mdm-2|O amplification|O /|O overexpression|O harbored|O the|O wild|variation-type -|variation-type type|variation-type p53|O gene|O and|O all|O the|O microsatellite|O instability|O -|O positive|O cases|O were|O from|O mass|O -|O forming|O (|O MF|O )|O +|O periductal|O -|O infiltrating|O (|O PI|O )|O subtype|O .|O 
CONCLUSIONS|O :|O 
These|O results|O suggest|O that|O mdm-2|O plays|O a|O role|O ,|O which|O might|O be|O partially|O through|O inhibiting|O p53|O activity|O ,|O in|O cholangiocarcinogenesis|O and|O that|O M|O 
Molecular|O analysis|O of|O p53|O and|O K-ras|O in|O lung|O carcinomas|O of|O coal|O miners|O .|O 
Thirty-three|O cases|O of|O non|O -|O small|O cell|O lung|O cancers|O (|O NSCLC|O )|O from|O the|O archives|O of|O National|O Coal|O Workers|O '|O Autopsy|O Study|O were|O studied|O for|O mutational|O alterations|O in|O p53|O and|O K-ras|O using|O PCR|O -|O SSCP|O ,|O DNA|O sequencing|O and|O PCR|O -|O oligonucleotide|O probe|O hybridization|O techniques|O .|O 
Mutations|O of|O the|O p53|O were|O observed|O in|O 4|O smokers|O (|O 19|O %|O )|O and|O one|O in|O a|O never|O smoker|O (|O 8|O %|O )|O .|O 
Two|O polymorphisms|variation-event in|O smokers|O were|O detected|O at|O codon|variation-location 213|variation-location ,|O a|O common|O site|O for|O sequence|O variation|O .|O 
Among|O the|O smokers|O the|O p53|O mutations|O were|O in|O the|O heavy|O smokers|O .|O 
In|O never|O smokers|O there|O was|O only|O a|O single|O p53|O mutation|O and|O two|O K-ras|O mutations|O .|O 
In|O never|O smokers|O the|O frequency|O of|O K-ras|O mutations|O was|O similar|O (|O 17|O %|O )|O in|O smokers|O ,|O but|O one|O never|O smoker|O had|O two|O K-ras|O mutations|O .|O 
Mutations|variation-event of|O p53|O were|O more|O frequent|O in|O adenocarcinomas|O (|O 27|O %|O )|O and|O they|O were|O AT|variation-state-original -->|O GC|variation-state-altered transitions|variation-type .|O 
Four|O of|O 11|O (|O 36|O %|O )|O adenocarcinomas|O were|O found|O to|O have|O K-ras|O codon|variation-location 12|variation-location mutations|variation-event ,|O and|O one|O adenocarcinoma|O had|O two|O K-ras|O mutations|O .|O 
There|O were|O two|O large|O cell|O undifferentiated|O carcinomas|O with|O p53|O mutation|O and|O one|O with|O a|O K-ras|O mutation|O .|O 
Two|O of|O the|O 16|O squamous|O cell|O carcinomas|O were|O positive|O for|O p53|O mutation|O ,|O while|O no|O K-ras|O mutations|O were|O found|O in|O this|O group|O .|O 
The|O results|O of|O these|O preliminary|O studies|O indicate|O a|O moderately|O different|O mutational|O spectrum|O of|O p53|O and|O K-ras|O in|O coal|O miners|O independent|O of|O cigarette|O smoking|O .|O 
The|O mutational|O spectrum|O observed|O in|O this|O study|O of|O coal|O miners|O with|O heavy|O cigarette|O smoking|O history|O suggest|O a|O protective|O effect|O of|O coal|O mine|O dust|O in|O preventing|O abnormal|O mutations|O induced|O by|O chemical|O carcinogens|O in|O cigarette|O smoke|O or|O reactive|O oxygen|O species|O .|O 
These|O limited|O preliminary|O studies|O provide|O insight|O into|O the|O possibility|O of|O accurately|O measuring|O changes|O in|O etiologic|O markers|O to|O unravel|O the|O uncertainties|O of|O cancer|O in|O coal|O miners|O .|O 
Lung|O tumor|O KRAS|O and|O TP53|O mutations|O in|O nonsmokers|O reflect|O exposure|O to|O PAH|O -|O rich|O coal|O combustion|O emissions|O .|O 
We|O determined|O the|O TP53|O and|O codon|variation-location 12|variation-location KRAS|O mutations|variation-event in|O lung|O tumors|O from|O 24|O nonsmokers|O whose|O tumors|O were|O associated|O with|O exposure|O to|O smoky|O coal|O .|O 
Among|O any|O tumors|O studied|O previously|O ,|O these|O showed|O the|O highest|O percentage|O of|O mutations|variation-event that|O (a)|O were|O G|variation-state-original -->|O T|variation-state-altered transversions|variation-type at|O either|O KRAS|O (|O 86|O %|O )|O or|O TP53|O (|O 76|O %|O )|O ,|O (b)|O clustered|O at|O the|O G|O -|O rich|O codons|variation-location 153|variation-location -|variation-location 158|variation-location of|O TP53|O (|O 33|O %|O )|O ,|O and|O (c)|O had|O 100|O %|O of|O the|O guanines|O of|O the|O G|variation-state-original -->|O T|variation-state-altered transversions|variation-type on|O the|O nontranscribed|O strand|O .|O 
This|variation-event mutation|variation-event spectrum|O is|O consistent|O with|O an|O exposure|O to|O polycyclic|O aromatic|O hydrocarbons|O ,|O which|O are|O the|O primary|O component|O of|O the|O smoky|O coal|O emissions|O .|O 
These|O results|O show|O that|O mutations|O in|O the|O TP53|O and|O KRAS|O genes|O can|O reflect|O a|O specific|O environmental|O exposure|O .|O 
Frequency|O of|O fibroblast|O growth|O factor|O receptor|O 3|O mutations|O in|O sporadic|O tumours|O .|O 
Mutations|O in|O FGFR3|O have|O been|O identified|O in|O several|O tumour|O types|O including|O bladder|O carcinoma|O ,|O cervical|O carcinoma|O ,|O and|O multiple|O myeloma|O .|O 
In|O bladder|O carcinoma|O ,|O we|O recently|O identified|O FGFR3|O mutations|O in|O 41|O %|O of|O tumours|O ,|O making|O this|O the|O most|O frequently|O mutated|O putative|O oncogene|O identified|O in|O bladder|O cancer|O to|O date|O .|O 
We|O have|O now|O investigated|O the|O frequency|O of|O FGFR3|O mutation|O in|O a|O panel|O of|O 125|O tumours|O and|O 13|O cell|O lines|O from|O various|O other|O organs|O .|O 
We|O analysed|O the|O mutation|O hotspots|O in|O exons|variation-location 7|variation-location ,|O 10|variation-location and|O 15|variation-location by|O direct|O DNA|O sequencing|O ,|O and|O found|O one|O mutation|variation-event in|O exon|variation-location 7|variation-location (|O S|variation-state-original 249|variation-location C|variation-state-altered )|O in|O 1|O /|O 28|O (|O 3.5|O %|O )|O cervical|O tumours|O .|O 
Mutations|O were|O not|O detected|O in|O stomach|O ,|O rectum|O ,|O colon|O ,|O prostate|O ,|O ovarian|O ,|O breast|O ,|O brain|O ,|O or|O renal|O tumours|O ,|O nor|O were|O they|O found|O in|O any|O of|O the|O cell|O lines|O included|O in|O this|O study|O .|O 
We|O conclude|O that|O FGFR3|O is|O commonly|O mutated|O in|O bladder|O carcinoma|O and|O only|O rarely|O in|O cervical|O carcinoma|O .|O 
Several|O tumour|O types|O appear|O not|O to|O possess|O any|O mutations|O in|O FGFR3|O ,|O suggesting|O that|O these|O mutations|O are|O important|O only|O in|O the|O development|O of|O certain|O types|O of|O tumour|O .|O 
Genetic|O alterations|O in|O gallbladder|O adenoma|O ,|O dysplasia|O and|O carcinoma|O .|O 
Adenoma|O and|O dysplasia|O in|O the|O gallbladder|O (|O GB|O )|O have|O been|O reported|O as|O precancerous|O lesions|O ,|O but|O the|O genetic|O evidence|O of|O this|O is|O not|O clearly|O defined|O .|O 
The|O purpose|O of|O this|O study|O was|O to|O analyze|O the|O frequencies|O of|O K-ras|O ,|O p53|O ,|O and|O p16|O gene|O mutations|O ,|O of|O microsatellite|O instability|O (|O MI|O )|O and|O of|O loss|variation-type of|variation-type heterozygosity|variation-type (|O LOH|variation-type )|O in|O GB|O cancer|O ,|O dysplasia|O ,|O and|O adenoma|O .|O 
Tissues|O from|O 15|O GB|O cancers|O ,|O five|O dysplasias|O around|O cancerous|O tumors|O ,|O and|O three|O adenomas|O were|O collected|O prospectively|O .|O 
The|O mutation|O rates|O of|O K-ras|O ,|O p53|O ,|O and|O p16|O were|O 20.0|O ,|O 35.7|O ,|O and|O 30.7|O %|O ,|O respectively|O ,|O in|O GB|O cancers|O .|O 
However|O ,|O no|O mutations|O were|O found|O in|O dysplasia|O or|O adenoma|O .|O 
Reduced|O staining|O for|O p16|O was|O seen|O in|O 23|O %|O of|O carcinomas|O .|O 
All|O of|O the|O GB|O carcinomas|O and|O four|O out|O of|O five|O (|O 80|O %|O )|O of|O the|O dysplasias|O showed|O LOH|variation-type in|O a|O minimum|O of|O one|O locus|O ,|O but|O one|O out|O of|O three|O (|O 33|O %|O )|O cases|O of|O adenoma|O displayed|O LOH|variation-type in|O only|O one|O locus|O .|O 
All|O of|O the|O loci|O of|O LOH|variation-type in|O the|O dysplasias|O ,|O except|O one|O ,|O showed|O the|O same|O patterns|O of|O allelic|variation-type loss|variation-type as|O the|O adjacent|O carcinomas|O .|O 
Only|O one|O dysplasia|O showed|O multiple|O MI|O .|O 
In|O conclusion|O ,|O multiple|O LOH|variation-type may|O be|O associated|O with|O the|O development|O of|O dysplasia|O and|O the|O malignant|O transformation|O of|O GB|O carcinoma|O .|O 
Gene|O alterations|O of|O K-ras|O ,|O p53|O ,|O and|O p16|O are|O important|O steps|O in|O the|O malignant|O changes|O of|O dysplasia|O .|O 
However|O ,|O MI|O seems|O to|O have|O only|O a|O limited|O role|O in|O GB|O cancer|O development|O .|O 
beta-Catenin|O expression|O pattern|O ,|O beta-catenin|O gene|O mutations|O ,|O and|O microsatellite|O instability|O in|O endometrioid|O ovarian|O carcinomas|O and|O synchronous|O endometrial|O carcinomas|O .|O 
beta-Catenin|O gene|O mutations|O and|O microsatellite|O instability|O (|O MI|O )|O have|O been|O reported|O in|O endometrioid|O ovarian|O carcinomas|O .|O 
In|O colon|O but|O not|O endometrial|O cancer|O ,|O beta-catenin|O gene|O mutations|O are|O associated|O with|O a|O replication|O error|O phenotype|O and|O MI|O .|O 
In|O this|O study|O the|O authors|O investigate|O whether|O beta-catenin|O mutations|O and|O MI|O are|O two|O independent|O oncogenic|O pathways|O in|O endometrioid|O ovarian|O carcinomas|O .|O 
They|O also|O evaluate|O the|O usefulness|O of|O these|O molecular|O markers|O in|O determining|O the|O primary|O origin|O of|O simultaneous|O tumors|O in|O the|O ovary|O and|O endometrium|O .|O 
This|O study|O was|O performed|O on|O 26|O patients|O diagnosed|O with|O primary|O endometrioid|O ovarian|O carcinoma|O ,|O five|O of|O whom|O also|O had|O pathologically|O diagnosed|O primary|O synchronous|O endometrioid|O endometrial|O carcinoma|O .|O 
Immunohistochemical|O and|O molecular|O analyses|O indicated|O that|O there|O were|O 25|O primary|O ovarian|O tumors|O with|O four|O primary|O synchronous|O endometrial|O cancers|O and|O one|O ovarian|O metastasis|O of|O a|O primary|O endometrial|O carcinoma|O .|O 
All|O studies|O were|O performed|O on|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissue|O samples|O .|O 
The|O beta-catenin|O expression|O pattern|O (|O nuclear|O vs.|O membranous|O )|O was|O analyzed|O immunohistochemically|O .|O 
Mutations|variation-event in|O exon|variation-location 3|variation-location of|O the|O beta-catenin|O gene|O were|O studied|O by|O polymerase|O chain|O reaction|O ,|O single|O -|O strand|O conformational|O polymorphism|O ,|O and|O direct|O sequencing|O .|O 
MI|O status|O was|O established|O by|O studying|O BAT-26|O and|O BAT-25|O mononucleotide|O repeats|O .|O 
In|O the|O group|O with|O 21|O single|O ovarian|O tumors|O ,|O 18|O (|O 85|O %|O )|O had|O beta-catenin|O nuclear|O expression|O ,|O eight|O (|O 38|O %|O )|O had|O beta-catenin|O gene|O mutations|O (|O always|O associated|O with|O beta-catenin|O nuclear|O expression|O )|O ,|O and|O four|O (|O 19|O %|O )|O had|O MI|O .|O 
Only|O one|O case|O (|O 5|O %|O )|O had|O both|O beta-catenin|O gene|O mutations|O and|O MI|O .|O 
The|O mutations|O affected|O one|O of|O the|O serine|O /|O threonine|O residues|O targeted|O for|O phosphorylation|O by|O glycogen|O synthase|O kinase-3beta|O or|O adjacent|O residues|O .|O 
At|O codon|variation-location 32|variation-location ,|O a|O GAC|variation-state-original -|O to|O -|O TAC|variation-state-altered (|O D|variation-state-original 32|variation-location Y|variation-state-altered )|O change|O was|O found|O ;|O at|O codon|variation-location 33|variation-location ,|O two|O TCT|variation-state-original -|O to|O -|O TGT|variation-state-altered (|O S|variation-state-original 33|variation-location C|variation-state-altered )|O changes|O were|O found|O ;|O at|O codon|variation-location 37|variation-location ,|O three|O TCT|variation-state-original -|O to|O -|O TTT|variation-state-altered (|O S|variation-state-original 37|variation-location F|variation-state-altered )|O changes|O and|O one|O TCT|variation-state-original -|O to|O -|O TGT|variation-state-altered (|O S|variation-state-original 37|variation-location C|variation-state-altered )|O change|O were|O found|O ;|O and|O ,|O lastly|O ,|O one|O ACC|variation-state-original -|O to|O -|O GCC|variation-state-altered change|O at|O codon|variation-location 41|variation-location (|O T|variation-state-original 41|variation-location A|variation-state-altered )|O was|O detected|O .|O 
Four|O of|O the|O 25|O endometrioid|O ovarian|O carcinomas|O (|O 16|O %|O )|O had|O an|O associated|O synchronous|O endometrial|O carcinoma|O .|O 
There|O was|O a|O higher|O percentage|O of|O beta-catenin|O mutations|O (|O n|O =|O 3|O ,|O 75|O %|O )|O in|O synchronous|O ovarian|O carcinomas|O than|O in|O single|O ones|O ,|O although|O with|O a|O similar|O percentage|O of|O MI|O (|O n|O =|O 1|O ,|O 25|O %|O )|O .|O 
beta-catenin|O mutations|variation-event were|O S|variation-state-original 37|variation-location C|variation-state-altered in|O two|O cases|O and|O D|variation-state-original 32|variation-location G|variation-state-altered in|O one|O .|O 
One|O of|O the|O four|O endometrial|O carcinomas|O showed|O an|O S|variation-state-original 33|variation-location C|variation-state-altered beta-catenin|O mutation|variation-event ,|O and|O two|O carcinomas|O had|O MI|O .|O 
None|O of|O the|O four|O tumors|O had|O both|O beta-catenin|O gene|O mutation|O and|O MI|O .|O 
beta-catenin|O gene|O mutations|O were|O always|O associated|O with|O a|O nuclear|O beta-catenin|O expression|O pattern|O ,|O whereas|O MI|O was|O associated|O with|O a|O membranous|O pattern|O .|O 
In|O one|O patient|O both|O the|O ovarian|O and|O the|O endometrial|O carcinomas|O had|O beta-catenin|O gene|O mutations|O ,|O in|O another|O patient|O both|O tumors|O showed|O MI|O ,|O whereas|O in|O the|O remaining|O two|O patients|O the|O ovarian|O carcinomas|O showed|O beta-catenin|O gene|O mutations|O and|O the|O endometrial|O carcinomas|O showed|O MI|O .|O 
To|O summarize|O ,|O the|O results|O of|O this|O study|O suggest|O that|O beta-catenin|O mutations|O and|O MI|O could|O represent|O two|O independent|O pathways|O in|O endometrioid|O ovarian|O carcinomas|O because|O they|O occur|O simultaneously|O very|O infrequently|O (|O in|O 5|O %|O of|O these|O cases|O )|O .|O 
beta-catenin|O mutations|O are|O always|O associated|O with|O a|O nuclear|O beta-catenin|O expression|O pattern|O ,|O whereas|O cases|O with|O a|O replication|O error|O -|O plus|O phenotype|O showed|O no|O abnormal|O beta-catenin|O subcellular|O localization|O .|O 
The|O study|O of|O the|O beta-catenin|O expression|O pattern|O ,|O beta-catenin|O mutations|O ,|O and|O MI|O ,|O together|O with|O conventional|O clinicopathologic|O findings|O ,|O could|O aid|O in|O distinguishing|O between|O the|O metastatic|O or|O independent|O origin|O of|O simultaneous|O endometrioid|O ovarian|O and|O endometrial|O carcinomas|O .|O 
Tumors|O with|O identical|O immunohistochemical|O and|O molecular|O features|O should|O therefore|O be|O considered|O to|O have|O a|O common|O origin|O .|O 
Unique|O K-ras|O mutational|O pattern|O in|O pancreatic|O adenocarcinoma|O from|O Taiwanese|O patients|O .|O 
To|O assess|O the|O prevalence|O and|O spectrum|O of|O K-ras|O mutations|O in|O Taiwanese|O patients|O with|O pancreatic|O adenocarcinoma|O ,|O we|O analyzed|O 20|O patients|O of|O ductal|O adenocarcinoma|O of|O the|O head|O of|O the|O pancreas|O undergoing|O pancreaticoduodenectomy|O .|O 
The|O study|O included|O K-ras|O mutations|O that|O were|O detected|O using|O DNA|O direct|O sequencing|O analysis|O of|O the|O polymerase|O chain|O reaction|O products|O and|O confirmed|O by|O reverse|O sequencing|O primers|O .|O 
The|O results|O showed|O that|O K-ras|O codon|variation-location 12|variation-location mutation|variation-event was|O detected|O in|O 90|O %|O of|O the|O cancer|O tissues|O (|O 18|O /|O 20|O )|O .|O 
Moreover|O ,|O the|O results|O from|O direct|O sequencing|O indicated|O that|O missense|variation-type mutations|variation-type were|O found|O to|O be|O a|O GGT|variation-state-original to|O GTT|variation-state-altered in|O 94.5|O %|O of|O the|O cases|O (|O 17|O /|O 18|O )|O and|O a|O GGT|variation-state-original to|O TTT|variation-state-altered in|O 5.5|O %|O of|O the|O cases|O (|O 1|O /|O 18|O )|O .|O 
All|O cases|O with|O K-ras|O codon|variation-location 12|variation-location mutations|variation-event were|O found|O to|O be|O G|variation-state-original to|O T|variation-state-altered transversion|variation-type .|O 
However|O ,|O no|O alterations|O were|O found|O at|O codons|variation-location 13|variation-location and|O 61|variation-location .|O 
From|O these|O findings|O ,|O the|O high|O prevalence|O of|O K-ras|O codon|variation-location 12|variation-location mutation|variation-event in|O pancreatic|O adenocarcinoma|O and|O the|O predominant|O G|variation-state-original to|O T|variation-state-altered transversion|variation-type with|O the|O preferential|O substitution|variation-type of|O glycine|variation-state-original with|O valine|variation-state-altered might|O indicate|O an|O unusual|O sensitivity|O and|O specificity|O of|O this|variation-location codon|variation-location in|O genetic|O alterations|O for|O pancreatic|O carcinogenesis|O .|O 
The|O strikingly|O high|O mutational|O rate|O and|O the|O unique|O mutational|O spectrum|O of|O K-ras|O codon|variation-location 12|variation-location in|O Taiwanese|O pancreatic|O adenocarcinoma|O can|O provide|O us|O with|O more|O information|O about|O the|O alternative|O diagnostic|O and|O therapeutic|O strategies|O in|O Taiwan|O .|O 
Prognostic|O value|O of|O K-ras|O mutations|O and|O allelic|variation-type imbalance|variation-type on|O chromosome|variation-location 18q|variation-location in|O patients|O with|O resected|O colorectal|O cancer|O .|O 
PURPOSE|O :|O 
We|O designed|O this|O study|O to|O assess|O the|O frequency|O of|O K-ras|O mutations|O in|O patients|O with|O resected|O colorectal|O tumors|O and|O their|O association|O with|O survival|O .|O 
A|O second|O objective|O was|O to|O analyze|O the|O prognostic|O value|O of|O different|O K-ras|O genotypes|O .|O 
In|O a|O subgroup|O of|O patients|O we|O also|O investigated|O the|O presence|O of|O allelic|variation-type imbalance|variation-type on|O chromosome|variation-location 18q|variation-location and|O its|O relationship|O to|O clinical|O outcome|O .|O 
METHODS|O :|O 
One|O hundred|O fourteen|O colorectal|O tumors|O resected|O between|O 1983|O and|O 1986|O were|O analyzed|O to|O detect|O K-ras|O point|variation-type mutations|variation-type at|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location by|O polymerase|O chain|O reaction|O followed|O by|O allele|O specific|O oligonucleotide|O hybridization|O .|O 
A|O subgroup|O of|O 77|O tumors|O was|O further|O screened|O to|O detect|O loss|variation-type of|variation-type heterozygosity|variation-type on|O chromosome|variation-location 18q|variation-location using|O three|O polymorphic|O microsatellite|O markers|O (|O D18S67|O ,|O D18S474|O and|O D18S58|O )|O .|O 
RESULTS|O :|O 
K-ras|O mutations|O were|O detected|O in|O 29|O percent|O (|O 33|O /|O 114|O )|O of|O patients|O .|O 
K-ras|O mutations|O correlated|O with|O age|O and|O preoperative|O carcinoembryonic|O antigen|O levels|O ,|O and|O there|O was|O some|O indication|O that|O they|O may|O be|O linked|O to|O poor|O survival|O ,|O especially|O in|O Stage|O II|O tumors|O ,|O where|O a|O subgroup|O of|O patients|O with|O aspartic|variation-state-generic and|O serine|variation-state-generic mutations|variation-event showed|O significantly|O reduced|O survival|O (|O P|O =|O 0.03|O )|O compared|O with|O K-ras|O -|O negative|O patients|O .|O 
18q|variation-location loss|variation-type of|variation-type heterozygosity|variation-type was|O present|O in|O 39|O percent|O (|O 25|O /|O 63|O )|O of|O tumors|O .|O 
A|O multivariate|O analysis|O of|O Stage|O II|O tumors|O showed|O that|O 18q|variation-location loss|variation-type of|variation-type heterozygosity|variation-type was|O significantly|O associated|O with|O a|O worse|O prognosis|O (|O P|O =|O 0.006|O )|O .|O 
A|O significant|O decrease|O in|O survival|O was|O identified|O in|O ten|O patients|O harboring|O both|variation-event genetic|variation-event alterations|variation-event (|O K-i|O mutations|O and|O 18q|variation-location loss|variation-type of|variation-type heterozygosity|variation-type ;|O P|O =|O 0.02|O )|O .|O 
CONCLUSIONS|O :|O 
In|O colorectal|O tumors|O ,|O K-ras|O mutations|O and|O 18q|variation-location loss|variation-type of|variation-type heterozygosity|variation-type are|O two|O genetic|O markers|O which|O may|O identify|O patients|O with|O more|O aggressive|O behavior|O ,|O mainly|O in|O Stage|O II|O tumors|O .|O 
These|O findings|O warrant|O further|O research|O ,|O because|O they|O can|O be|O useful|O in|O customizing|O adjuvant|O chemotherapy|O .|O 
Inverse|O relationship|O between|O microsatellite|O instability|O and|O K-ras|O and|O p53|O gene|O alterations|O in|O colon|O cancer|O .|O 
Some|O studies|O have|O shown|O an|O inverse|O relationship|O between|O microsatellite|O instability|O in|O colon|O cancer|O and|O mutations|O in|O p53|O and|O K-ras|O ,|O whereas|O others|O have|O not|O .|O 
We|O therefore|O evaluated|O these|O features|O in|O a|O population|O -|O based|O sample|O of|O 496|O individuals|O with|O colon|O cancer|O .|O 
Microsatellite|O instability|O was|O determined|O by|O a|O panel|O of|O 10|O tetranucleotide|O repeats|O ,|O the|O Bethesda|O consensus|O panel|O of|O mono|O -|O and|O di|O nucleotide|O repeats|O ,|O and|O coding|O mononucleotide|O repeats|O in|O transforming|O growth|O factor|O -|O beta|O receptor|O type|O II|O ,|O hMSH3|O ,|O BAX|O ,|O hMSH6|O ,|O and|O insulin|O -|O like|O growth|O factor|O receptor|O type|O II|O .|O 
Mutations|variation-event in|O codons|variation-location 12|variation-location and|O 13|variation-location in|O K-ras|O were|O evaluated|O by|O sequencing|O .|O 
p53|O overexpression|O (|O as|O detected|O by|O immunohistochemistry|O )|O was|O used|O as|O an|O indicator|O of|O p53|O mutation|O ;|O this|O was|O evaluated|O in|O 275|O of|O the|O tumors|O .|O 
K-ras|O mutations|O were|O present|O in|O 33.2|O %|O of|O tumors|O ,|O p53|O overexpression|O in|O 51.5|O %|O ,|O and|O microsatellite|O instability|O (|O as|O determined|O by|O the|O Bethesda|O consensus|O panel|O )|O in|O 12.5|O %|O .|O 
K-ras|O mutations|O were|O significantly|O less|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 11.8|O %|O versus|O 36.9|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
p53|O overexpression|O was|O significantly|O less|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 20.0|O %|O versus|O 55.7|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
These|O inverse|O relationships|O between|O microsatellite|O instability|O and|O ras|O gene|O mutations|O and|O p53|O overexpression|O were|O shown|O to|O be|O independent|O of|O tumor|O site|O in|O logistic|O regression|O analyses|O .|O 
All|O other|O measures|O of|O instability|O also|O showed|O statistically|O significant|O inverse|O relationships|O independent|O of|O tumor|O site|O with|O alterations|O in|O ras|O and|O p53|O ,|O and|O instability|O results|O determined|O by|O the|O panel|O of|O 10|O tetranucleotide|O repeats|O were|O highly|O significantly|O related|O to|O those|O determined|O by|O the|O Bethesda|O consensus|O panel|O .|O 
Coding|O mononucleotide|O repeat|O mutations|O were|O significantly|O more|O common|O in|O unstable|O tumors|O than|O stable|O tumors|O (|O 85.7|O %|O versus|O 1.0|O %|O ,|O P|O :|O <|O 0.001|O )|O .|O 
We|O conclude|O that|O there|O is|O an|O inverse|O relationship|O between|O microsatellite|O instability|O and|O mutations|O in|O p53|O and|O K-ras|O ,|O and|O that|O the|O molecular|O profile|O of|O colon|O cancers|O with|O microsatellite|O instability|O is|O characterized|O by|O relatively|O infrequent|O mutations|O in|O K-ras|O and|O p53|O and|O relatively|O frequent|O mutations|O in|O coding|O mononucleotide|O repeats|O .|O 
Colloid|O (|O mucinous|O noncystic|O )|O carcinoma|O of|O the|O pancreas|O .|O 
In|O the|O past|O ,|O colloid|O (|O mucinous|O noncystic|O )|O carcinoma|O (|O CC|O )|O of|O the|O pancreas|O had|O been|O included|O under|O the|O category|O of|O ordinary|O ductal|O adenocarcinoma|O ,|O a|O tumor|O with|O a|O dismal|O prognosis|O ,|O or|O was|O frequently|O misdiagnosed|O as|O mucinous|O cystadenocarcinoma|O .|O 
The|O clinicopathologic|O features|O of|O CC|O have|O not|O yet|O been|O well|O characterized|O ,|O because|O most|O cases|O on|O record|O have|O been|O parts|O of|O studies|O on|O either|O mucinous|O cystic|O neoplasms|O (|O MCN|O )|O or|O intraductal|O papillary|O mucinous|O neoplasms|O (|O IPMN|O )|O ,|O with|O which|O colloid|O carcinomas|O are|O frequently|O associated|O .|O 
To|O determine|O the|O clinicopathologic|O characteristics|O of|O CC|O ,|O 17|O pancreatic|O tumors|O composed|O predominantly|O (|O >|O 80|O %|O )|O of|O CC|O (|O defined|O as|O nodular|O extracellular|O mucin|O lakes|O with|O scanty|O malignant|O epithelial|O cells|O )|O and|O in|O which|O the|O invasive|O carcinoma|O measured|O larger|O than|O 1|O cm|O were|O studied|O .|O 
Ten|O of|O these|O were|O originally|O classified|O as|O mucinous|O ductal|O adenocarcinoma|O and|O four|O as|O mucinous|O cystadenocarcinoma|O .|O 
The|O mean|O age|O of|O the|O patients|O was|O 61|O years|O ;|O 9|O were|O men|O and|O 8|O were|O women|O .|O 
The|O mean|O size|O of|O the|O CC|O was|O 5.3|O cm|O (|O range|O ,|O 1.2|O -|O 16|O cm|O )|O .|O 
In|O more|O than|O half|O of|O the|O patients|O ,|O CC|O represented|O the|O invasive|O component|O of|O an|O IPMN|O (|O in|O nine|O cases|O )|O or|O MCN|O (|O in|O one|O case|O )|O .|O 
The|O tumors|O were|O composed|O of|O well|O -|O defined|O pools|O of|O mucin|O with|O sparse|O malignant|O cells|O in|O various|O patterns|O of|O distribution|O .|O 
Signet|O -|O ring|O cells|O floating|O in|O the|O mucin|O (|O but|O not|O as|O individual|O cells|O infiltrating|O stroma|O ,|O a|O characteristic|O finding|O of|O signet|O -|O ring|O cell|O adenocarcinomas|O )|O were|O commonly|O identified|O and|O were|O prominent|O in|O five|O cases|O .|O 
Perineurial|O invasion|O was|O noted|O in|O six|O cases|O and|O regional|O lymph|O node|O metastases|O in|O eight|O .|O 
Mutation|variation-event in|O codon|variation-location 12|variation-location of|O the|O k-ras|O gene|O was|O detected|O in|O only|O 4|O of|O 12|O cases|O studied|O and|O p53|O mutation|O in|O 2|O of|O 9|O .|O 
Immunohistochemical|O and|O histochemical|O mucin|O stains|O suggested|O luminalization|O of|O the|O basal|O aspects|O of|O the|O cells|O .|O 
Five|O -|O year|O survival|O was|O 57|O %|O .|O 
At|O an|O overall|O mean|O follow|O up|O of|O 57|O months|O ,|O 10|O patients|O were|O alive|O with|O no|O evidence|O of|O disease|O (|O median|O ,|O 79|O mos|O )|O ,|O including|O four|O with|O lymph|O node|O metastasis|O ,|O three|O others|O with|O perineurial|O invasion|O ,|O and|O another|O with|O vascular|O invasion|O .|O 
Four|O patients|O died|O of|O disease|O (|O 18|O ,|O 18|O ,|O 25|O ,|O and|O 26|O mos|O )|O ,|O and|O three|O died|O of|O thromboembolism|O (|O with|O persistent|O disease|O )|O at|O 2|O ,|O 5|O ,|O 10|O months|O .|O 
All|O seven|O patients|O who|O died|O with|O or|O of|O tumor|O had|O undergone|O incisional|O biopsy|O of|O the|O tumor|O either|O before|O the|O operation|O or|O intraoperatively|O ,|O whereas|O none|O of|O the|O patients|O who|O were|O alive|O had|O incisional|O biopsy|O .|O 
When|O compared|O with|O 82|O cases|O of|O resectable|O ordinary|O ductal|O adenocarcinoma|O on|O whom|O follow-up|O and|O staging|O information|O was|O complete|O ,|O it|O was|O found|O that|O the|O patients|O with|O CC|O present|O with|O larger|O tumors|O (|O p|O =|O 0.03|O )|O but|O lower|O stage|O (|O p|O =|O 0.01|O )|O .|O 
The|O prognosis|O of|O CC|O is|O significantly|O better|O :|O 2|O -|O year|O and|O 5|O -|O year|O survival|O are|O 70|O %|O versus|O 28|O %|O and|O 57|O %|O versus|O 12|O %|O ,|O respectively|O (|O p|O =|O 0.001|O )|O .|O 
In|O conclusion|O ,|O pancreatic|O CC|O may|O occur|O with|O or|O without|O an|O identifiable|O IPMN|O and|O MCN|O component|O ,|O and|O should|O be|O distinguished|O from|O mucinous|O cystadenocarcinoma|O ,|O ordinary|O ductal|O adenocarcinoma|O ,|O and|O signet|O -|O ring|O cell|O adenocarcinoma|O .|O 
CC|O of|O the|O pancreas|O is|O associated|O with|O a|O significantly|O better|O prognosis|O than|O ordinary|O ductal|O adenocarcinoma|O .|O 
In|O addition|O to|O its|O distinctive|O morphologic|O and|O clinical|O characteristics|O ,|O CC|O of|O the|O pancreas|O also|O appears|O to|O have|O a|O low|O incidence|O of|O mutation|variation-event in|O codon|variation-location 12|variation-location of|O the|O k-ras|O gene|O .|O 
In|O cases|O with|O a|O clinical|O suspicion|O of|O colloid|O carcinoma|O ,|O the|O possibility|O that|O an|O incisional|O biopsy|O may|O contribute|O to|O thromboembolic|O complications|O or|O even|O dissemination|O of|O the|O tumor|O may|O need|O to|O be|O considered|O .|O 
The|O luminalization|O of|O the|O basal|O aspects|O of|O the|O tumor|O cells|O may|O be|O the|O cause|O of|O stromal|O mucin|O accumulation|O that|O characterizes|O colloid|O carcinoma|O and|O may|O act|O as|O a|O containing|O factor|O .|O 
Characterization|O of|O the|O mutations|O of|O the|O K-ras|O ,|O p53|O ,|O p16|O ,|O and|O SMAD4|O genes|O in|O 15|O human|O pancreatic|O cancer|O cell|O lines|O .|O 
Human|O pancreatic|O cancer|O is|O one|O of|O the|O most|O malignant|O diseases|O in|O the|O world|O .|O 
In|O order|O to|O save|O patients|O with|O pancreatic|O cancer|O ,|O it|O is|O necessary|O to|O develop|O novel|O methods|O for|O treatment|O .|O 
For|O such|O a|O purpose|O ,|O a|O series|O of|O well|O -|O characterized|O cancer|O cell|O lines|O are|O of|O great|O help|O for|O in|O vitro|O studies|O that|O are|O generally|O the|O first|O step|O in|O approaching|O the|O invention|O of|O novel|O methods|O for|O treatment|O .|O 
In|O the|O present|O study|O ,|O we|O analyzed|O 15|O human|O pancreatic|O cancer|O cell|O lines|O for|O genetic|O alterations|O of|O the|O K-ras|O ,|O p53|O ,|O p16|O ,|O and|O SMAD4|O genes|O ,|O which|O are|O very|O frequent|O targets|O for|O mutation|O in|O pancreatic|O cancer|O ;|O these|O cell|O lines|O are|O useful|O resources|O in|O cancer|O research|O .|O 
Mast|O cell|O disease|O associated|O with|O acute|O myeloid|O leukemia|O :|O detection|O of|O a|O new|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location His|variation-state-altered .|O 
Mast|O cell|O disease|O (|O MCD|O )|O ,|O a|O proliferation|O of|O mast|O cells|O (|O MC|O )|O ,|O is|O occasionally|O associated|O with|O hematologic|O malignancies|O .|O 
Neoplastic|O MC|O have|O activating|O c-kit|O mutations|O .|O 
c-kit|O is|O a|O receptor|O tyrosine|O kinase|O required|O for|O the|O development|O ,|O proliferation|O ,|O and|O survival|O of|O MC|O .|O 
Interaction|O of|O c-kit|O with|O its|O ligand|O stem|O cell|O factor|O induces|O dimerization|O ,|O receptor|O phosphorylation|O ,|O and|O signal|O transduction|O .|O 
The|O most|O common|O c-kit|O mutation|O detected|O in|O neoplastic|O MCD|O is|O Asp|variation-state-original 816|variation-location Val|variation-state-altered ,|O which|O results|O in|O ligand|O -|O independent|O autophosphorylation|O of|O the|O receptor|O leading|O to|O MC|O proliferation|O .|O 
We|O describe|O the|O rare|O occurrence|O of|O MCD|O associated|O with|O acute|O myeloid|O leukemia|O ,|O report|O a|O novel|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location His|variation-state-altered ,|O and|O discuss|O the|O pathogenesis|O of|O MCD|O associated|O with|O hematologic|O malignancies|O .|O 
Molecular|O changes|O in|O second|O primary|O lung|O and|O breast|O cancers|O after|O therapy|O for|O Hodgkin|O 's|O disease|O .|O 
The|O risk|O of|O lung|O and|O breast|O cancer|O is|O significantly|O increased|O after|O therapy|O for|O Hodgkin|O 's|O disease|O (|O HD|O )|O ,|O but|O there|O are|O few|O data|O that|O describe|O the|O molecular|O profiles|O of|O these|O tumors|O .|O 
We|O investigated|O the|O genetic|O abnormalities|O in|O second|O primary|O lung|O (|O n|O =|O 19|O )|O and|O breast|O cancers|O (|O n|O =|O 19|O )|O that|O follow|O therapy|O for|O HD|O (|O "|O post|O -|O HD|O cancers|O "|O )|O and|O compared|O these|O with|O changes|O observed|O in|O corresponding|O tumor|O types|O (|O 57|O lung|O and|O 20|O breast|O cancers|O )|O arising|O in|O the|O general|O population|O (|O "|O sporadic|O cancers|O "|O )|O .|O 
DNA|O obtained|O from|O archival|O tissues|O was|O examined|O using|O PCR|O -|O based|O analyses|O for|O loss|variation-type of|variation-type heterozygosity|variation-type and|O microsatellite|O alterations|O (|O MAs|O )|O at|O several|O chromosomal|O regions|O ,|O TP53|O and|O K-ras|O gene|O mutations|O ,|O and|O frameshift|variation-type mutations|variation-event at|O minisatellite|O sequences|O at|O the|O coding|O regions|O of|O several|O genes|O (|O TGF-betaRII|O ,|O IGFIIR|O ,|O BAX|O ,|O hMSH6|O ,|O and|O hMSH3|O )|O .|O 
The|O occurrence|O of|O loss|variation-type of|variation-type heterozygosity|variation-type at|O all|O chromosomal|O regions|O taken|O together|O and|O frequencies|O at|O most|O individual|O areas|O were|O similar|O for|O the|O post|O -|O HD|O and|O sporadic|O cancers|O for|O both|O lung|O and|O breast|O sites|O .|O 
The|O overall|O frequency|O of|O MAs|O in|O the|O post|O -|O HD|O tumors|O was|O substantially|O greater|O (|O lung|O ,|O 2.4|O -|O fold|O ,|O P|O =|O 0.004|O ;|O breast|O ,|O 4.2|O -|O fold|O ,|O P|O =|O 0.16|O )|O than|O that|O in|O the|O respective|O sporadic|O cancers|O .|O 
No|O differences|O in|O the|O pattern|O of|O TP53|O and|O K-ras|O mutations|O were|O detected|O between|O post|O -|O HD|O and|O sporadic|O cancers|O .|O 
No|O mutations|O were|O detected|O at|O the|O minisatellite|O sequences|O examined|O .|O 
MAs|O ,|O which|O reflect|O widespread|O genomic|O instability|O ,|O occur|O at|O greatly|O increased|O frequency|O in|O post|O -|O HD|O lung|O and|O breast|O cancers|O .|O 
Although|O the|O mechanisms|O underlying|O the|O development|O of|O increased|O MAs|O are|O unknown|O ,|O they|O have|O been|O associated|O with|O immunosuppression|O and|O radiation|O exposure|O .|O 
Future|O research|O should|O address|O the|O role|O that|O MAs|O ,|O as|O well|O as|O other|O influences|O ,|O may|O play|O in|O the|O development|O of|O neoplasias|O that|O occur|O after|O therapy|O for|O HD|O .|O 
Detection|O of|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location to|O Val|variation-state-altered in|O microdissected|O bone|O marrow|O infiltrates|O in|O a|O case|O of|O systemic|O mastocytosis|O associated|O with|O chronic|O myelomonocytic|O leukaemia|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
The|O occurrence|O of|O myeloid|O leukaemia|O in|O patients|O with|O systemic|O mastocytosis|O is|O a|O well|O recognised|O phenomenon|O .|O 
However|O ,|O the|O pathophysiological|O basis|O of|O such|O a|O coevolution|O has|O not|O been|O clarified|O .|O 
Recent|O data|O have|O shown|O that|O the|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location to|O Val|variation-state-altered is|O detectable|O in|O neoplastic|O mast|O cells|O in|O most|O patients|O with|O systemic|O mastocytosis|O ,|O including|O those|O who|O have|O associated|O haematological|O disorders|O .|O 
The|O aim|O of|O this|O study|O was|O to|O study|O clonal|O disease|O evolution|O by|O analysing|O bone|O marrow|O cells|O from|O a|O patient|O with|O systemic|O mastocytosis|O and|O associated|O chronic|O myelomonocytic|O leukaemia|O (|O CMML|O )|O for|O the|O presence|O of|O this|O mutation|variation-event .|O 
METHODS|O :|O 
The|O DNA|O of|O microdissected|O bone|O marrow|O cells|O from|O a|O patient|O with|O systemic|O mastocytosis|O and|O associated|O CMML|O was|O analysed|O for|O the|O presence|O of|O the|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location to|O Val|variation-state-altered by|O means|O of|O HinfI|O digestion|O and|O direct|O sequencing|O of|O semi|O -|O nested|O polymerase|O chain|O reaction|O (|O PCR|O )|O products|O .|O 
RESULTS|O :|O 
The|O two|O neoplasms|O could|O easily|O be|O identified|O and|O discriminated|O in|O paraffin|O wax|O embedded|O bone|O marrow|O sections|O by|O tryptase|O and|O chloroacetate|O esterase|O staining|O .|O 
A|O total|O number|O of|O 10|O tryptase|O positive|O systemic|O mastocytosis|O infiltrates|O and|O 10|O tryptase|O negative|O CMML|O infiltrates|O were|O removed|O by|O microdissection|O .|O 
As|O assessed|O by|O HinfI|O digestion|O and|O direct|O sequencing|O of|O semi|O -|O nested|O PCR|O products|O ,|O the|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location to|O Val|variation-state-altered was|O detected|O in|O five|O of|O seven|O systemic|O mastocytosis|O infiltrates|O and|O four|O of|O six|O CMML|O infiltrates|O .|O 
By|O contrast|O ,|O no|O c-kit|O mutation|O Asp|variation-state-original 816|variation-location to|O Val|variation-state-altered was|O found|O in|O bone|O marrow|O infiltrates|O in|O patients|O with|O CMML|O without|O associated|O systemic|O mastocytosis|O (|O n|O =|O 20|O )|O .|O 
CONCLUSION|O :|O 
These|O data|O support|O a|O monoclonal|O evolution|O of|O systemic|O mastocytosis|O and|O concurrent|O CMML|O in|O the|O patient|O studied|O .|O 
Activation|O of|O the|O beta-catenin|O gene|O by|O interstitial|O deletions|variation-type involving|O exon|variation-location 3|variation-location as|O an|O early|O event|O in|O colorectal|O tumorigenesis|O .|O 
beta-Catenin|O has|O been|O identified|O as|O an|O oncogene|O in|O several|O tumors|O including|O colorectal|O cancers|O .|O 
beta-Catenin|O gene|O is|O activated|O by|O interstitial|O deletions|variation-type involving|O exon|variation-location 3|variation-location in|O colorectal|O carcinomas|O of|O Japanese|O population|O ,|O in|O contrast|O to|O amino|O acid|O substitutions|variation-type detected|O among|O Caucasian|O population|O .|O 
The|O aim|O of|O this|O study|O was|O to|O examine|O the|O type|O and|O frequency|O of|O beta-catenin|O gene|O mutation|O during|O early|O stages|O of|O colorectal|O tumorigenesis|O .|O 
We|O screened|O 100|O colorectal|O adenomas|O for|O somatic|O mutations|O in|O the|O beta-catenin|O gene|O by|O single|O -|O strand|O conformation|O polymorphism|O method|O ,|O as|O well|O as|O polymerase|O chain|O reaction|O amplification|O .|O 
In|O cases|O with|O mutations|O ,|O sequencing|O analyses|O and|O immunohistochemical|O staining|O were|O also|O performed|O .|O 
Somatic|O interstitial|O deletions|variation-type of|O 272|O -|O 413|O bp|O ,|O each|O of|O which|O included|O all|O parts|O of|O exon|variation-location 3|variation-location ,|O were|O detected|O in|O three|O tumors|O .|O 
However|O ,|O no|O adenoma|O carried|O missense|variation-type mutations|variation-type .|O 
We|O confirmed|O accumulation|O of|O aberrant|O beta-catenin|O protein|O in|O cytoplasm|O and|O nuclei|O of|O adenoma|O cells|O by|O immunohistochemical|O analysis|O .|O 
Our|O results|O suggested|O that|O activation|O of|O the|O beta-catenin|O gene|O by|O interstitial|O deletions|variation-type involving|O exon|variation-location 3|variation-location might|O be|O less|O frequent|O compared|O with|O frequent|O alterations|O of|O adenomatous|O polyposis|O coli|O (|O APC|O )|O gene|O ,|O but|O could|O be|O an|O early|O event|O in|O colorectal|O tumorigenesis|O equivalent|O to|O APC|O gene|O alterations|O in|O the|O Japanese|O population|O .|O 
High|O frequency|O of|O K-ras|O mutations|O in|O biliary|O duct|O carcinomas|O of|O cases|O with|O a|O long|O common|O channel|O in|O the|O papilla|O of|O Vater|O .|O 
The|O frequency|O of|O K-ras|O mutation|O in|O biliary|O duct|O carcinomas|O in|O different|O locations|O and|O the|O relationship|O to|O the|O form|O of|O the|O junction|O of|O the|O pancreaticobiliary|O duct|O (|O JPBD|O )|O are|O not|O understood|O clearly|O .|O 
These|O points|O were|O investigated|O in|O the|O present|O study|O .|O 
Thirty-seven|O biliary|O duct|O carcinomas|O in|O patients|O without|O anomalous|O JPBD|O were|O investigated|O for|O K-ras|O mutations|O .|O 
Regarding|O location|O ,|O 12|O were|O hilar|O ,|O 4|O in|O the|O upper|O ,|O 11|O in|O the|O middle|O ,|O and|O 10|O in|O the|O lower|O portion|O of|O the|O duct|O .|O 
Furthermore|O ,|O with|O 14|O cases|O for|O which|O the|O form|O of|O the|O JPBD|O could|O be|O confirmed|O by|O endoscopic|O retrograde|O cholangiopancreatography|O or|O postoperative|O cholangiopancreatography|O ,|O division|O was|O made|O into|O two|O types|O :|O those|O with|O a|O long|O common|O channel|O (|O >|O 5|O mm|O )|O in|O the|O papilla|O of|O Vater|O (|O type|O 1|O ,|O n|O =|O 4|O )|O ,|O and|O the|O other|O with|O a|O shorter|O or|O nonapparent|O common|O channel|O (|O type|O 2|O ,|O n|O =|O 10|O )|O .|O 
The|O overall|O frequency|O of|O K-ras|O mutation|O was|O 30|O %|O ,|O the|O incidence|O gradually|O increasing|O from|O upper|O to|O lower|O regions|O .|O 
K-ras|O mutations|O were|O significantly|O more|O frequent|O in|O biliary|O duct|O carcinomas|O associated|O with|O long|O common|O channels|O (|O P|O <|O 0.05|O )|O .|O 
These|O results|O suggest|O that|O a|O long|O common|O channel|O may|O bear|O a|O relation|O to|O K-ras|O mutations|O in|O biliary|O duct|O carcinogenesis|O ,|O presumably|O through|O its|O influence|O on|O pancreatic|O juice|O regurgitation|O .|O 
Rapid|O and|O reliable|O detection|O of|O N-ras|O mutations|O in|O acute|O lymphoblastic|O leukemia|O by|O melting|O curve|O analysis|O using|O LightCycler|O technology|O .|O 
We|O applied|O a|O new|O strategy|O for|O the|O detection|O of|O N-ras|O gene|O mutations|O based|O on|O LightCycler|O technology|O .|O 
We|O designed|O two|O sets|O of|O amplimers|O and|O internal|O hybridization|O probes|O representing|O N-ras|O codons|variation-location 12|variation-location /|O 13|variation-location and|O codon|variation-location 61|variation-location ,|O respectively|O .|O 
Genomic|O DNAs|O from|O 134|O childhood|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O patients|O (|O 83|O common|O ALL|O ,|O nine|O pre|O -|O pre|O -|O B|O ALL|O ,|O 19|O pre|O -|O B|O ALL|O ,|O 23|O T|O -|O ALL|O )|O were|O amplified|O ,|O followed|O by|O the|O analysis|O of|O the|O melting|O temperatures|O of|O the|O PCR|O products|O on|O the|O LightCycler|O .|O 
PCR|O products|O exhibiting|O an|O abnormal|O melting|O characteristic|O were|O directly|O sequenced|O .|O 
Sequence|O analyses|O unravelled|O nucleotide|variation-type substitutions|variation-type at|O codon|variation-location 12|variation-location in|O 10|O patients|O ,|O at|O codon|variation-location 13|variation-location in|O three|O ,|O and|O at|O codon|variation-location 61|variation-location in|O one|O case|O .|O 
The|O incidence|O of|O N-ras|O mutations|O (|O 10|O %|O )|O is|O compatible|O with|O previous|O reports|O .|O 
The|O LightCycler|O technology|O facilitates|O the|O rapid|O analysis|O of|O other|O genes|O exhibiting|O hot|O spot|O mutations|O in|O human|O malignancies|O .|O 
Ras|O mutations|O are|O uncommon|O in|O sporadic|O thyroid|O cancer|O in|O children|O and|O young|O adults|O .|O 
Mutations|O in|O the|O ras|O genes|O (|O H-ras|O ,|O K-ras|O ,|O and|O N-ras|O )|O occur|O in|O 10|O -|O 15|O %|O of|O all|O human|O cancers|O ,|O and|O commonly|O arise|O from|O single|variation-type base|variation-type substitutions|variation-type at|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O or|O 61|variation-location .|O 
Although|O ras|O mutations|O have|O been|O found|O in|O adult|O thyroid|O cancers|O ,|O they|O were|O absent|O from|O the|O two|O studies|O which|O examined|O childhood|O thyroid|O cancers|O .|O 
Both|O studies|O included|O only|O children|O with|O radiation|O induced|O thyroid|O cancer|O ,|O and|O it|O remains|O unclear|O if|O ras|O mutations|O occur|O in|O children|O without|O radiation|O exposure|O .|O 
To|O answer|O this|O question|O ,|O we|O examined|O archival|O tissue|O blocks|O from|O 31|O children|O with|O papillary|O thyroid|O cancer|O (|O PTC|O )|O 4|O with|O follicular|O thyroid|O cancer|O (|O FTC|O )|O ,|O 2|O with|O medullary|O thyroid|O cancer|O (|O MTC|O )|O ,|O and|O 1|O with|O lymphoma|O (|O LYM|O )|O .|O 
Only|O 1|O patient|O with|O PTC|O had|O previous|O radiation|O exposure|O .|O 
Genomic|O DNA|O was|O extracted|O and|O used|O for|O PCR|O amplification|O of|O the|O ras|O genes|O .|O 
The|O PCR|O products|O were|O analyzed|O by|O oligospecific|O hybridization|O for|O mutations|variation-event at|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location .|O 
Two|O of|O the|O PTCs|O (|O 6.5|O %|O )|O contained|O ras|O mutations|O .|O 
Both|O patients|O had|O class|O II|O disease|O and|O no|O history|O of|O previous|O radiation|O exposure|O .|O 
One|O patient|O subsequently|O developed|O bone|O and|O lung|O metastases|O .|O 
The|O patient|O with|O lymphoma|O also|O had|O a|O ras|O mutation|O (|O N|O -|O 61|variation-location )|O ,|O but|O ras|O mutations|O were|O absent|O from|O all|O FTC|O and|O MTC|O .|O 
These|O results|O suggest|O that|O ras|O mutations|O are|O uncommon|O in|O spontaneous|O childhood|O thyroid|O cancer|O ,|O but|O occur|O with|O a|O frequency|O similar|O to|O that|O found|O in|O previous|O reports|O of|O adult|O differentiated|O thyroid|O cancers|O .|O 
The|O number|O of|O subjects|O was|O too|O small|O to|O determine|O if|O ras|O mutations|O are|O more|O common|O in|O patients|O with|O aggressive|O papillary|O thyroid|O cancer|O .|O 
Effect|O of|O c-kit|O mutation|O on|O prognosis|O of|O gastrointestinal|O stromal|O tumors|O .|O 
Gastrointestinal|O stromal|O tumor|O (|O GIST|O )|O is|O the|O most|O common|O mesenchymal|O tumor|O of|O the|O gastrointestinal|O tract|O .|O 
Gain|variation-type -|variation-type of|variation-type -|variation-type function|variation-type mutations|variation-type in|O the|O juxtamembrane|O domain|O of|O the|O c-kit|O gene|O have|O been|O found|O in|O several|O GISTs|O .|O 
In|O this|O study|O ,|O we|O examined|O the|O correlation|O between|O the|O presence|O of|O c-kit|O mutation|O and|O prognosis|O in|O 124|O cases|O of|O GIST|O .|O DNA|O samples|O were|O extracted|O from|O paraffin|O sections|O .|O 
Exon|variation-location 11|variation-location of|O the|O c-kit|O gene|O encoding|O the|O juxtamembrane|O domain|O and|O exon|variation-location 17|variation-location encoding|O the|O kinase|O domain|O were|O amplified|O by|O PCR|O and|O sequenced|O .|O 
Most|O GISTs|O (|O 89|O %|O )|O express|O the|O KIT|O protein|O ,|O and|O missense|variation-type mutations|variation-type of|O exon|variation-location 11|variation-location were|O found|O in|O 71|O of|O 124|O GISTs|O (|O 57|O %|O )|O .|O 
No|O mutations|variation-event were|O detectable|O in|O exon|variation-location 17|variation-location .|O 
These|O 71|O mutation|O -|O positive|O GISTs|O were|O larger|O in|O size|O and|O had|O more|O frequently|O invaded|O adjacent|O tissues|O than|O did|O the|O 53|O mutation|O -|O negative|O GISTs|O .|O 
Histologically|O ,|O the|O mutation|O -|O positive|O GISTs|O showed|O higher|O mitotic|O figures|O and|O more|O necrosis|O and|O hemorrhage|O .|O 
The|O patients|O with|O mutation|O -|O positive|O GISTs|O showed|O more|O frequent|O recurrences|O (|O P|O =|O 0.0005|O )|O and|O higher|O mortality|O (|O P|O =|O 0.0001|O )|O than|O did|O those|O with|O mutation|O -|O negative|O GISTs|O .|O 
The|O c-kit|O mutation|O was|O an|O independent|O prognostic|O factor|O for|O overall|O and|O cause|O -|O specific|O survival|O of|O the|O patients|O with|O GISTs|O .|O 
These|O results|O suggest|O that|O GISTs|O may|O be|O divided|O into|O mutation|O -|O positive|O and|O -|O negative|O subtypes|O .|O 
The|O prognosis|O was|O worse|O in|O patients|O with|O mutation|O -|O positive|O GISTs|O than|O in|O those|O with|O mutation|O -|O negative|O GISTs|O .|O 
Thus|O ,|O mutation|O of|O the|O c-kit|O gene|O may|O be|O a|O good|O prognostic|O marker|O of|O GISTs|O .|O 
Activating|O c-kit|O gene|O mutations|O in|O human|O germ|O cell|O tumors|O .|O 
The|O c-kit|O gene|O encodes|O a|O tyrosine|O kinase|O receptor|O (|O KIT|O )|O that|O is|O required|O in|O normal|O spermatogenesis|O and|O is|O expressed|O in|O seminomas|O and|O dysgerminomas|O ,|O a|O subset|O of|O human|O germ|O cell|O tumors|O (|O GCTs|O )|O .|O 
To|O determine|O whether|O activating|O mutations|O of|O the|O c-kit|O gene|O occur|O in|O GCTs|O ,|O primary|O tissue|O samples|O of|O 33|O testicular|O and|O ovarian|O tumors|O were|O examined|O for|O mutations|O in|O the|O juxtamembrane|O and|O phosphotransferase|O domains|O by|O polymerase|O chain|O reaction|O amplification|O and|O DNA|O sequencing|O .|O 
A|O novel|O missense|variation-type mutation|variation-type (|O D|variation-state-original 816|variation-location H|variation-state-altered )|O was|O found|O in|O the|O phosphotransferase|O domain|O in|O tumors|O of|O seminoma|O /|O dysgerminoma|O differentiation|O .|O 
The|O c-kit|O alleles|O in|O nonneoplastic|O tissues|O from|O these|O patients|O were|O wild|O type|O ,|O suggesting|O that|O the|O mutant|O alleles|O were|O acquired|O and|O selected|O for|O during|O malignant|O transformation|O .|O 
In|O cell|O transfection|O experiments|O ,|O the|O D|variation-state-original 816|variation-location H|variation-state-altered mutant|O protein|O was|O a|O constitutively|O activated|O kinase|O and|O was|O constitutively|O phosphorylated|O on|O tyrosine|O residues|O .|O 
This|O is|O the|O first|O description|O of|O an|O activating|O c-kit|O mutation|O in|O GCTs|O and|O is|O evidence|O that|O the|O KIT|O signal|O transduction|O pathway|O is|O important|O in|O the|O pathogenesis|O of|O neoplasms|O with|O seminoma|O differentiation|O .|O 
A|O clinicopathologic|O and|O immunohistochemical|O study|O of|O 22|O intraductal|O papillary|O mucinous|O neoplasms|O of|O the|O pancreas|O ,|O with|O a|O review|O of|O the|O literature|O .|O 
Intraductal|O papillary|O -|O mucinous|O neoplasms|O (|O IPMNs|O )|O of|O the|O pancreas|O are|O rare|O lesions|O .|O 
We|O undertook|O this|O study|O to|O analyze|O these|O tumors|O by|O focusing|O on|O the|O diagnostic|O criteria|O and|O correlating|O the|O histologic|O features|O with|O clinical|O prognosis|O .|O 
Twenty-two|O cases|O of|O IPMN|O were|O retrieved|O from|O the|O Endocrine|O Tumor|O Registry|O of|O the|O Armed|O Forces|O Institute|O of|O Pathology|O .|O 
Blocks|O or|O unstained|O slides|O were|O available|O for|O histochemical|O and|O immunohistochemical|O studies|O (|O including|O proliferative|O markers|O and|O cell|O cycle|O regulators|O )|O and|O K-ras|O oncogene|O mutations|O in|O 15|O cases|O .|O 
Patient|O follow|O -|O up|O was|O obtained|O in|O all|O of|O the|O cases|O .|O 
IPMN|O occurs|O in|O both|O genders|O with|O a|O slight|O male|O predominance|O ,|O with|O a|O mean|O age|O at|O presentation|O of|O 64.4|O years|O (|O range|O ,|O 48|O -|O 85|O yr|O )|O .|O 
The|O patients|O presented|O with|O abdominal|O pain|O .|O 
The|O neoplasms|O were|O radiologically|O and|O grossly|O cystic|O ,|O usually|O (|O 18|O cases|O of|O 22|O )|O located|O in|O the|O head|O of|O the|O pancreas|O .|O 
Histologically|O ,|O the|O tumors|O consisted|O of|O intraductal|O papillary|O proliferations|O protruding|O into|O and|O expanding|O the|O pancreatic|O ducts|O .|O 
Invasion|O into|O the|O surrounding|O pancreatic|O parenchyma|O was|O detected|O in|O 15|O cases|O .|O 
Chronic|O pancreatitis|O was|O present|O in|O all|O of|O the|O cases|O .|O 
p27|O immunoreactivity|O always|O exceeded|O the|O immunoreactivity|O of|O cyclin|O E|O .|O 
K-ras|O oncogene|O mutations|O were|O detected|O in|O two|O cases|O .|O 
Patients|O were|O treated|O with|O a|O complete|O surgical|O resection|O (|O n|O =|O 7|O )|O or|O a|O Whipple|O procedure|O (|O n|O =|O 13|O )|O .|O 
Only|O 2|O of|O 22|O patients|O died|O of|O disease|O (|O 3|O died|O immediately|O postoperatively|O and|O 3|O died|O of|O unrelated|O causes|O )|O ,|O whereas|O the|O remaining|O 14|O patients|O were|O alive|O at|O last|O follow|O -|O up|O ,|O without|O evidence|O of|O disease|O ,|O an|O average|O of|O 58.2|O months|O after|O initial|O presentation|O .|O 
IPMNs|O are|O rare|O ,|O distinctive|O neoplasms|O ,|O with|O complex|O intraductal|O papillae|O ,|O that|O can|O be|O easily|O separated|O from|O in|O situ|O ductal|O adenocarcinoma|O and|O mucinous|O cystic|O neoplasms|O .|O 
The|O high|O ratio|O of|O p27|O protein|O to|O cyclin|O E|O supports|O the|O excellent|O prognosis|O of|O these|O neoplasms|O ,|O despite|O the|O presence|O of|O invasion|O and|O K-ras|O oncogene|O mutation|O .|O 
Prognostic|O significance|O of|O K-ras|O codon|variation-location 12|variation-location mutations|O in|O patients|O with|O resected|O stage|O I|O and|O II|O non|O -|O small|O -|O cell|O lung|O cancer|O .|O 
PURPOSE|O :|O 
The|O aim|O of|O this|O study|O was|O to|O investigate|O the|O prognostic|O importance|O of|O codon|variation-location 12|variation-location K-ras|O mutations|O in|O patients|O with|O early|O -|O stage|O non|O -|O small|O -|O cell|O lung|O cancer|O (|O NSCLC|O )|O .|O 
PATIENTS|O AND|O METHODS|O :|O 
We|O identified|O 260|O patients|O with|O surgically|O resected|O stage|O I|O (|O n|O =|O 193|O )|O and|O stage|O II|O (|O n|O =|O 67|O )|O NSCLC|O with|O at|O least|O a|O 5|O -|O year|O follow|O -|O up|O .|O 
We|O performed|O polymerase|O chain|O reaction|O analysis|O of|O DNA|O obtained|O from|O paraffin|O -|O embedded|O NSCLC|O tissue|O ,|O using|O mutation|O -|O specific|O probes|O for|O codon|variation-location 12|variation-location K-ras|O .|O 
RESULTS|O :|O 
K-ras|O mutations|O were|O detected|O in|O 35|O of|O 213|O assessable|O specimens|O (|O 16.4|O %|O )|O .|O 
K-ras|O mutations|O were|O detected|O in|O 27|O of|O 93|O adenocarcinomas|O (|O 29.0|O %|O )|O ,|O one|O of|O 61|O squamous|O cell|O carcinomas|O (|O 1.6|O %|O )|O ,|O five|O of|O 39|O large|O -|O cell|O carcinomas|O (|O 12.8|O %|O )|O ,|O and|O two|O of|O 20|O adenosquamous|O carcinomas|O (|O 10|O %|O )|O (|O P|O =|O .001|O )|O .|O 
G|variation-state-original to|O T|variation-state-altered transversions|variation-type accounted|O for|O 71|O %|O of|O the|O mutations|variation-event .|O 
There|O was|O no|O statistically|O significant|O difference|O in|O overall|O survival|O for|O all|O patients|O with|O K-ras|O mutations|O (|O median|O survival|O ,|O 39|O months|O )|O compared|O with|O patients|O without|O K-ras|O mutations|O (|O median|O survival|O ,|O 53|O months|O ;|O P|O =|O .33|O )|O .|O 
There|O was|O no|O statistically|O significant|O difference|O in|O overall|O or|O disease|O -|O free|O survival|O for|O subgroups|O with|O stage|O I|O disease|O ,|O adenocarcinoma|O ,|O or|O non|O -|O squamous|O cell|O carcinoma|O or|O for|O specific|O amino|O acid|O substitutions|variation-type .|O 
The|O median|O survival|O time|O for|O stage|O II|O patients|O with|O K-ras|O mutations|O was|O 13|O months|O ,|O compared|O with|O 38|O months|O for|O patients|O without|O K-ras|O mutations|O (|O P|O =|O .03|O )|O .|O 
CONCLUSION|O :|O 
Codon|variation-location 12|variation-location K-ras|O mutations|O were|O more|O common|O in|O adenocarcinomas|O than|O in|O squamous|O cell|O carcinomas|O .|O 
For|O the|O subgroup|O with|O stage|O II|O NSCLC|O ,|O there|O was|O a|O statistically|O significant|O adverse|O effect|O on|O survival|O for|O the|O presence|O of|O K-ras|O mutations|O .|O 
However|O ,|O when|O the|O entire|O group|O was|O considered|O ,|O the|O presence|O of|O K-ras|O mutations|O was|O not|O of|O prognostic|O significance|O in|O this|O cohort|O of|O patients|O with|O resected|O early|O -|O stage|O NSCLC|O .|O 
Frequent|O nuclear|O /|O cytoplasmic|O localization|O of|O beta-catenin|O without|O exon|variation-location 3|variation-location mutations|O in|O malignant|O melanoma|O .|O 
Beta-Catenin|O has|O a|O critical|O role|O in|O E-cadherin|O -|O mediated|O cell|O -|O cell|O adhesion|O ,|O and|O it|O also|O functions|O as|O a|O downstream|O signaling|O molecule|O in|O the|O wnt|O pathway|O .|O 
Mutations|O in|O the|O putative|O glycogen|O synthase|O kinase|O 3beta|O phosphorylation|O sites|O near|O the|O beta-catenin|O amino|O terminus|O have|O been|O found|O in|O some|O cancers|O and|O cancer|O cell|O lines|O .|O 
The|O mutations|O render|O beta-catenin|O resistant|O to|O regulation|O by|O a|O complex|O containing|O the|O glycogen|O synthase|O kinase|O 3beta|O ,|O adenomatous|O polyposis|O coli|O ,|O and|O axin|O proteins|O .|O 
As|O a|O result|O ,|O beta-catenin|O accumulates|O in|O the|O cytosol|O and|O nucleus|O and|O activates|O T-cell|O factor|O /|O lymphoid|O enhancing|O factor|O transcription|O factors|O .|O 
Previously|O ,|O 6|O of|O 27|O melanoma|O cell|O lines|O were|O found|O to|O have|O beta-catenin|O exon|variation-location 3|variation-location mutations|O affecting|O the|O N|O -|O terminal|O phosphorylation|O sites|O (|O Rubinfeld|O B|O ,|O Robbins|O P|O ,|O Elgamil|O M|O ,|O Albert|O I|O ,|O Porfiri|O E|O ,|O Polakis|O P|O :|O Stabilization|O of|O beta-catenin|O by|O genetic|O defects|O in|O melanoma|O cell|O lines|O .|O Science|O 1997|O ,|O 275|O :|O 1790|O -|O 1792|O )|O .|O 
To|O assess|O the|O role|O of|O beta-catenin|O defects|O in|O primary|O melanomas|O ,|O we|O undertook|O immunohistochemical|O and|O DNA|O sequencing|O studies|O in|O 65|O melanoma|O specimens|O .|O 
Nuclear|O and/or|O cytoplasmic|O localization|O of|O beta-catenin|O ,|O a|O potential|O indicator|O of|O wnt|O pathway|O activation|O ,|O was|O seen|O focally|O within|O roughly|O one|O third|O of|O the|O tumors|O ,|O though|O a|O clonal|O somatic|O mutation|O in|O beta-catenin|O was|O found|O in|O only|O one|O case|O (|O codon|variation-location 45|variation-location Ser|variation-state-original -->|O Pro|variation-state-altered )|O .|O 
Our|O findings|O demonstrate|O that|O beta-catenin|O mutations|O are|O rare|O in|O primary|O melanoma|O ,|O in|O contrast|O to|O the|O situation|O in|O melanoma|O cell|O lines|O .|O 
Nonetheless|O ,|O activation|O of|O beta-catenin|O ,|O as|O indicated|O by|O its|O nuclear|O and/or|O cytoplasmic|O localization|O ,|O appears|O to|O be|O frequent|O in|O melanoma|O ,|O and|O in|O some|O cases|O ,|O it|O may|O reflect|O focal|O and|O transient|O activation|O of|O the|O wnt|O pathway|O within|O the|O tumor|O .|O 
Beta-catenin|O mutations|O in|O human|O prostate|O cancer|O .|O 
Beta-catenin|O plays|O essential|O roles|O in|O both|O intercellular|O adhesion|O and|O signal|O transduction|O .|O 
As|O a|O signaling|O molecule|O ,|O beta-catenin|O supplies|O an|O activating|O domain|O to|O the|O T-cell|O factor|O /|O lymphoid|O enhancer|O -|O binding|O factor|O family|O of|O DNA|O -|O binding|O proteins|O and|O activates|O gene|O transcription|O .|O 
Posttranslational|O stabilization|O of|O beta-catenin|O ,|O leading|O to|O elevated|O protein|O levels|O and|O constitutive|O gene|O activation|O ,|O has|O been|O proposed|O as|O an|O important|O step|O in|O oncogenesis|O .|O 
Stabilization|O of|O beta-catenin|O can|O occur|O through|O mutation|O to|O highly|O conserved|O amino|O acids|O encoded|O in|O exon|variation-location 3|variation-location of|O the|O beta-catenin|O gene|O (|O CTNNB1|O )|O .|O 
To|O determine|O whether|O this|O pathway|O of|O malignant|O transformation|O is|O important|O in|O prostate|O cancer|O ,|O we|O analyzed|O 104|O prostate|O cancer|O tissue|O specimens|O ,|O 4|O prostate|O cancer|O cell|O lines|O ,|O and|O 3|O prostate|O tumor|O xenografts|O for|O activating|O mutations|O in|O exon|variation-location 3|variation-location of|O CTNNB1|O .|O 
Mutations|O were|O detected|O in|O 5|O of|O the|O 104|O prostate|O cancer|O tissue|O samples|O .|O 
Four|O of|O the|O five|O mutations|O involved|O serine|O or|O threonine|O residues|O implicated|O in|O the|O degradation|O of|O beta-catenin|O .|O 
A|O fifth|O tumor|O had|O a|O mutation|variation-event at|O codon|variation-location 32|variation-location ,|O changing|O a|O highly|O conserved|O aspartic|variation-state-original acid|variation-state-original to|O a|O tyrosine|variation-state-altered .|O 
Mutational|O analysis|O of|O multiple|O regions|O from|O several|O tumor|O samples|O showed|O that|O the|O beta-catenin|O mutations|O were|O present|O focally|O and|O therefore|O may|O occur|O during|O tumor|O progression|O .|O 
K-ras|O mutations|O in|O sinonasal|O adenocarcinomas|O in|O patients|O occupationally|O exposed|O to|O wood|O or|O leather|O dust|O .|O 
Of|O 39|O males|O diagnosed|O with|O sinonasal|O adenocarcinomas|O over|O 30|O years|O in|O the|O Lund|O University|O Hospital|O catchment|O area|O (|O 1.5|O million|O inhabitants|O )|O ,|O archival|O tumor|O tissue|O was|O available|O from|O 29|O .|O 
Of|O these|O ,|O 16|O had|O been|O exposed|O to|O wood|O dust|O and|O three|O had|O been|O exposed|O to|O leather|O dust|O .|O 
The|O intestinal|O -|O type|O and|O papillary|O adenocarcinomas|O were|O more|O common|O in|O the|O exposed|O patients|O (|O P|O =|O 0.0002|O ,|O Fisher|O 's|O exact|O test|O )|O .|O 
The|O tumors|O from|O all|O but|O one|O of|O the|O 29|O sinonasal|O adenocarcinomas|O could|O be|O analyzed|O for|O point|variation-type mutations|variation-type at|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location of|O the|O K-ras|O gene|O .|O 
Four|O mutations|O were|O detected|O in|O the|O 28|O tumors|O .|O 
The|O three|O mutations|O in|O the|O patients|O exposed|O to|O wood|O and|O leather|O dust|O were|O all|O G|variation-state-original :|O C|variation-state-original -->|O A|variation-state-altered :|O T|variation-state-altered transitions|variation-type ,|O with|O two|O at|O position|variation-location 2|variation-location of|variation-location codon|variation-location 12|variation-location and|O one|O at|O position|variation-location 2|variation-location of|variation-location codon|variation-location 13|variation-location .|O 
The|O high|O proportion|O of|O G|variation-state-original :|O C|variation-state-original -->|O A|variation-state-altered :|O T|variation-state-altered mutations|O in|O this|O rare|O tumor|O may|O reflect|O a|O genotoxic|O agent|O in|O wood|O and|O leather|O dust|O .|O 
Mutational|O analysis|O of|O the|O APC|O /|O beta-catenin|O /|O Tcf|O pathway|O in|O colorectal|O cancer|O .|O 
Mutation|O of|O the|O adenomatous|O polyposis|O coli|O (|O APC|O )|O tumor|O suppressor|O gene|O initiates|O the|O majority|O of|O colorectal|O (|O CR|O )|O cancers|O .|O 
One|O consequence|O of|O this|O inactivation|O is|O constitutive|O activation|O of|O beta-catenin|O /|O Tcf|O -|O mediated|O transcription|O .|O 
To|O further|O explore|O the|O role|O of|O the|O APC|O /|O beta-catenin|O /|O Tcf|O pathway|O in|O CR|O tumorigenesis|O ,|O we|O searched|O for|O mutations|O in|O genes|O implicated|O in|O this|O pathway|O in|O CR|O tumors|O lacking|O APC|O mutations|O .|O 
No|O mutations|O of|O the|O gamma-catenin|O (|O CTNNG1|O )|O ,|O GSK-3alpha|O (|O GSK3A|O )|O ,|O or|O GSK-3beta|O (|O GSK3B|O )|O genes|O were|O detected|O .|O 
In|O contrast|O ,|O mutations|O in|O the|O NH2|O -|O terminal|O regulatory|O domain|O of|O beta-catenin|O (|O CTNNB1|O )|O were|O found|O in|O 13|O of|O 27|O (|O 48|O %|O )|O CR|O tumors|O lacking|O APC|O mutations|O .|O 
Mutations|O in|O the|O beta-catenin|O regulatory|O domain|O and|O APC|O were|O observed|O to|O be|O mutually|O exclusive|O ,|O consistent|O with|O their|O equivalent|O effects|O on|O beta-catenin|O stability|O and|O Tcf|O transactivation|O .|O 
In|O addition|O ,|O we|O found|O that|O CTNNB1|O mutations|O can|O occur|O in|O the|O early|O ,|O adenomatous|O stage|O of|O CR|O neoplasia|O ,|O as|O has|O been|O observed|O previously|O with|O APC|O mutations|O .|O 
These|O results|O suggest|O that|O CTNNB1|O mutations|O can|O uniquely|O substitute|O for|O APC|O mutations|O in|O CR|O tumors|O and|O that|O beta-catenin|O signaling|O plays|O a|O critical|O role|O in|O CR|O tumorigenesis|O .|O 
K-ras|O point|variation-type mutation|variation-type occurs|O in|O the|O early|O stage|O of|O carcinogenesis|O in|O lung|O cancer|O .|O 
In|O order|O to|O determine|O the|O topographical|O distribution|O of|O the|O K-ras|O codon|variation-location 12|variation-location mutations|O in|O carcinoma|O and|O preneoplastic|O lesions|O of|O the|O lung|O ,|O selective|O ultraviolet|O radiation|O fractionation|O ,|O as|O well|O as|O microdissection|O followed|O by|O polymerase|O chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O (|O PCR|O -|O RELP|O )|O ,|O was|O performed|O .|O 
Fourteen|O of|O 61|O samples|O amplified|O (|O 23.0|O %|O )|O had|O a|O mutation|variation-event in|O the|O K-ras|O codon|variation-location 12|variation-location .|O 
Of|O 41|O adenocarcinoma|O ,|O 12|O samples|O (|O 29.3|O %|O )|O had|O a|O mutation|O ,|O whereas|O none|O of|O the|O squamous|O cell|O carcinomas|O had|O a|O mutation|O .|O 
One|O of|O six|O large|O -|O cell|O carcinomas|O ,|O one|O of|O three|O carcinoid|O tumours|O and|O none|O of|O three|O other|O carcinomas|O had|O a|O mutation|variation-event .|O 
Direct|O sequencing|O revealed|O that|O K-ras|O codon|variation-location 12|variation-location of|O six|O samples|O were|O TGT|variation-state-generic (|O Cys|variation-state-generic )|O ,|O five|O samples|O were|O GTT|variation-state-generic (|O Val|variation-state-generic )|O ,|O two|O samples|O were|O GCT|variation-state-generic (|O Ala|variation-state-generic )|O and|O one|O sample|O was|O TTT|variation-state-generic (|O Phe|variation-state-generic )|O .|O 
A|O total|O of|O 113|O lesions|O of|O 13|O cases|O covered|O by|O dot|O were|O amplified|O after|O UV|O radiation|O .|O 
All|O of|O 74|O carcinoma|O lesions|O had|O the|O mutation|variation-event ,|O and|O intratumour|O heterogeneity|O was|O not|O observed|O .|O 
Of|O 39|O non|O -|O malignant|O lesions|O ,|O one|O type|O II|O cell|O hyperplasia|O had|O the|O mutation|variation-event ,|O which|O suggests|O that|O the|O K-ras|O mutation|O occurs|O in|O the|O early|O stage|O of|O carcinogenesis|O .|O 
The|O lack|O of|O intratumour|O heterogeneity|O supports|O the|O hypothesis|O .|O 
Molecular|O analysis|O of|O occupational|O cancer|O :|O infrequent|O p53|O and|O ras|O mutations|O in|O renal|O -|O cell|O cancer|O in|O workers|O exposed|O to|O gasoline|O .|O 
Occupational|O exposure|O to|O gasoline|O has|O been|O identified|O in|O several|O studies|O as|O a|O risk|O factor|O for|O renal|O -|O cell|O cancer|O .|O 
Cases|O of|O renal|O -|O cell|O cancer|O with|O and|O without|O work|O -|O related|O exposure|O to|O gasoline|O or|O gasoline|O and|O diesel|O fuel|O were|O studied|O for|O the|O presence|O of|O mutations|O in|O the|O tumour|O -|O suppressor|O gene|O p53|O (|O n|O =|O 23|O exposed|O and|O 30|O non|O -|O exposed|O cases|O studied|O )|O and|O ras|O oncogene|O (|O n|O =|O 30|O exposed|O and|O 36|O non|O -|O exposed|O cases|O studied|O )|O .|O 
An|O average|O cumulative|O exposure|O was|O estimated|O at|O 10|O ppm|O -|O years|O benzene|O among|O the|O exposed|O .|O 
Three|O p53|O mutations|O were|O detected|O by|O denaturing|O -|O gradient|O gel|O electrophoresis|O (|O DGGE|O )|O among|O the|O 23|O exposed|O cases|O (|O 3|O /|O 23|O ,|O 13|O %|O )|O .|O 
Of|O the|O non|O -|O exposed|O referent|O cases|O ,|O 4|O had|O a|O mutation|O (|O 4|O /|O 30|O ,|O 13|O %|O )|O .|O 
All|O but|O one|O of|O the|O cases|O with|O a|O p53|O mutation|O had|O smoked|O .|O 
A|O ras|O gene|O (|O K-ras|O or|O N-ras|O )|O mutation|O was|O found|O in|O 3|O (|O 3|O /|O 66|O ,|O 4.5|O %|O )|O cases|O ,|O all|O of|O whom|O were|O smoker|O referents|O .|O 
We|O conclude|O that|O p53|O and|O ras|O mutations|O are|O infrequent|O in|O renal|O -|O cell|O cancer|O associated|O with|O occupational|O exposure|O to|O gasoline|O .|O 
However|O ,|O the|O majority|O of|O the|O mutations|O (|O 6|O /|O 7|O for|O p53|O ,|O and|O 3|O /|O 3|O for|O ras|O genes|O )|O were|O seen|O in|O smokers|O .|O 
Mutations|O of|O the|O RAS|O genes|O in|O childhood|O acute|O myeloid|O leukemia|O ,|O myelodysplastic|O syndrome|O and|O juvenile|O chronic|O myelocytic|O leukemia|O .|O 
Using|O the|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O method|O and|O direct|O sequencing|O ,|O 12|O acute|O myeloid|O leukemia|O (|O AML|O )|O cell|O lines|O and|O 108|O fresh|O childhood|O myeloid|O tumor|O specimens|O ,|O including|O 67|O AML|O ,|O 29|O myelodysplastic|O syndrome|O (|O MDS|O )|O ,|O and|O 12|O juvenile|O chronic|O myelocytic|O leukemia|O (|O JCML|O )|O were|O examined|O for|O mutation|O in|O H|O -|O ,|O K|O -|O ,|O and|O N|O -|O RAS|O genes|O .|O 
The|O mutation|O was|O found|O in|O eight|O of|O the|O 120|O samples|O (|O 6.7|O %|O )|O ,|O which|O consisted|O of|O four|O cell|O lines|O (|O 33.3|O %|O )|O and|O four|O fresh|O myeloid|O tumors|O (|O 3.7|O %|O )|O .|O 
The|O frequency|O of|O the|O mutation|O in|O the|O cell|O lines|O was|O apparently|O higher|O than|O that|O in|O fresh|O myeloid|O tumors|O .|O 
K-RAS|O gene|O mutations|O were|O found|O in|O two|O of|O the|O 67|O fresh|O AML|O specimens|O (|O 3|O %|O )|O .|O 
Interestingly|O ,|O these|O two|O patients|O had|O 11q23|variation-location translocations|variation-type .|O 
The|O N-RAS|O gene|O mutation|O was|O found|O in|O one|O of|O the|O 29|O specimens|O (|O 3.4|O %|O )|O of|O MDS|O and|O in|O one|O of|O the|O 12|O specimens|O (|O 8.3|O %|O )|O of|O JCML|O .|O 
All|O mutations|variation-event were|O found|O in|O codon|variation-location 12|variation-location ,|O 13|variation-location or|O 61|variation-location of|O the|O N-RAS|O and|O K-RAS|O genes|O .|O 
Frequency|O of|O mutation|O of|O RAS|O genes|O in|O fresh|O myeloid|O malignancies|O was|O very|O low|O .|O 
These|O findings|O suggest|O that|O mutation|O of|O RAS|O genes|O does|O not|O play|O an|O important|O role|O in|O the|O development|O of|O childhood|O myeloid|O malignancies|O .|O 
Frequent|O somatic|O mutations|O of|O the|O APC|O and|O p53|O genes|O in|O sporadic|O ampullary|O carcinomas|O .|O 
Although|O a|O close|O relation|O of|O somatic|O mutations|O of|O the|O adenomatous|O polyposis|O coli|O gene|O with|O ampullary|O carcinomas|O in|O familial|O adenomatous|O polyposis|O patients|O has|O been|O reported|O ,|O the|O possible|O association|O with|O sporadic|O ampullary|O neoplasms|O has|O not|O been|O fully|O examined|O .|O 
We|O have|O therefore|O investigated|O loss|variation-type of|variation-type heterozygosity|variation-type at|O the|O adenomatous|O polyposis|O coli|O locus|O and|O the|O mutational|O status|O of|O a|O portion|O of|O the|O adenomatous|O polyposis|O coli|O gene|O ,|O including|O the|O mutation|O cluster|O region|O ,|O in|O 17|O ampullary|O carcinomas|O of|O non|O -|O familial|O adenomatous|O polyposis|O patients|O .|O 
Alteration|O of|O the|O adenomatous|O polyposis|O coli|O gene|O was|O found|O in|O 8|O of|O 17|O (|O 47.1|O %|O )|O cases|O ,|O as|O missense|variation-type or|O insertion|variation-type mutations|variation-event ,|O with|O or|O without|O loss|variation-type of|variation-type heterozygosity|variation-type .|O 
Additional|O investigation|O of|O p53|O (|O exons|variation-location 5|variation-location -|variation-location 8|variation-location )|O and|O K-ras|O (|O codons|variation-location 12|variation-location and|O 13|variation-location )|O gene|O mutations|O revealed|O a|O striking|O mutational|O pattern|O of|O the|O p53|O gene|O .|O 
Nine|O of|O the|O 17|O cases|O demonstrated|O a|O total|O of|O 12|O mutations|variation-event ,|O 6|O clustered|O at|O codon|variation-location 189|variation-location and|O 3|O at|O codon|variation-location 166|variation-location .|O 
Furthermore|O ,|O 5|O of|O the|O 12|O mutations|variation-event were|O nonsense|variation-type mutations|variation-type .|O 
Regarding|O the|O K-ras|O gene|O ,|O 4|O of|O the|O 17|O (|O 23.5|O %|O )|O cases|O had|O mutations|variation-event in|O codon|variation-location 12|variation-location ,|O 3|O of|O the|O 4|O cases|O being|O derived|O from|O the|O intraduodenal|O bile|O duct|O .|O 
The|O findings|O indicate|O that|O alterations|O of|O the|O adenomatous|O polyposis|O coli|O and|O the|O p53|O genes|O are|O relatively|O frequent|O in|O sporadic|O ampullary|O carcinomas|O .|O 
In|O particular|O ,|O the|O clustering|O at|O specific|O p53|O codons|O might|O offer|O an|O etiological|O clue|O to|O clarify|O ampullary|O carcinogenesis|O .|O 
Mutations|O of|O the|O K-ras|O gene|O ,|O on|O the|O other|O hand|O ,|O might|O be|O characteristic|O of|O intraduodenal|O bile|O duct|O origin|O .|O 
Frequent|O translocation|variation-type t|variation-type (|O 4|variation-state-original ;|O 14|variation-state-altered )|O (|O p16.3|variation-state-original ;|O q32.3|variation-state-altered )|O in|O multiple|O myeloma|O is|O associated|O with|O increased|O expression|O and|O activating|O mutations|O of|O fibroblast|O growth|O factor|O receptor|O 3|O .|O 
Dysregulation|O of|O oncogenes|O by|O translocation|variation-type to|O the|O IgH|O locus|O (|O 14q32|variation-location )|O is|O a|O seminal|O event|O in|O the|O pathogenesis|O of|O B-cell|O tumours|O .|O 
In|O multiple|O myeloma|O (|O MM|O )|O ,|O translocations|variation-type to|O the|O IgH|O locus|O have|O been|O reported|O at|O an|O incidence|O of|O 20|O -|O 60|O %|O .|O 
For|O most|O translocations|variation-type ,|O the|O partner|O chromosome|O is|O unknown|O (|O 14q|variation-location +|variation-location )|O ;|O for|O the|O others|O ,|O a|O diverse|O array|O of|O chromosomal|O partners|O have|O been|O identified|O ,|O with|O 11q13|variation-location (|O cyclin|O D1|O )|O the|O only|O chromosome|O that|O is|O frequently|O involved|O .|O 
Recently|O ,|O we|O developed|O a|O Southern|O -|O blot|O assay|O that|O detects|O translocation|variation-type breakpoint|O fragments|O in|O most|O MM|O tumours|O ,|O including|O those|O with|O no|O translocation|variation-type detected|O by|O conventional|O karyotyping|O .|O 
In|O a|O continuing|O analysis|O of|O translocation|variation-type in|O 21|O myeloma|O cell|O lines|O and|O primary|O tumours|O ,|O we|O show|O that|O the|O novel|O ,|O karyotypically|O silent|O translocation|variation-type t|variation-type (|O 4|variation-state-original ;|O 14|variation-state-altered )|O (|O p16.3|variation-state-original ;|O q32.3|variation-state-altered )|O is|O present|O in|O five|O lines|O and|O at|O least|O three|O of|O ten|O primary|O tumours|O .|O 
The|O chromosome|variation-location -|variation-location 4|variation-location breakpoints|O are|O clustered|O in|O a|O 70|O -|O kb|O region|O centromeric|O to|O the|O fibroblast|O growth|O factor|O receptor|O 3|O gene|O (|O FGFR3|O )|O ,|O the|O apparent|O dysregulated|O oncogene|O .|O 
Two|O lines|O and|O one|O primary|O tumour|O with|O this|O translocation|variation-type selectively|O express|O an|O FGFR3|O allele|O containing|O activating|O mutations|O identified|O previously|O in|O thanatophoric|O dwarfism|O .|O 
We|O propose|O that|O after|O the|O t|variation-type (|O 4|variation-state-original ;|O 14|variation-state-altered )|O translocation|variation-type ,|O somatic|O mutation|O during|O tumour|O progression|O frequently|O generates|O in|O FGFR3|O protein|O that|O is|O active|O in|O the|O absence|O of|O ligand|O .|O 
No|O concomitant|O occurrence|O of|O the|O N-ras|O and|O p53|O gene|O mutations|O in|O myelodysplastic|O syndromes|O .|O 
Mutations|O of|O the|O N-ras|O oncogene|O and|O p53|O tumor|O suppressor|O gene|O were|O simultaneously|O investigated|O in|O bone|O marrow|O cells|O from|O 44|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O MDS|O -|O derived|O leukemia|O by|O single|O -|O strand|O conformation|O polymorphism|O (|O SSCP|O )|O analysis|O followed|O by|O direct|O sequencing|O .|O 
The|O mutations|O of|O the|O N-ras|O gene|O were|O detected|O only|O in|O two|O cases|O with|O MDS|O -|O derived|O leukemia|O .|O 
Three|O patients|O with|O MDS|O -|O derived|O leukemia|O and|O one|O with|O refractory|O anemia|O with|O excess|O of|O blasts|O exhibited|O five|O mutations|O of|O the|O p53|O gene|O .|O 
No|O concomitant|O mutations|O of|O both|O genes|O were|O observed|O in|O our|O study|O ,|O suggesting|O that|O alterations|O of|O both|O genes|O could|O play|O an|O important|O role|O in|O the|O progression|O of|O MDS|O in|O a|O non|O -|O cooperative|O manner|O .|O 
c-kit|O Point|variation-type mutation|variation-type in|O patients|O with|O myeloproliferative|O disorders|O .|O 
Myeloproliferative|O disorders|O (|O MPD|O )|O constitute|O a|O group|O of|O hematopoietic|O neoplasms|O at|O the|O myeloid|O stem|O cell|O level|O .|O 
Myeloid|O stem|O cells|O and/or|O progenitor|O cells|O from|O MPD|O have|O been|O considered|O sensitive|O to|O hematopoietic|O growth|O factors|O ,|O including|O erythropoietin|O ,|O thrombopoietin|O and|O stem|O cell|O factor|O (|O SCF|O )|O .|O 
SCF|O is|O a|O ligand|O for|O c-kit|O receptor|O with|O tyrosine|O kinase|O .|O 
We|O analysed|O the|O gene|O alteration|O of|O the|O c-kit|O extracellular|O domain|O in|O MPD|O patients|O by|O PCR|O -|O SSCP|O and|O subsequent|O nucleotide|O sequencing|O .|O 
The|O point|variation-type mutation|variation-type in|O the|O N|O -|O terminal|O part|O of|O the|O domain|O ,|O codon|variation-location 52|variation-location (|O Asp|variation-state-original -->|O Asn|variation-state-altered )|O ,|O was|O found|O in|O two|O patients|O with|O primary|O myelofibrosis|O and|O one|O with|O chronic|O myelogenous|O leukemia|O .|O 
We|O review|O the|O literature|O regarding|O the|O role|O of|O SCF|O /|O c-kit|O system|O in|O the|O oncogenesis|O of|O leukemia|O and|O MPD|O ,|O and|O then|O discuss|O the|O significance|O of|O our|O finding|O in|O the|O context|O of|O growth|O advantage|O of|O the|O mutated|O clones|O over|O the|O normal|O clones|O .|O 
N-ras|O gene|O point|variation-type mutations|variation-type in|O Brazilian|O acute|O myelogenous|O leukemia|O patients|O correlate|O with|O a|O poor|O prognosis|O .|O 
The|O frequency|O of|O ras|O gene|O mutations|O varies|O from|O 11|O to|O 27|O %|O in|O AML|O populations|O from|O the|O United|O States|O and|O Europe|O but|O it|O seems|O that|O there|O is|O no|O study|O regarding|O the|O frequency|O of|O mutated|O N-ras|O gene|O in|O patients|O with|O AML|O in|O South|O America|O .|O 
In|O order|O to|O study|O the|O frequency|O of|O N-ras|O gene|O mutations|O (|O exons|variation-location 1|variation-location and|O 2|variation-location )|variation-location in|O Brazilian|O patients|O with|O AML|O and|O to|O evaluate|O the|O possible|O correlation|O between|O the|O presence|O of|O the|O mutation|variation-event and|O clinical|O features|O ,|O 40|O patients|O were|O analyzed|O .|O 
N-ras|O mutations|O were|O identified|O in|O DNA|O samples|O from|O eight|O of|O 40|O AML|O patients|O (|O 20|O %|O )|O .|O 
No|O significant|O correlation|O was|O found|O between|O N-ras|O mutation|O and|O age|O ,|O sex|O ,|O race|O ,|O response|O to|O therapy|O ,|O FAB|O subtype|O or|O occupational|O exposure|O .|O 
However|O ,|O the|O overall|O survival|O and|O AML|O -|O free|O survival|O were|O significantly|O shorter|O in|O patients|O with|O N-ras|O mutations|O than|O in|O those|O without|O these|O abnormalities|O .|O 
Germline|O and|O somatic|O mutations|O in|O the|O tyrosine|O kinase|O domain|O of|O the|O MET|O proto|O -|O oncogene|O in|O papillary|O renal|O carcinomas|O .|O 
Hereditary|O papillary|O renal|O carcinoma|O (|O HPRC|O )|O is|O a|O recently|O recognized|O form|O of|O inherited|O kidney|O cancer|O characterized|O by|O a|O predisposition|O to|O develop|O multiple|O ,|O bilateral|O papillary|O renal|O tumours|O .|O 
The|O pattern|O of|O inheritance|O of|O HPRC|O is|O consistent|O with|O autosomal|O dominant|O transmission|O with|O reduced|O penetrance|O .|O 
HPRC|O is|O histologically|O and|O genetically|O distinct|O from|O two|O other|O causes|O of|O inherited|O renal|O carcinoma|O ,|O von|O Hippel|O -|O Lindau|O disease|O (|O VHL|O )|O and|O the|O chromosome|O translocation|variation-type (|O 3|variation-state-original ;|O 8|variation-state-altered )|O .|O 
Malignant|O papillary|O renal|O carcinomas|O are|O characterized|O by|O trisomy|variation-type of|O chromosomes|variation-location 7|variation-location ,|O 16|variation-location and|O 17|variation-location ,|O and|O in|O men|O ,|O by|O loss|variation-type of|O the|O Y|variation-location chromosome|variation-location .|O 
Inherited|O and|O sporadic|O clear|O cell|O renal|O carcinomas|O are|O characterized|O by|O inactivation|O of|O both|O copies|O of|O the|O VHL|O gene|O by|O mutation|O ,|O and/or|O by|O hypermethylation|O .|O 
We|O found|O that|O the|O HPRC|O gene|O was|O located|O at|O chromosome|variation-location 7q|variation-location 31|variation-location .|variation-location 1|variation-location -|variation-location 34|variation-location in|variation-location a|variation-location 27|variation-location -|variation-location centimorgan|variation-location (|variation-location cM|variation-location )|variation-location interval|variation-location between|variation-location D7S496|variation-location and|variation-location D7S1837|variation-location .|O 
We|O identified|O missense|variation-type mutations|variation-type located|O in|O the|O tyrosine|O kinase|O domain|O of|O the|O MET|O gene|O in|O the|O germline|O of|O affected|O members|O of|O HPRC|O families|O and|O in|O a|O subset|O of|O sporadic|O papillary|O renal|O carcinomas|O .|O 
Three|O mutations|O in|O the|O MET|O gene|O are|O located|O in|O codons|O that|O are|O homologous|O to|O those|O in|O c-kit|O and|O RET|O ,|O proto|O -|O oncogenes|O that|O are|O targets|O of|O naturally|O -|O occurring|O mutations|O .|O 
The|O results|O suggest|O that|O missense|variation-type mutations|variation-type located|O in|O the|O MET|O proto|O -|O oncogene|O lead|O to|O constitutive|O activation|O of|O the|O MET|O protein|O and|O papillary|O renal|O carcinomas|O .|O 
Stabilization|O of|O beta-catenin|O by|O genetic|O defects|O in|O melanoma|O cell|O lines|O .|O 
Signal|O transduction|O by|O beta-catenin|O involves|O its|O posttranslational|O stabilization|O and|O downstream|O coupling|O to|O the|O Lef|O and|O Tcf|O transcription|O factors|O .|O 
Abnormally|O high|O amounts|O of|O beta-catenin|O were|O detected|O in|O 7|O of|O 26|O human|O melanoma|O cell|O lines|O .|O 
Unusual|O messenger|O RNA|O splicing|O and|O missense|variation-type mutations|variation-type in|O the|O beta-catenin|O gene|O (|O CTNNB1|O )|O that|O result|O in|O stabilization|O of|O the|O protein|O were|O identified|O in|O six|O of|O the|O lines|O ,|O and|O the|O adenomatous|O polyposis|O coli|O tumor|O suppressor|O protein|O (|O APC|O )|O was|O altered|O or|O missing|O in|O two|O others|O .|O 
In|O the|O APC|O -|O deficient|O cells|O ,|O ectopic|O expression|O of|O wild|O -|O type|O APC|O eliminated|O the|O excess|O beta-catenin|O .|O 
Cells|O with|O stabilized|O beta-catenin|O contained|O a|O constitutive|O beta-catenin|O -|O Lef-1|O complex|O .|O 
Thus|O ,|O genetic|O defects|O that|O result|O in|O up|O -|O regulation|O of|O beta-catenin|O may|O play|O a|O role|O in|O melanoma|O progression|O .|O 
Prevalence|O of|O activating|O ras|O mutations|O in|O morphologically|O characterized|O thyroid|O nodules|O .|O 
Ras|O proteins|O are|O signal|O -|O transducing|O proteins|O that|O share|O common|O properties|O with|O membrane|O -|O anchored|O G|O proteins|O .|O 
Mutations|O at|O codon|variation-location 12|variation-location /|O 13|variation-location or|O codon|variation-location 61|variation-location alter|O GTP|O -|O binding|O or|O GTPase|O activity|O ,|O respectively|O .|O 
Such|O activating|O mutations|variation-event are|O present|O in|O nearly|O 30|O -|O 50|O %|O of|O various|O malignancies|O including|O colon|O ,|O breast|O ,|O and|O lung|O carcinomas|O .|O 
There|O are|O conflicting|O data|O regarding|O the|O prevalence|O of|O ras|O mutations|O in|O the|O thyroid|O and|O their|O possible|O pathogenetic|O role|O in|O the|O different|O tumor|O types|O .|O 
To|O address|O this|O question|O ,|O we|O examined|O 45|O morphologically|O characterized|O thyroid|O carcinomas|O ,|O adenomas|O ,|O and|O hyperplastic|O nodules|O using|O a|O highly|O sensitive|O single|O -|O stranded|O conformation|O polymorphism|O (|O SSCP|O )|O approach|O combined|O with|O DNA|O -|O sequencing|O .|O 
DNA|O from|O cell|O lines|O with|O known|O mutations|variation-event served|O as|O controls|O .|O 
A|O G|variation-state-original to|O A|variation-state-altered H|O 13|variation-location codon|variation-location substitution|variation-type replacing|O an|O Asp|variation-state-original for|O a|O Gly|variation-state-altered residue|O was|O detected|O in|O 1|O papillary|O carcinoma|O .|O 
Although|O no|O H|O 12|variation-location or|O H|O 61|variation-location codon|variation-location substitutions|variation-type were|O identified|O ,|O 2|O discrete|O alterations|O were|O identified|O in|O codons|variation-location H|O 17|variation-location and|O 22|variation-location .|O 
No|O N|O 12|variation-location /|O 13|variation-location codon|variation-location substitutions|variation-type were|O identified|O .|O 
N|O 61|variation-location codon|variation-location substitutions|variation-type of|O A|variation-state-original to|O G|variation-state-altered resulting|O in|O a|O Gly|variation-state-original to|O Arg|variation-state-altered substitution|variation-type were|O detected|O in|O 2|O papillary|O carcinomas|O ;|O the|O same|O mutation|variation-event was|O also|O found|O in|O one|O follicular|O adenoma|O .|O 
Interestingly|O ,|O K|O 12|variation-location /|O 13|variation-location and|O K|O 61|variation-location ras|O mutations|O were|O not|O present|O in|O any|O of|O the|O tumors|O examined|O .|O 
These|O data|O establish|O a|O low|O prevalence|O of|O mutations|O in|O all|O ras|O gene|O family|O members|O in|O human|O thyroid|O neoplasms|O .|O 
This|O difference|O from|O neoplasms|O of|O other|O organs|O may|O explain|O the|O relatively|O indolent|O biologic|O behavior|O of|O many|O thyroid|O tumors|O and|O supports|O an|O alternate|O early|O genetic|O mutation|O that|O is|O more|O characteristic|O of|O these|O neoplasms|O .|O 
Relevance|O of|O ultraviolet|O -|O induced|O N-ras|O oncogene|O point|variation-type mutations|variation-type in|O development|O of|O primary|O human|O cutaneous|O melanoma|O .|O 
Intermittent|O or|O recreational|O exposure|O to|O sunlight|O is|O thought|O to|O contribute|O to|O development|O of|O human|O cutaneous|O melanoma|O .|O 
We|O investigated|O the|O incidence|O of|O ras|O oncogene|O mutation|O in|O human|O cutaneous|O melanoma|O in|O connection|O to|O sun|O -|O exposed|O body|O sites|O in|O the|O patient|O ,|O using|O a|O large|O series|O of|O DNA|O samples|O derived|O from|O paraffin|O -|O embedded|O material|O as|O well|O as|O from|O fresh|O tumor|O samples|O and|O cell|O lines|O .|O 
We|O first|O show|O that|O ,|O of|O the|O ras|O family|O ,|O predominantly|O N-ras|O is|O activated|O (|O 15|O %|O )|O ,|O whereas|O rarely|O H-ras|O or|O K-ras|O are|O mutated|O .|O 
The|O occurrence|O of|O N-ras|O mutations|O correlates|O with|O continuous|O exposure|O to|O sunlight|O of|O the|O primary|O tumor|O site|O .|O 
Of|O all|O tumors|O initiated|O on|O chronically|O sun|O -|O exposed|O body|O sites|O ,|O 26|O %|O contained|O mutated|O N-ras|O ,|O in|O contrast|O to|O 0|O %|O of|O sun|O -|O protected|O melanomas|O .|O 
Melanoma|O lesions|O obtained|O from|O patients|O from|O North|O or|O Central|O Europe|O contained|O fewer|O N-ras|O mutations|O (|O 12|O %|O )|O as|O compared|O with|O patients|O from|O Australia|O (|O 24|O %|O )|O .|O 
Mutations|O were|O specifically|O associated|O with|O nodular|O melanoma|O and|O to|O a|O lesser|O extent|O with|O lentigo|O malignant|O melanoma|O .|O 
N-ras|O mutations|O did|O not|O correlate|O with|O metastasis|O or|O survival|O parameters|O .|O 
This|O study|O identifies|O a|O subset|O of|O cutaneous|O melanomas|O that|O contain|O in|O the|O primary|O lesion|O ultraviolet|O -|O induced|O N-ras|O mutations|O ,|O which|O are|O maintained|O through|O further|O progression|O .|O 
N-ras|O and|O p53|O gene|O mutations|O are|O very|O rare|O events|O in|O multiple|O myeloma|O .|O 
The|O frequencies|O of|O p53|O and|O N-ras|O gene|O mutations|O were|O examined|O in|O multiple|O myeloma|O .|O 
DNA|O samples|O of|O 45|O cases|O of|O multiple|O myeloma|O were|O obtained|O from|O stored|O bone|O marrow|O smears|O .|O 
All|O samples|O were|O analyzed|O for|O the|O N-ras|O gene|O at|O codon|variation-location 12|variation-location by|O the|O allele|O specific|O restriction|O analysis|O method|O and|O at|O codon|variation-location 61|variation-location by|O direct|O sequencing|O .|O 
DNA|O was|O screened|O for|O mutations|variation-event by|O single|O -|O strand|O conformation|O polymorphism|O analysis|O for|O the|O p53|O gene|O in|O exons|variation-location 5|variation-location to|variation-location 8|variation-location .|O 
DNA|O fragments|O showing|O an|O altered|O electrophoretic|O pattern|O were|O further|O studied|O by|O direct|O sequencing|O to|O confirm|O the|O mutations|O .|O 
Ras|O mutations|O were|O found|O in|O two|O cases|O at|O codon|variation-location 61|variation-location (|O 4.4|O %|O )|O .|O 
A|O point|variation-type mutation|variation-type of|O the|O p53|O gene|O was|O detected|O in|O one|O of|O 45|O cases|O (|O 2.2|O %|O )|O .|O 
These|O 3|O cases|O with|O mutations|variation-event were|O in|O an|O advanced|O stage|O .|O 
In|O conclusion|O ,|O N-ras|O and|O p53|O gene|O mutations|O may|O occur|O at|O a|O late|O stage|O of|O multiple|O myeloma|O ,|O but|O the|O frequencies|O of|O the|O mutations|variation-event are|O very|O low|O .|O 
Detection|O of|O c-ras|O gene|O mutation|O and|O expression|O of|O p21|O protein|O in|O dysplasias|O and|O carcinomas|O complicating|O ulcerative|O colitis|O .|O 
Point|variation-type mutations|variation-type of|O c-ras|O genes|O and|O the|O expression|O of|O p21|O protein|O were|O analyzed|O in|O 13|O patients|O with|O colorectal|O carcinoma|O complicating|O ulcerative|O colitis|O ;|O in|O 12|O of|O the|O 13|O ,|O there|O were|O dysplastic|O lesions|O close|O to|O the|O carcinomas|O .|O 
Point|variation-type mutations|variation-type of|O c-ras|O genes|O were|O studied|O by|O polymerase|O chain|O reaction|O and|O dot|O blot|O hybridization|O with|O 32p|O -|O labeled|O oligonucleotide|O probes|O .|O 
Findings|O indicated|O mutations|O of|O c-Ki-ras|O at|O condons|variation-location 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location and|O c-Ha-ras|O and|O c-N-ras|O at|O condons|variation-location 12|variation-location and|O 61|variation-location .|O 
The|O expression|O of|O p21|O protein|O was|O analyzed|O by|O immunohistochemical|O staining|O using|O a|O monoclonal|O antibody|O .|O 
Only|O 1|O of|O the|O 13|O patients|O with|O carcinoma|O showed|O a|O point|variation-type mutation|variation-type ,|O this|O being|O from|O G|variation-state-original to|O A|variation-state-altered transition|variation-type at|O the|O second|variation-location position|variation-location of|variation-location codon|variation-location 12|variation-location of|O c-Ki-ras|O .|O 
No|O point|variation-type mutations|variation-type of|O c-Ki-ras|O ,|O c-Ha-ras|O ,|O or|O c-N-ras|O were|O found|O in|O other|O carcinomatous|O lesions|O and|O dysplasias|O .|O 
In|O the|O dysplastic|O or|O carcinomatous|O lesions|O of|O 11|O patients|O ,|O the|O increased|O expression|O of|O p21|O protein|O was|O observed|O .|O 
These|O results|O suggest|O that|O point|variation-type mutations|variation-type of|O c-ras|O genes|O are|O rare|O in|O dysplasias|O and|O carcinomas|O complicating|O ulcerative|O colitis|O and|O that|O the|O increased|O expression|O of|O p21|O protein|O is|O not|O always|O correlated|O with|O point|variation-type mutations|variation-type of|O c-ras|O genes|O .|O 
Clonal|O analysis|O of|O multiple|O point|variation-type mutations|variation-type in|O the|O N-ras|O gene|O in|O patients|O with|O acute|O myeloid|O leukemia|O .|O 
We|O have|O screened|O mutations|O of|O the|O N-ras|O gene|O at|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location in|O leukemia|O cells|O obtained|O from|O 100|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O and|O found|O mutated|O N-ras|O alleles|O in|O 9|O patients|O .|O 
We|O further|O analyzed|O the|O polyclonality|O of|O multiple|O N-ras|O gene|O mutations|O in|O 4|O AML|O patients|O .|O 
One|O patient|O ,|O who|O had|O the|O monoclonal|O karyotype|O ,|O t|variation-type (|O 11|variation-state-original ;|O 17|variation-state-altered )|O ,|O had|O two|O types|O of|O double|O missense|variation-type mutations|variation-type at|O codons|variation-location 13|variation-location and|O 61|variation-location in|O the|O same|O allele|O .|O 
Each|O of|O the|O remaining|O three|O patients|O ,|O one|O of|O whom|O had|O t|variation-type (|O 15|variation-state-original ;|O 17|variation-state-altered )|O with|O a|O monoclonal|O rearrangement|O of|O the|O retinoic|O acid|O receptor|O alpha|O and|O PML|O genes|O ,|O carried|O two|O missense|variation-type mutations|variation-type in|O a|O relatively|O small|O population|O of|O leukemia|O cells|O .|O 
We|O have|O demonstrated|O that|O multiple|O clonality|O of|O the|O N-ras|O gene|O is|O occasionally|O observed|O in|O leukemia|O with|O a|O monoclonal|O karyotype|O .|O 
These|O findings|O indicate|O that|O the|O N-ras|O mutations|O may|O not|O always|O be|O characterized|O simply|O by|O an|O accumulative|O process|O and|O that|O the|O activated|O N-ras|O gene|O alone|O is|O not|O sufficient|O to|O cause|O leukemia|O .|O 
High|O mutation|O frequency|O in|O ras|O genes|O of|O skin|O tumors|O isolated|O from|O DNA|O repair|O deficient|O xeroderma|O pigmentosum|O patients|O .|O 
Xeroderma|O pigmentosum|O (|O XP|O )|O patients|O are|O clinically|O characterized|O by|O a|O very|O high|O incidence|O of|O skin|O cancers|O on|O exposed|O skin|O ,|O at|O an|O early|O age|O .|O 
XP|O cells|O in|O vitro|O are|O strongly|O deficient|O in|O excision|O -|O repair|O and|O highly|O mutagenized|O by|O UV|O light|O .|O 
We|O were|O ,|O therefore|O ,|O interested|O in|O measuring|O mutation|O frequency|O and|O in|O determining|O mutation|O spectra|O in|O patients|O '|O tumors|O exposed|O to|O UV|O lesions|O .|O 
We|O chose|O to|O look|O at|O oncogene|O activation|O in|O skin|O tumors|O with|O the|O idea|O that|O more|O mutations|O ,|O particularly|O of|O the|O ras|O gene|O family|O ,|O would|O be|O found|O in|O XP|O tumors|O where|O lesions|O remain|O unrepaired|O compared|O to|O normal|O individuals|O .|O 
Our|O results|O clearly|O show|O that|O more|O than|O a|O 2|O -|O fold|O significantly|O higher|O mutation|O frequency|O (|O 50|O %|O )|O of|O the|O ras|O genes|O was|O found|O in|O XP|O in|O contrast|O to|O control|O tumors|O (|O 22|O %|O )|O .|O 
The|O majority|O of|O the|O mutations|O were|O found|O at|O codon|variation-location 12|variation-location of|O all|O three|O ras|O genes|O with|O a|O preponderance|O for|O N-ras|O in|O XP|O samples|O .|O 
The|O mutation|O spectra|O indicate|O that|O all|O mutations|variation-event found|O were|O located|O opposite|O pyrimidine|O -|O pyrimidine|O sequences|O which|O represent|O a|O hot|O spot|O for|O UV|O -|O induced|O DNA|variation-state-generic lesions|variation-state-generic .|O 
Most|O of|O the|O mutations|variation-event were|O of|O the|O type|O expected|O from|O studies|O performed|O in|O vitro|O with|O model|O systems|O .|O 
This|O high|O mutation|O frequency|O in|O XP|O was|O accompanied|O by|O a|O very|O high|O level|O of|O Ha-ras|O and|O c-myc|O gene|O amplification|variation-type and|O rearrangement|O .|O 
All|O these|O data|O are|O consistent|O with|O a|O fundamental|O role|O of|O unrepaired|O UV|O -|O induced|O DNA|variation-state-generic lesions|variation-state-generic as|O an|O initiating|O event|O in|O human|O skin|O tumors|O on|O exposed|O parts|O of|O the|O body|O .|O 
N-ras|O mutation|O and|O karyotypic|O evolution|O are|O closely|O associated|O with|O leukemic|O transformation|O in|O myelodysplastic|O syndrome|O .|O 
We|O performed|O a|O longitudinal|O analysis|O of|O the|O karyotypes|O and|O N-ras|O gene|O configuration|O of|O bone|O marrow|O cells|O in|O 35|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O 
Karyotypic|O evolution|O was|O found|O in|O eight|O patients|O ,|O and|O was|O associated|O with|O disease|O progression|O ,|O including|O leukemic|O transformation|O ,|O in|O all|O the|O patients|O .|O 
We|O identified|O N-ras|O mutations|O in|O six|O patients|O ,|O using|O a|O polymerase|O chain|O reaction|O (|O PCR|O )|O technique|O ,|O in|O which|O oligonucleotide|O primers|O were|O constructed|O with|O induced|O mismatches|O ,|O followed|O by|O endonuclease|O digestion|O .|O 
Direct|O sequencing|O confirmed|O single|variation-type base|variation-type substitutions|variation-type at|O codon|variation-location 12|variation-location in|O two|O patients|O and|O at|O codon|variation-location 13|variation-location in|O four|O .|O 
The|O incidence|O of|O N-ras|O gene|O mutations|O was|O significantly|O higher|O in|O the|O karyotypically|O evolved|O group|O (|O five|O of|O eight|O patients|O )|O than|O in|O the|O stable|O group|O (|O one|O of|O 27|O patients|O )|O .|O 
All|O of|O five|O patients|O harboring|O both|O karyotypic|O evolution|O and|O an|O N-ras|O mutation|O showed|O concomitant|O disease|O progression|O to|O overt|O leukemia|O or|O refractory|O anemia|O with|O excess|O of|O blasts|O in|O transformation|O (|O RAEB-T|O )|O .|O 
Two|O of|O four|O patients|O with|O either|O karyotypic|O evolution|O or|O N-ras|O mutation|O and|O six|O of|O 26|O patients|O without|O any|O of|O these|O alterations|O also|O progressed|O to|O overt|O leukemia|O .|O 
Our|O results|O indicate|O that|O the|O accumulation|O of|O these|O genetic|O alterations|O is|O closely|O associated|O with|O leukemic|O transformation|O of|O MDS|O ,|O although|O other|O genetic|O alterations|O may|O also|O play|O a|O key|O role|O in|O the|O remaining|O patients|O .|O 
Point|variation-type mutations|variation-type in|O the|O N-ras|O oncogene|O in|O malignant|O melanoma|O and|O congenital|O naevi|O .|O 
DNA|O from|O formalin|O -|O fixed|O and|O paraffin|O -|O processed|O samples|O from|O 100|O melanocytic|O lesions|O (|O 39|O malignant|O melanomas|O ,|O 18|O cases|O of|O dysplastic|O naevi|O ,|O and|O 43|O congenital|O naevi|O )|O was|O extracted|O ,|O and|O the|O sequences|O around|O codons|variation-location 12|variation-location /|O 13|variation-location and|O 61|variation-location of|O the|O N-ras|O oncogene|O were|O amplified|O using|O the|O polymerase|O chain|O reaction|O .|O 
The|O amplified|O product|O was|O then|O analysed|O both|O by|O dot|O -|O blotting|O and|O by|O direct|O sequencing|O for|O point|variation-type mutations|variation-type .|O 
By|O the|O dot|O -|O blotting|O technique|O ,|O mutations|O were|O seen|O in|O 18|O of|O 100|O lesions|O .|O 
These|O were|O in|O one|O of|O five|O distant|O metastases|O (|O 20|O %|O )|O ,|O in|O one|O of|O three|O nodal|O metastases|O (|O 33|O %|O )|O ,|O in|O four|O of|O 31|O (|O 13|O %|O )|O primary|O melanomas|O ,|O in|O none|O of|O 18|O dysplastic|O naevi|O ,|O and|O in|O 12|O of|O 43|O (|O 28|O %|O )|O congenital|O naevi|O ,|O all|O at|O codon|variation-location 61|variation-location .|O 
On|O direct|O sequencing|O ,|O nine|O of|O 18|O mutations|O were|O confirmed|O ,|O in|O two|O of|O 31|O (|O 6|O %|O )|O primary|O tumours|O ,|O one|O distant|O metastasis|O ,|O and|O six|O of|O 43|O (|O 14|O %|O )|O congenital|O naevi|O .|O 
Of|O the|O 23|O superficial|O spreading|O melanomas|O examined|O ,|O eight|O were|O on|O sun|O -|O exposed|O skin|O .|O 
A|O superficial|O spreading|O melanoma|O ,|O in|O which|O the|O N-ras|O mutation|O at|O codon|variation-location 61|variation-location was|O confirmed|O ,|O was|O on|O non|O -|O exposed|O skin|O ,|O and|O an|O unconfirmed|O mutation|O was|O from|O an|O exposed|O site|O .|O 
One|O of|O three|O nodular|O melanomas|O with|O a|O confirmed|O mutation|O was|O on|O a|O light|O -|O exposed|O site|O ,|O and|O the|O other|O two|O nodular|O melanomas|O were|O from|O non|O -|O exposed|O areas|O .|O 
All|O four|O lentigo|O maligna|O melanomas|O were|O from|O exposed|O sites|O ,|O and|O one|O of|O these|O had|O an|O unconfirmed|O mutation|O .|O 
The|O only|O acral|O lentiginous|O melanoma|O ,|O which|O had|O no|O mutation|O ,|O was|O from|O a|O sun|O -|O exposed|O area|O .|O 
The|O incidence|O and|O prognostic|O significance|O of|O mutations|variation-event in|O codon|variation-location 13|variation-location of|O the|O N-ras|O gene|O in|O acute|O myeloid|O leukemia|O .|O 
To|O determine|O the|O incidence|O and|O prognostic|O significance|O of|O mutation|O in|O the|O N-ras|O gene|O in|O de|O novo|O acute|O myeloid|O leukemia|O (|O AML|O )|O we|O performed|O an|O analysis|O of|O bone|O marrow|O smears|O from|O 219|O patients|O with|O de|O novo|O AML|O treated|O between|O 1984|O and|O 1986|O and|O followed|O for|O at|O least|O six|O years|O .|O 
DNA|O extracted|O from|O bone|O marrow|O smears|O taken|O at|O diagnosis|O was|O screened|O for|O the|O presence|O of|O mutations|variation-event in|O codons|variation-location 12|variation-location and|O 13|variation-location of|O exon|variation-location 1|variation-location by|O using|O the|O polymerase|O chain|O reaction|O to|O insert|O an|O Hph1|O restriction|O enzyme|O site|O into|O DNA|O .|O 
Presumptive|O mutations|O were|O confirmed|O by|O direct|O sequencing|O .|O 
Mutations|variation-event were|O detected|O in|O a|O total|O of|O 26|O patients|O (|O 12|O %|O )|O ;|O in|O nine|O patients|O (|O 4|O %|O )|O in|O codon|variation-location 12|variation-location only|O ,|O in|O ten|O patients|O (|O 5|O %|O )|O in|O codon|variation-location 13|variation-location only|O ,|O and|O in|O seven|O patients|O (|O 3|O %|O )|O in|O both|variation-location codons|variation-location .|O 
Mutations|variation-event in|O codon|variation-location 12|variation-location or|O codon|variation-location 13|variation-location were|O not|O associated|O with|O any|O clinical|O features|O .|O 
Mutations|variation-event in|O codon|variation-location 12|variation-location had|O no|O prognostic|O significance|O but|O mutations|variation-event in|O codon|variation-location 13|variation-location were|O associated|O with|O an|O increased|O remission|O rate|O ,|O a|O more|O durable|O remission|O ,|O and|O a|O significantly|O prolonged|O survival|O which|O appeared|O to|O be|O independent|O of|O other|O prognostic|O factors|O .|O 
Glutathione|O transferase|O P1-1|O expression|O in|O human|O melanoma|O metastases|O :|O correlation|O to|O N-RAS|O mutations|O and|O expression|O .|O 
Expression|O of|O the|O detoxication|O enzyme|O glutathione|O transferase|O P1-1|O (|O GST|O P1-1|O )|O at|O elevated|O levels|O has|O been|O noted|O in|O many|O types|O of|O human|O tumors|O ,|O including|O melanomas|O .|O 
The|O products|O of|O the|O human|O H-RAS|O ,|O K-RAS|O and|O N-RAS|O genes|O play|O a|O key|O role|O in|O intracellular|O signal|O transduction|O leading|O to|O transcriptional|O activation|O of|O AP-1|O (|O Fos|O /|O Jun|O )|O responsive|O genes|O .|O 
The|O oncogenic|O mutated|O forms|O of|O the|O ras|O proteins|O are|O constitutively|O active|O and|O interfere|O with|O normal|O signal|O transduction|O .|O 
Mutated|O RAS|O genes|O as|O well|O as|O increased|O expression|O of|O wild|O -|O type|O ras|O proteins|O are|O common|O features|O in|O human|O tumors|O including|O melanoma|O .|O 
We|O have|O characterized|O 30|O melanoma|O metastases|O from|O 23|O melanoma|O patients|O with|O reference|O to|O N-RAS|O expression|O and|O mutation|O as|O well|O as|O to|O GST|O P1|O expression|O (|O immunohistochemistry|O and|O genetic|O analysis|O )|O .|O 
Twenty-three|O of|O 30|O samples|O (|O 70|O %|O )|O had|O high|O N-Ras|O p21|O and/or|O N-RAS|O codon|variation-location 61|variation-location mutations|variation-event and|O 18|O of|O these|O 23|O samples|O also|O had|O high|O GST|O P1-1|O immunoreactivity|O .|O 
Seven|O of|O 30|O (|O 23|O %|O )|O samples|O had|O low|O N-Ras|O p21|O immunoreactivity|O and|O no|O detectable|O N-RAS|O codon|variation-location 61|variation-location mutations|variation-event .|O 
Six|O of|O these|O 7|O samples|O (|O 86|O %|O )|O also|O had|O low|O GST|O P1-1|O immunoreactivity|O .|O 
The|O results|O indicate|O a|O statistically|O significant|O correlation|O (|O Spearman|O correlation|O coefficient|O ,|O r|O =|O 0.56|O ,|O p|O =|O 0.001|O ,|O 2|O -|O tailed|O test|O )|O and|O provide|O ,|O for|O the|O first|O time|O ,|O indirect|O evidence|O for|O a|O possible|O coregulation|O of|O N-RAS|O and|O GST|O P1|O in|O human|O malignant|O melanoma|O which|O should|O be|O further|O evaluated|O .|O 
[|O Detection|O of|O ras|O gene|O mutations|O of|O pancreatic|O tumors|O by|O polymerase|O chain|O reaction|O and|O direct|O sequencing|O method|O ]|O 
Ras|O genes|O (|O H|O -|O ,|O K|O -|O ,|O N|O -|O ras|O )|O are|O converted|O to|O active|O oncogenes|O by|O point|variation-type mutations|variation-type occurring|O in|O either|O codon|variation-location 12|variation-location ,|O 13|variation-location or|O 61|variation-location .|O 
We|O analyzed|O 19|O pancreatic|O tumors|O (|O formalin|O fixed|O paraffin|O embedded|O tissue|O )|O of|O these|variation-location codons|variation-location by|O a|O method|O to|O directly|O sequence|O nucleotides|O around|O codons|variation-location 12|variation-location /|O 13|variation-location and|O 61|variation-location of|O the|O three|O ras|O genes|O ,|O using|O polymerase|O chain|O reaction|O and|O direct|O sequencing|O method|O .|O 
Of|O 19|O pancreatic|O tumors|O ,|O all|O 17|O duct|O cell|O carcinomas|O involving|O 2|O mucous|O producing|O pancreatic|O cancers|O had|O point|variation-type mutations|variation-type of|O the|O K-ras|O codon|variation-location 12|variation-location ,|O but|O 2|O islet|O cell|O tumors|O had|O ano|O point|variation-type mutation|variation-type around|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O 61|variation-location of|O the|O three|O ras|O genes|O .|O 
Extremely|O high|O incidence|O of|O ras|O gene|O mutation|O may|O be|O relevant|O to|O certain|O pathogenesis|O of|O pancreatic|O cancers|O .|O 
c-myc|O amplification|variation-type coexistent|O with|O activating|O N-ras|O point|variation-type mutation|variation-type in|O the|O biphenotypic|O leukemic|O cell|O line|O RED-3|O .|O 
While|O activation|O of|O the|O protooncogene|O c-N-ras|O is|O observed|O regularly|O in|O acute|O myelogenous|O leukemia|O ,|O amplification|variation-type of|O c-myc|O in|O AML|O cells|O or|O derived|O lines|O is|O uncommon|O .|O 
In|O particular|O ,|O concurrent|O ras|O /|O myc|O activation|O ,|O which|O has|O been|O shown|O to|O be|O critical|O in|O several|O elegant|O models|O of|O malignancy|O ,|O has|O been|O demonstrated|O in|O a|O very|O small|O number|O of|O human|O tumors|O or|O derivative|O cell|O lines|O .|O 
A|O cell|O line|O ,|O RED-3|O ,|O is|O described|O which|O was|O derived|O from|O cells|O of|O a|O patient|O with|O aggressive|O acute|O leukemia|O which|O exhibits|O many|O markers|O of|O lineage|O infidelity|O .|O 
DNA|O from|O this|O cell|O line|O contains|O an|O activating|O point|variation-type mutation|variation-type of|O c-N-ras|O as|O well|O as|O 20|O -|O 30|O -|O fold|O amplification|variation-type of|O c-myc|O .|O 
After|O HL-60|O ,|O this|O is|O the|O second|O example|O of|O ras|O /|O myc|O activation|O in|O AML|O derived|O cells|O and|O demonstrates|O that|O this|O lesion|O is|O not|O unique|O to|O HL-60|O .|O 
Rather|O ,|O it|O may|O be|O important|O in|O leukemogenesis|O in|O a|O small|O proportion|O of|O AML|O patients|O .|O 
High|O frequency|O of|O ras|O oncogene|O activation|O in|O all|O stages|O of|O human|O thyroid|O tumorigenesis|O .|O 
Using|O polymerase|O chain|O reaction|O amplification|O and|O oligonucleotide|O probing|O ,|O the|O activation|O of|O ras|O oncogenes|O in|O 24|O benign|O and|O 20|O malignant|O human|O thyroid|O neoplasms|O was|O examined|O .|O 
The|O frequency|O of|O ras|O oncogene|O activation|O was|O similar|O at|O all|O stages|O of|O tumorigenesis|O in|O this|O system|O ,|O being|O found|O in|O 33|O %|O of|O adenomas|O overall|O (|O 50|O %|O of|O microfollicular|O tumours|O )|O ,|O 53|O %|O of|O differentiated|O follicular|O carcinomas|O and|O 60|O %|O of|O undifferentiated|O carcinomas|O .|O 
This|O supports|O the|O contention|O that|O mutation|O of|O these|O oncogenes|O occurs|O at|O an|O early|O step|O in|O tumorigenesis|O .|O 
The|O predominant|O amino|variation-type acid|variation-type substitution|variation-type in|O the|O differentiated|O tumours|O was|O glutamine|variation-state-original to|O arginine|variation-state-altered at|O position|variation-location 61|variation-location of|O Ha-ras|O or|O N-ras|O ,|O but|O this|O mutation|variation-event was|O not|O found|O in|O any|O of|O the|O undifferentiated|O tumours|O .|O 
It|O was|O noted|O that|O while|O transition|variation-type mutations|variation-type predominated|O in|O differentiated|O tumours|O (|O both|O benign|O and|O malignant|O )|O ,|O transversions|variation-type were|O more|O common|O in|O the|O undifferentiated|O tumours|O .|O 
Incidence|O of|O activating|O ras|O oncogene|O mutations|O associated|O with|O primary|O and|O metastatic|O human|O breast|O cancer|O .|O 
To|O test|O the|O hypothesis|O that|O ras|O activation|O is|O involved|O in|O the|O final|O stages|O of|O breast|O cancer|O progression|O ,|O we|O analyzed|O tumor|O DNA|O derived|O from|O 60|O different|O patients|O and|O extracted|O from|O 40|O invasive|O primary|O breast|O tumors|O ,|O seven|O lymph|O node|O and|O skin|O metastases|O ,|O nine|O metastatic|O effusions|O ,|O and|O five|O established|O breast|O cancer|O cell|O lines|O .|O 
The|O polymerase|O chain|O reaction|O technique|O was|O used|O to|O amplify|O DNA|O fragments|O containing|O Kirsten|O -|O (|O Ki|O -|O )|O ,|O Harvey|O -|O (|O Ha|O -|O )|O ,|O and|O N|O -|O ras|O codons|variation-location 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location which|O were|O then|O probed|O on|O slot|O -|O blots|O with|O labeled|O synthetic|O oligomers|O to|O detect|O nonconservative|O single|variation-type base|variation-type mutations|variation-type .|O 
Activating|O mutations|variation-event were|O found|O in|O one|O of|O 40|O primary|O tumors|O (|O Ki-ras|O codon|variation-location 13|variation-location )|O ,|O zero|O of|O seven|O lymph|O node|O and|O skin|O metastases|O ,|O one|O of|O nine|O metastatic|O effusions|O (|O Ki-ras|O codon|variation-location 12|variation-location )|O ,|O and|O two|O of|O five|O cell|O lines|O (|O Ki-ras|O codons|variation-location 12|variation-location and|O 13|variation-location )|O .|O 
These|O results|O indicate|O that|O activating|O ras|O mutations|O are|O rarely|O involved|O in|O either|O the|O initiation|O or|O metastatic|O progression|O of|O human|O breast|O cancer|O .|O 
Low|O incidence|O of|O ras|O oncogene|O activation|O in|O human|O squamous|O cell|O carcinomas|O .|O 
Activation|O of|O the|O ras|O gene|O family|O by|O point|variation-type mutation|variation-type at|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location has|O been|O demonstrated|O in|O up|O to|O 20|O %|O of|O unselected|O series|O of|O human|O tumours|O .|O 
The|O present|O study|O was|O carried|O out|O to|O assess|O the|O incidence|O of|O ras|O activation|O in|O 37|O squamous|O cell|O carcinomas|O of|O the|O head|O and|O neck|O ,|O seven|O squamous|O cell|O carcinomas|O of|O the|O skin|O and|O eight|O squamous|O carcinoma|O cell|O lines|O .|O 
Oligonucleotide|O probes|O and|O the|O polymerase|O chain|O reaction|O were|O used|O on|O DNA|O extracted|O from|O achival|O paraffin|O embedded|O material|O .|O 
Mutations|O in|O codon|variation-location 12|variation-location of|O the|O Harvey|O ras|O gene|O was|O found|O in|O a|O carcinoma|O of|O the|O larynx|O and|O a|O carcinoma|O of|O the|O lip|O ,|O both|O of|O which|O had|O received|O prior|O irradiation|O .|O 
A|O cell|O line|O (|O LICR-LON-HN8|O )|O established|O from|O the|O same|O laryngeal|O cancer|O showed|O the|O same|O mutation|variation-event .|O 
This|O study|O indicates|O that|O there|O is|O a|O low|O incidence|O of|O ras|O mutation|O in|O human|O squamous|O cell|O carcinomas|O and|O that|O activation|O of|O this|O family|O of|O genes|O is|O probably|O not|O a|O common|O factor|O in|O the|O development|O of|O this|O group|O of|O tumours|O .|O 
RAS|O mutations|O in|O patients|O following|O cytotoxic|O therapy|O for|O lymphoma|O .|O 
The|O occurrence|O of|O Myelodysplastic|O Syndrome|O (|O MDS|O )|O and|O Acute|O Myeloblastic|O Leukaemia|O (|O AML|O )|O following|O cytotoxic|O therapy|O for|O neoplastic|O disease|O is|O well|O recognised|O .|O 
RAS|O mutations|O are|O common|O in|O patients|O with|O MDS|O and|O AML|O .|O 
To|O determine|O whether|O these|O lesions|O are|O found|O as|O early|O markers|O of|O secondary|O disease|O ,|O we|O have|O studied|O the|O incidence|O of|O RAS|O mutations|O in|O the|O peripheral|O blood|O of|O 70|O patients|O in|O complete|O remission|O from|O lymphoma|O .|O 
Patients|O were|O treated|O by|O standard|O chemotherapy|O regimes|O and/or|O localised|O radiotherapy|O .|O 
Treatment|O had|O been|O given|O 6|O months|O to|O 14|O 1|O /|O 2|O years|O previously|O and|O no|O patient|O showed|O any|O sign|O of|O residual|O disease|O .|O 
Genomic|O DNA|O from|O peripheral|O blood|O leukocytes|O was|O amplified|O in|O vitro|O at|O target|O codons|O of|O N|O ,|O K|O and|O H|O RAS|O genes|O ,|O and|O mutations|O detected|O by|O hybridisation|O with|O oligonucleotide|O probes|O .|O 
RAS|O mutations|variation-event were|O detected|O in|O 9|O subjects|O .|O 
One|O patient|O with|O an|O N|O 12|variation-location valine|variation-state-generic (|O Val|variation-state-generic )|O substitution|variation-type had|O been|O in|O complete|O remission|O from|O Hodgkin|O 's|O disease|O (|O HD|O )|O for|O 9|O years|O .|O 
DNA|O from|O this|O patient|O registered|O in|O a|O nude|O mouse|O tumorigenicity|O assay|O (|O NMT|O )|O .|O 
The|O N|O 12|variation-location Val|variation-state-generic mutation|variation-event was|O not|O detected|O in|O the|O original|O tumour|O tissue|O from|O the|O same|O patient|O .|O 
A|O second|O patient|O in|O remission|O from|O HD|O showed|O evidence|O of|O co|O -|O existent|O N|O 12|variation-location cysteine|variation-state-generic (|O Cys|variation-state-generic )|O and|O N|O 13|variation-location valine|variation-state-generic (|O Val|variation-state-generic )|O substitutions|variation-type which|O were|O not|O detected|O in|O presentation|O material|O or|O unaffected|O tissues|O .|O 
All|O patients|O are|O currently|O haematologically|O normal|O ,|O indicating|O that|O clones|O of|O mutant|O RAS|O bearing|O cells|O may|O be|O detected|O prior|O to|O any|O overt|O sign|O of|O disease|O .|O 
Ras|O oncogene|O mutations|O in|O basal|O cell|O carcinomas|O and|O squamous|O cell|O carcinomas|O of|O human|O skin|O .|O 
Activated|O ras|O oncogenes|O have|O been|O detected|O in|O a|O variety|O of|O human|O malignancies|O .|O 
Activation|O of|O ras|O oncogenes|O usually|O occurs|O by|O point|variation-type mutations|variation-type within|O specific|O codons|O of|O the|O H-ras|O ,|O N-ras|O ,|O and|O K-ras|O genes|O .|O 
For|O the|O present|O study|O ,|O DNA|O was|O isolated|O from|O 30|O basal|O cell|O carcinomas|O (|O BCC|O )|O and|O 12|O squamous|O cell|O carcinomas|O (|O SCC|O )|O .|O 
After|O amplification|O of|O genomic|O DNA|O by|O using|O the|O polymerase|O chain|O reaction|O ,|O the|O occurrence|O of|O point|variation-type mutations|variation-type was|O investigated|O with|O 32P|O -|O labeled|O synthetic|O oligonucleotides|O .|O 
These|O probes|O are|O complementary|O to|O the|O known|O point|O -|O mutated|O nucleotide|O sequences|O of|O the|O ras|O genes|O .|O 
In|O four|O out|O of|O the|O 30|O BCC|O studied|O ,|O point|variation-type mutations|variation-type were|O detected|O at|O codon|variation-location 12|variation-location of|O the|O K-ras|O gene|O and|O at|O codon|variation-location 61|variation-location of|O the|O H-ras|O gene|O .|O 
The|O K-ras|O mutations|variation-event involve|O glycine|variation-state-original to|O cysteine|variation-state-altered and|O glycine|variation-state-original to|O asparagine|variation-state-altered amino|variation-type acid|variation-type changes|variation-type .|O 
The|O mutation|variation-event at|O codon|variation-location 61|variation-location of|O the|O H-ras|O gene|O is|O consistent|O with|O a|O replacement|O of|O glutamine|variation-state-original by|O histidine|variation-state-altered .|O 
In|O one|O SCC|O ,|O a|O point|variation-type mutation|variation-type was|O detected|O at|O codon|variation-location 12|variation-location of|O the|O K-ras|O gene|O ,|O involving|O a|O glycine|variation-state-original to|O cysteine|variation-state-altered substitution|variation-type in|O the|O gene|O product|O .|O 
These|O findings|O demonstrate|O that|O mutational|O activation|O of|O ras|O genes|O takes|O place|O in|O skin|O carcinomas|O ,|O but|O the|O rate|O at|O which|O these|O mutations|variation-event occur|O seems|O to|O be|O relatively|O low|O .|O 
High|O frequency|O mutation|O in|O codons|variation-location 12|variation-location and|O 61|variation-location of|O H-ras|O oncogene|O in|O chewing|O tobacco|O -|O related|O human|O oral|O carcinoma|O in|O India|O .|O 
57|O primary|O tumour|O samples|O from|O Indian|O oral|O cancer|O patients|O with|O a|O 5|O -|O 15|O year|O tobacco|O chewing|O habit|O ,|O were|O examined|O for|O mutational|O activation|O in|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location of|O the|O H-ras|O ,|O K-ras|O and|O N-ras|O oncogenes|O .|O 
The|O highly|O sensitive|O assay|O based|O on|O specific|O oligonucleotide|O hybridisation|O following|O in|O vitro|O amplification|O of|O unique|O sequences|O by|O polymerase|O chain|O reaction|O was|O employed|O .|O 
Mutations|variation-event were|O detected|O in|O twenty|O (|O 35|O %|O )|O of|O the|O samples|O and|O were|O restricted|O to|O H-ras|O ,|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location .|O 
Two|O cases|O had|O concurrent|O mutations|variation-event in|O codons|variation-location 12|variation-location and|O 61|variation-location .|O 
The|O majority|O of|O the|O mutations|variation-event were|O at|O H-ras|O 61.2|variation-location (|O Glutamine|variation-state-original to|O Arginine|variation-state-altered )|O and|O H-ras|O 12.2|variation-location (|O Glycine|variation-state-original to|O Valine|variation-state-altered )|O .|O 
Three|O of|O the|O less|O frequent|O mutations|variation-event are|O apparently|O novel|O .|O 
Interestingly|O ,|O eight|O of|O the|O samples|O with|O H-ras|O mutations|O also|O showed|O loss|O of|O wild|O -|O type|O H-ras|O ,|O as|O judged|O by|O absence|O of|O signals|O for|O wild|O -|O type|O codons|variation-location 12|variation-location or|O 61|variation-location on|O dot|O blots|O .|O 
The|O specific|O H-ras|O mutations|O in|O these|O oral|O malignancies|O associated|O with|O tobacco|O chewing|O ,|O may|O represent|O an|O important|O example|O of|O an|O environmental|O carcinogen|O -|O induced|O step|O ,|O in|O a|O pathway|O leading|O to|O malignant|O transformation|O .|O 
Alteration|O of|O N-ras|O gene|O mutation|O after|O relapse|O in|O acute|O lymphoblastic|O leukemia|O .|O 
We|O investigated|O N-ras|O activation|O in|O childhood|O acute|O lymphoblastic|O leukemia|O (|O dALL|O )|O by|O the|O polymerase|O chain|O reaction|O (|O PCR|O )|O and|O the|O oligonucleotide|O hybridization|O method|O .|O 
The|O frequency|O of|O point|variation-type -|variation-type mutation|variation-type of|O the|O N-ras|O gene|O was|O not|O high|O (|O 2|O of|O 15|O )|O ,|O and|O one|O positive|O case|O who|O relapsed|O was|O analyzed|O in|O detail|O .|O 
Although|O N-ras|O gene|O activation|O was|O detected|O at|O both|O onset|O and|O relapse|O ,|O the|O mutation|O sites|O were|O different|O .|O 
At|O onset|O ,|O Gly|variation-state-original (|O GGT|variation-state-original )|O was|O changed|O to|O Ser|variation-state-altered (|O AGT|variation-state-altered )|O at|O codon|variation-location 12|variation-location ,|O and|O at|O relapse|O ,|O Gly|variation-state-original (|O GGT|variation-state-original )|O to|O Asp|variation-state-altered (|O GAT|variation-state-altered )|O was|O observed|O at|O the|variation-location same|variation-location codon|variation-location .|O 
In|O addition|O ,|O the|O DNA|O at|O relapse|O showed|O a|O remarkably|O higher|O transforming|O activity|O than|O the|O DNA|O at|O onset|O on|O two|O independent|O recipient|O cell|O lines|O .|O 
The|O identical|O cell|O surface|O phenotype|O and|O the|O same|O rearrangement|O patterns|O of|O both|O the|O immunoglobulin|O (|O Ig|O )|O heavy|O chain|O and|O T-cell|O receptor|O (|O TCR|O )|O gamma|O chain|O genes|O indicated|O that|O the|O leukemic|O cells|O at|O onset|O and|O those|O at|O relapse|O were|O derived|O from|O the|O same|O precursor|O cell|O .|O 
Therefore|O ,|O this|O case|O supports|O the|O concept|O that|O ras|O activation|O is|O not|O the|O event|O initiating|O leukemogenesis|O ,|O but|O may|O be|O involved|O in|O leukemic|O progression|O .|O 
Low|O incidence|O of|O Ha-ras|O oncogene|O mutations|O in|O human|O epidermal|O tumors|O .|O 
Activation|O of|O the|O Ha-ras|O oncogene|O by|O point|variation-type mutations|variation-type has|O been|O suggested|O to|O play|O a|O role|O in|O animal|O skin|O carcinogenesis|O models|O .|O 
In|O this|O study|O ,|O we|O investigated|O the|O significance|O of|O the|O Ha-ras|O mutations|O in|O human|O epidermal|O tumors|O .|O 
DNAs|O from|O paraffin|O -|O embedded|O tissues|O of|O benign|O and|O malignant|O human|O epidermal|O tumors|O (|O 27|O samples|O from|O 25|O patients|O )|O were|O prepared|O and|O examined|O for|O point|variation-type mutations|variation-type of|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location of|O Ha-ras|O gene|O by|O polymerase|O chain|O reaction|O and|O oligonucleotide|O hybridization|O .|O 
Only|O one|O sample|O of|O basal|O cell|O carcinoma|O and|O one|O sample|O of|O keratoacanthoma|O were|O found|O to|O carry|O an|O A|variation-state-original to|O T|variation-state-altered transversion|variation-type at|O the|O second|variation-location position|variation-location of|variation-location codon|variation-location 61|variation-location .|O 
This|O low|O incidence|O of|O Ha-ras|O mutations|O suggests|O that|O the|O mutational|O activation|O of|O the|O gene|O may|O not|O be|O primarily|O involved|O in|O human|O epidermal|O tumorigenesis|O .|O 
Infrequent|O mutation|O of|O the|O ras|O genes|O in|O skin|O tumors|O of|O xeroderma|O pigmentosum|O patients|O in|O Japan|O .|O 
By|O using|O PCR|O amplification|O and|O oligonucleotide|O mismatch|O hybridization|O ,|O base|variation-type -|variation-type substitution|variation-type mutations|O of|O the|O ras|O genes|O in|O 26|O skin|O tumors|O of|O Japanese|O xeroderma|O pigmentosum|O (|O XP|O )|O patients|O were|O studied|O .|O 
Thin|O sections|O of|O tumor|O tissues|O which|O were|O fixed|O and|O embedded|O in|O paraffin|O blocks|O were|O used|O in|O this|O study|O .|O 
After|O analyzing|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location of|O the|O H|O -|O ,|O K|O -|O and|O N|O -|O ras|O genes|O by|O using|O 66|O oligomer|O probes|O ,|O we|O detected|O only|O one|O mutation|variation-event of|O the|O K-ras|O gene|O at|O codon|variation-location 61|variation-location in|O one|O tumor|O sample|O .|O 
All|O the|O other|O tumors|O were|O therefore|O considered|O not|O to|O have|O a|O mutation|O in|O the|O ras|O genes|O .|O 
These|O results|O suggest|O that|O mutations|O of|O the|O ras|O genes|O are|O not|O particularly|O associated|O with|O skin|O tumors|O of|O Japanese|O XP|O patients|O .|O 
Detection|O of|O H-ras|O gene|O point|variation-type mutations|variation-type in|O transitional|O cell|O carcinoma|O of|O human|O urinary|O bladder|O using|O polymerase|O chain|O reaction|O .|O 
It|O has|O been|O reported|O that|O the|O H-ras|O gene|O is|O activated|O as|O oncogene|O in|O human|O bladder|O cancer|O cases|O ,|O and|O that|O codon|variation-location 12|variation-location and|O codon|variation-location 61|variation-location are|O the|O major|O "|O hot|O spots|O "|O of|O its|O activation|O .|O 
A|O simple|O method|O to|O detect|O point|variation-type mutations|variation-type in|O these|O codons|variation-location of|O H-ras|O gene|O was|O established|O for|O the|O use|O of|O clinical|O diagnosis|O .|O 
In|O this|O method|O ,|O the|O DNA|O segments|O including|O codon|variation-location 12|variation-location or|O codon|variation-location 61|variation-location were|O amplified|O by|O polymerase|O chain|O reaction|O (|O PCR|O )|O ,|O and|O the|O reaction|O products|O were|O examined|O for|O their|O susceptibility|O to|O the|O restriction|O enzyme|O NaeI|O or|O BstNI|O ,|O and|O by|O dot|O blot|O hybridization|O assay|O with|O oligonucleotide|O probes|O .|O 
Point|variation-type mutations|variation-type were|O detectable|O in|O small|O amounts|O of|O DNAs|O isolated|O from|O fresh|O or|O frozen|O tumor|O tissues|O ,|O urine|O cells|O and|O paraffin|O sections|O .|O 
The|O method|O was|O applied|O for|O a|O clinical|O sample|O and|O a|O case|O that|O had|O a|O point|variation-type mutation|variation-type at|O codon|variation-location 12|variation-location of|O H-ras|O gene|O was|O detected|O .|O 
The|O point|variation-type mutation|variation-type was|O existed|O in|O DNAs|O of|O primary|O tumor|O tissue|O ,|O all|O recurrent|O tumor|O tissues|O and|O cells|O isolated|O from|O urine|O of|O this|O case|O .|O 
Clinical|O implications|O of|O K-ras|O mutations|O in|O malignant|O epithelial|O tumors|O of|O the|O endometrium|O .|O 
Tumorigenesis|O in|O humans|O and|O experimental|O animals|O appears|O to|O involve|O the|O activation|O of|O ras|O protooncogenes|O for|O a|O number|O of|O organ|O systems|O and|O seems|O to|O be|O important|O to|O the|O development|O of|O the|O metastatic|O phenotype|O in|O several|O model|O systems|O .|O 
Clinically|O ,|O the|O presence|O of|O activated|O ras|O protooncogenes|O has|O been|O reported|O to|O be|O a|O negative|O prognostic|O factor|O in|O the|O myelodysplastic|O syndrome|O and|O in|O adenocarcinoma|O of|O the|O lung|O .|O 
In|O the|O present|O study|O we|O examined|O 49|O cases|O of|O endometrial|O carcinoma|O for|O mutations|variation-event in|O the|O first|variation-location exon|variation-location of|O K-ras|O using|O the|O polymerase|O chain|O reaction|O and|O direct|O sequencing|O .|O 
Mutations|variation-event in|O codon|variation-location 12|variation-location or|O 13|variation-location of|O K-ras|O were|O detected|O in|O 6|O of|O 49|O cases|O (|O 12.2|O %|O )|O .|O 
These|O six|O cases|O consisted|O of|O five|O endometrioid|O endometrial|O carcinomas|O ,|O each|O of|O which|O had|O a|O mutation|variation-event in|O codon|variation-location 12|variation-location ,|O and|O one|O case|O of|O clear|O cell|O carcinoma|O ,|O which|O had|O a|O mutation|variation-event in|O codon|variation-location 13|variation-location .|O 
In|O our|O study|O the|O presence|O of|O mutations|O in|O K-ras|O appeared|O to|O be|O an|O unfavorable|O prognostic|O factor|O .|O 
Three|O of|O six|O patients|O with|O the|O mutation|variation-event died|O during|O follow|O -|O up|O ,|O while|O only|O 7|O %|O of|O the|O 43|O patients|O without|O K-ras|O mutations|O expired|O during|O this|O same|O period|O .|O 
In|O multivariate|O analysis|O using|O the|O Cox|O proportional|O hazard|O model|O ,|O K-ras|O activation|O appeared|O to|O be|O an|O independent|O risk|O factor|O when|O compared|O with|O clinical|O stage|O ,|O depth|O of|O myometrial|O invasion|O ,|O and|O patient|O age|O .|O 
Thus|O ,|O our|O findings|O support|O the|O hypothesis|O that|O K-ras|O protooncogene|O activation|O plays|O an|O important|O role|O in|O determining|O the|O aggressiveness|O of|O endometrial|O carcinoma|O .|O 
Concurrent|O mutations|O of|O coding|O and|O regulatory|O sequences|O of|O the|O Ha-ras|O gene|O in|O urinary|O bladder|O carcinomas|O .|O 
This|O report|O concerns|O the|O study|O of|O Ha-ras|O gene|O mutations|O and|O ras|O p21|O expression|O in|O primary|O tumors|O of|O the|O urinary|O bladder|O .|O 
Polymerase|O chain|O reaction|O -|O based|O techniques|O and|O computerized|O image|O analysis|O were|O used|O .|O 
The|O data|O obtained|O were|O related|O to|O tumor|O grade|O ,|O DNA|O ploidy|O ,|O and|O tumor|O invasion|O .|O 
A|O point|variation-type mutation|variation-event (|O G|variation-state-original -->|O T|variation-state-altered )|O at|O Ha-ras|O codon|variation-location 12|variation-location was|O found|O in|O 30|O of|O 67|O tumors|O .|O 
The|O mutation|O frequency|O was|O greater|O in|O grade|O III|O (|O 65|O %|O )|O than|O in|O grade|O II|O (|O 44|O %|O )|O tumors|O ;|O no|O mutations|O were|O observed|O in|O grade|O I|O tumors|O .|O 
The|O mutation|variation-event was|O observed|O more|O often|O in|O aneuploid|O (|O 58|O %|O )|O than|O in|O diploid|O (|O 28|O %|O )|O tumors|O .|O 
No|O other|O substitution|variation-type at|O codon|variation-location 12|variation-location was|O seen|O and|O no|O codon|variation-location 61|variation-location mutation|variation-event was|O detected|O .|O 
The|O tumors|O were|O also|O tested|O for|O the|O A|variation-state-original -->|O G|variation-state-altered mutation|variation-event at|O position|variation-location 2719|variation-location of|variation-location Ha-ras|O intron|variation-location D|variation-location .|O 
Concurrent|O codon|variation-location 12|variation-location and|O intron|variation-location D|variation-location mutations|variation-event were|O identified|O in|O seven|O high|O -|O grade|O aneuploid|O tumors|O ;|O six|O were|O invasive|O .|O 
The|O levels|O of|O the|O ras|O gene|O product|O p21|O were|O approximately|O 10|O times|O higher|O in|O tumors|O with|O intron|variation-location D|variation-location mutation|variation-event than|O in|O those|O without|O .|O 
These|O findings|O confirm|O on|O human|O bladder|O tumors|O the|O observations|O of|O the|O effect|O of|O synchronous|O exon|O -|O intron|O mutations|O reported|O on|O the|O bladder|O cancer|O cell|O line|O T24|O .|O 
Our|O results|O are|O the|O first|O demonstration|O of|O Ha-ras|O intron|variation-location D|variation-location alterations|variation-event in|O human|O tumor|O tissues|O and|O suggest|O that|O concurrent|O mutations|variation-event at|O codon|variation-location 12|variation-location and|O intron|variation-location D|variation-location of|O this|O gene|O within|O the|O same|O tumor|O may|O contribute|O to|O the|O aggressive|O behavior|O of|O human|O bladder|O carcinomas|O .|O 
Detection|O of|O RAS|O mutations|O in|O archival|O testicular|O germ|O cell|O tumors|O by|O polymerase|O chain|O reaction|O and|O oligonucleotide|O hybridization|O .|O 
Preliminary|O studies|O of|O RAS|O mutational|O activation|O in|O human|O testicular|O germ|O cell|O neoplasms|O have|O yielded|O conflicting|O results|O .|O 
Whereas|O two|O studies|O of|O clinical|O material|O revealed|O a|O significant|O incidence|O of|O N|O -|O and|O K|O RAS|O mutations|O ,|O two|O studies|O of|O a|O variety|O of|O germ|O cell|O lines|O failed|O to|O document|O RAS|O mutations|O .|O 
To|O clarify|O the|O incidence|O of|O RAS|O mutations|O in|O these|O tumors|O ,|O we|O studied|O archival|O paraffin|O -|O embedded|O ,|O formalin|O -|O fixed|O orchiectomy|O specimens|O from|O 25|O nonseminomas|O (|O NSGCT|O )|O ,|O 18|O seminomas|O (|O SEM|O )|O ,|O and|O one|O Leydig|O cell|O tumor|O .|O 
For|O 14|O of|O the|O 44|O neoplasms|O ,|O DNA|O was|O also|O available|O from|O nonmalignant|O testis|O adjacent|O to|O the|O tumor|O .|O 
Six|O age|O -|O matched|O patients|O had|O testes|O removed|O because|O of|O nonmalignant|O disease|O and|O were|O studied|O as|O controls|O .|O 
Polymerase|O chain|O reaction|O (|O PCR|O )|O amplified|O the|O K|O -|O ,|O N|O -|O ,|O and|O H|O RAS|O 12|variation-location ,|O 13|variation-location ,|O and|O 61|variation-location codons|variation-location of|O these|O specimens|O ,|O and|O mutations|variation-event were|O detected|O with|O mutation|O -|O specific|O oligonucleotide|O probe|O hybridization|O of|O Southern|O and|O slot|O blots|O .|O 
Four|O mutations|variation-event were|O found|O in|O KRAS|O 12|variation-location (|O 4|O /|O 44|O ;|O [|O 9.1|O %|O ]|O )|O .|O 
One|O seminoma|O [|O 1|O /|O 18|O (|O 5.6|O %|O )|O ]|O contained|O the|O mutation|variation-event GGT|variation-state-original (|O GLY|variation-state-original )|O ----|O CGT|variation-state-altered (|O ARG|variation-state-altered )|O ,|O and|O three|O NSGCT|O [|O 3|O /|O 25|O (|O 12|O %|O )|O ]|O were|O found|O to|O have|O GGT|variation-state-original (|O GLY|variation-state-original )|O ----|O GAT|variation-state-altered (|O ASP|variation-state-altered )|O mutations|variation-event .|O 
One|O of|O the|O NSGCT|O mutations|variation-event was|O detected|O in|O adjacent|O nonmalignant|O tissue|O ,|O but|O the|O corresponding|O tumor|O did|O not|O contain|O any|O detectable|O mutation|O .|O 
No|O mutations|O were|O detected|O at|O KRAS|O 13|variation-location or|O 61|variation-location ,|O in|O NRAS|O or|O HRAS|O 12|variation-location ,|O 13|variation-location ,|O or|O 61|variation-location ,|O or|O in|O the|O control|O normal|O testes|O .|O 
PCR|O ,|O slot|O blots|O ,|O and|O hybridizations|O were|O performed|O twice|O by|O two|O separate|O investigators|O for|O confirmation|O of|O results|O .|O 
PCR|O -|O generated|O mutation|O -|O specific|O positive|O controls|O were|O created|O for|O all|O possible|O RAS|O mutations|O ,|O and|O these|O along|O with|O wild|O -|O type|O DNA|O controls|O were|O integral|O to|O interpretation|O of|O the|O oligonucleotide|O mismatch|O hybridization|O assay|O .|O 
By|O using|O positive|O and|O negative|O controls|O ,|O we|O have|O detected|O a|O relatively|O low|O incidence|O of|O RAS|O mutations|O in|O archival|O human|O testicular|O germ|O cell|O tumors|O .|O 
Frequent|O deletions|variation-type of|O tumor|O suppressor|O genes|O in|O pure|O pancreatic|O juice|O from|O patients|O with|O tumoral|O or|O nontumoral|O pancreatic|O diseases|O .|O 
BACKGROUND|O /|O AIMS|O :|O 
K-ras|O codon|variation-location 12|variation-location mutation|O is|O the|O most|O frequent|O genetic|O alteration|O in|O pancreatic|O cancer|O .|O 
Sensitivity|O and|O specificity|O of|O K-ras|O are|O not|O high|O enough|O to|O detect|O all|O pancreatic|O cancers|O ,|O especially|O at|O early|O stage|O .|O 
This|O study|O investigated|O whether|O detection|O of|O p16|O and/or|O DPC4|O deletions|variation-type along|O with|O K-ras|O mutation|O in|O DNA|O samples|O could|O improve|O the|O definition|O of|O patients|O at|O risk|O of|O pancreatic|O cancer|O .|O 
METHODS|O :|O 
K-ras|O mutations|O were|O investigated|O by|O sequencing|O .|O 
p16|O and|O DPC4|O homozygous|O deletions|variation-type were|O studied|O using|O comparative|O multiplex|O polymerase|O chain|O reaction|O of|O DNA|O in|O pancreatic|O juice|O sampled|O during|O endoscopic|O retrograde|O pancreatography|O in|O 57|O patients|O with|O either|O pancreatic|O cancer|O (|O group|O I|O ,|O 18|O patients|O )|O ,|O chronic|O pancreatitis|O (|O group|O II|O ,|O 20|O patients|O )|O ,|O or|O nontumoral|O pancreatobiliary|O disease|O (|O group|O III|O ,|O 19|O patients|O )|O .|O 
RESULTS|O :|O 
The|O frequencies|O of|O Ki-ras|O mutations|O were|O 61|O %|O in|O group|O I|O ,|O 10|O %|O in|O group|O II|O ,|O and|O 10.5|O %|O in|O group|O III|O .|O 
The|O frequencies|O of|O p16|O exon|variation-location 2|variation-location and|O DPC4|O deletions|variation-type were|O ,|O respectively|O ,|O 28|O and|O 36|O %|O in|O group|O I|O ,|O 50|O and|O 58|O %|O in|O group|O II|O ,|O and|O 24|O and|O 36|O %|O in|O group|O III|O .|O 
CONCLUSIONS|O :|O 
The|O combination|O of|O p16|O and|O DPC4|O deletions|variation-type with|O K-ras|O mutation|O does|O not|O improve|O the|O diagnosis|O of|O pancreatic|O cancer|O based|O on|O K-ras|O mutation|O alone|O .|O 
These|O data|O suggest|O that|O tumor|O suppressor|O gene|O inactivation|O can|O occur|O with|O a|O high|O frequency|O during|O nonmalignant|O pancreatic|O diseases|O .|O 
C-Ki-ras|O mutations|O in|O peripheral|O blood|O of|O pancreatic|O cancer|O patients|O :|O a|O marker|O for|O early|O tumor|O metastasis|O .|O 
PURPOSE|O :|O 
To|O determine|O the|O incidence|O of|O circulating|O minimal|O malignant|O clone|O (|O CMMC|O )|O (|O harboring|O c-Ki-ras-2|O mutation|O )|O in|O peripheral|O blood|O (|O PB|O )|O samples|O of|O untreated|O pancreatic|O cancer|O using|O polymerase|O chain|O reaction|O (|O PCR|O )|O analysis|O of|O c-Ki-ras-2|O oncogene|O .|O 
METHODS|O AND|O MATERIALS|O :|O 
Experiments|O were|O carried|O out|O in|O fresh|O tumor|O ,|O peritoneal|O washings|O (|O PW|O )|O ,|O and|O PB|O samples|O of|O untreated|O pancreatic|O adenocarcinoma|O patients|O (|O both|O resectable|O and|O unresectable|O )|O .|O 
Samples|O were|O taken|O from|O 16|O patients|O diagnosed|O with|O pancreatic|O adenocarcinoma|O for|O the|O PCR|O analysis|O of|O mutated|O c-Ki-ras|O oncogene|O .|O 
Five|O tumor|O samples|O ,|O 15|O PB|O samples|O ,|O and|O 3|O PW|O samples|O were|O analyzed|O for|O point|variation-type mutation|variation-type of|O the|O c-Ki-ras|O gene|O at|O codon|variation-location 12|variation-location .|O 
RESULTS|O :|O 
Out|O of|O five|O tumor|O samples|O analyzed|O for|O c-Ki-ras|O mutation|O ,|O four|O were|O positive|O at|O the|O 12th|variation-location codon|variation-location .|O 
Out|O of|O total|O 15|O PB|O samples|O ,|O nine|O were|O positive|O for|O the|O c-Ki-ras|O point|variation-type mutation|variation-type at|O the|O 12th|variation-location codon|variation-location .|O 
All|O the|O positive|O PB|O samples|O showed|O a|O base|O substitution|variation-type from|O GGT|variation-state-original to|O GAT|variation-state-altered in|O the|O second|variation-location position|variation-location of|variation-location the|variation-location 12th|variation-location codon|variation-location .|O 
Out|O of|O three|O PW|O samples|O ,|O two|O showed|O mutation|variation-event at|O the|O second|variation-location position|variation-location from|O GGT|variation-state-original to|O GAT|variation-state-altered similar|O to|O their|O PB|O and|O tumor|O samples|O .|O 
CONCLUSION|O :|O 
Our|O study|O indicated|O the|O presence|O of|O the|O tumor|O cells|O (|O CMMC|O )|O in|O PB|O of|O pancreatic|O adenocarcinoma|O that|O can|O be|O identified|O by|O PCR|O analysis|O of|O c-Ki-ras|O oncogene|O .|O 
Patients|O with|O presence|O of|O CMMC|O in|O PB|O and|O mutation|O in|O PW|O had|O aggressive|O tumors|O that|O responded|O poorly|O to|O treatment|O .|O 
Mutations|O of|O p53|O ,|O c-kit|O ,|O K-ras|O ,|O and|O beta-catenin|O gene|O in|O non|O -|O Hodgkin|O 's|O lymphoma|O of|O adrenal|O gland|O .|O 
Malignant|O lymphoma|O of|O the|O adrenal|O gland|O is|O a|O rare|O disease|O ,|O usually|O with|O diffuse|O large|O cell|O morphology|O and|O B-cell|O immunophenotype|O ,|O and|O often|O associated|O with|O Epstein|O -|O Barr|O virus|O infection|O .|O 
In|O this|O study|O ,|O mutations|O of|O p53|O ,|O c-kit|O ,|O K-ras|O ,|O and|O beta-catenin|O gene|O were|O analyzed|O in|O 17|O cases|O (|O 13|O males|O and|O four|O females|O with|O ages|O ranging|O from|O 25|O to|O 84|O years|O )|O of|O such|O lymphomas|O by|O polymerase|O chain|O reaction|O -|O single|O strand|O conformation|O polymorphism|O followed|O by|O direct|O sequencing|O .|O 
Selected|O exons|O in|O each|O gene|O ,|O representing|O hot|O spots|O ,|O were|O analyzed|O .|O 
All|O 44|O mutations|O detected|O were|O single|O -|O nucleotide|O substitutions|variation-type and|O 33|O were|O missense|variation-type mutations|variation-type .|O 
Nineteen|O mutations|variation-event were|O detected|O in|O exon|variation-location 5|variation-location and|O /|O or|O 7|variation-location of|O the|O p53|O gene|O in|O nine|O of|O 17|O cases|O (|O 52.9|O %|O )|O and|O 21|O in|O exon|variation-location 11|variation-location and|O /|O or|O 17|variation-location of|O the|O c-kit|O gene|O in|O 10|O of|O 14|O cases|O (|O 71.4|O %|O )|O .|O 
Bilateral|O adrenal|O lesions|O in|O one|O case|O who|O had|O not|O received|O any|O adjuvant|O therapy|O showed|O different|O mutational|O patterns|O of|O the|O p53|O and|O c-kit|O genes|O ,|O suggesting|O different|O clonal|O evolution|O of|O lymphoma|O between|O the|O left|O and|O right|O sides|O .|O 
Mutation|O at|O codon|variation-location 13|variation-location of|O the|O K-ras|O gene|O was|O detected|O in|O one|O of|O 14|O cases|O (|O 7.1|O %|O )|O ,|O and|O in|O exon|variation-location 3|variation-location of|O the|O beta-catenin|O gene|O in|O three|O of|O 12|O cases|O (|O 25|O %|O )|O .|O 
All|O but|O one|O mutation|O were|O transition|variation-type mutations|O ,|O indicating|O that|O some|O endogenous|O mutagens|O act|O in|O lymphomagenesis|O in|O the|O adrenal|O gland|O .|O 
Our|O results|O suggest|O that|O p53|O and|O c-kit|O gene|O mutations|O might|O play|O a|O role|O in|O adrenal|O lymphomagenesis|O .|O 
Gene|O mutations|O in|O lymphoproliferative|O disorders|O of|O T|O and|O NK|O /|O T|O cell|O phenotypes|O developing|O in|O renal|O transplant|O patients|O .|O 
Post|O -|O transplantation|O lymphoproliferative|O disorder|O (|O PT-LPD|O )|O is|O characterized|O by|O lymphoid|O proliferation|O after|O organ|O or|O bone|O marrow|O transplantation|O .|O 
In|O Western|O countries|O ,|O most|O cases|O of|O PT-LPD|O are|O B-cell|O -|O derived|O and|O Epstein|O -|O Barr|O virus|O -|O associated|O ,|O in|O which|O alterations|O of|O c-myc|O ,|O p53|O ,|O and|O N-ras|O genes|O might|O play|O a|O role|O in|O disease|O progression|O .|O 
In|O Japan|O ,|O PT-LPD|O of|O T|O -|O and|O NK|O /|O T|O -|O cell|O types|O are|O not|O uncommon|O in|O renal|O transplant|O patients|O .|O 
Mutations|O of|O p53|O (|O exons|variation-location 4|variation-location through|variation-location 8|variation-location )|O ,|O K-ras|O (|O exons|variation-location 1|variation-location and|O 2|variation-location )|O ,|O c-kit|O (|O exons|variation-location 11|variation-location and|O 17|variation-location )|O ,|O and|O beta-catenin|O genes|O (|O exon|variation-location 3|variation-location )|O in|O 12|O cases|O of|O these|O diseases|O were|O analyzed|O by|O PCR|O single|O strand|O conformation|O polymorphism|O and|O then|O by|O direct|O sequencing|O .|O 
p53|O gene|O mutations|O were|O detected|O in|O 5|O of|O 5|O cases|O of|O peripheral|O T-cell|O lymphoma|O ,|O 3|O (|O 60|O %|O )|O of|O 5|O cases|O of|O adult|O T-cell|O leukemia|O /|O lymphoma|O ,|O and|O 1|O of|O 2|O cases|O of|O NK|O /|O T|O cell|O lymphoma|O .|O 
Twenty-five|O percent|O of|O T|O and|O NK|O /|O T|O cell|O lymphomas|O showed|O K-ras|O mutations|O .|O 
Mutations|O of|O c-kit|O and|O beta-catenin|O genes|O were|O found|O in|O 33|O %|O of|O cases|O .|O 
Among|O a|O total|O of|O 42|O substitution|variation-type mutations|O ,|O 40|O were|O transitions|variation-type with|O involvement|O of|O CpG|O sites|O in|O 20|O to|O 30|O %|O of|O cases|O .|O 
Most|O cases|O had|O at|O least|O one|O mutation|O that|O changed|O an|O amino|O acid|O ,|O which|O might|O have|O provided|O the|O selection|O pressure|O for|O expansion|O .|O 
These|O findings|O suggested|O that|O p53|O gene|O mutations|O might|O play|O a|O central|O role|O in|O development|O of|O peripheral|O T-cell|O lymphoma|O including|O adult|O T-cell|O leukemia|O /|O lymphoma|O in|O renal|O transplant|O patients|O .|O 
Detection|O of|O genetic|O alterations|O in|O the|O p53|O suppressor|O gene|O and|O the|O K-ras|O oncogene|O among|O different|O grades|O of|O dysplasia|O in|O patients|O with|O colorectal|O adenomas|O .|O 
BACKGROUND|O :|O 
Although|O it|O is|O believed|O that|O p53|O suppressor|O gene|O mutations|O ,|O compared|O with|O mutations|O in|O the|O K-ras|O oncogene|O ,|O occur|O at|O a|O later|O stage|O of|O colorectal|O tumorigenesis|O ,|O the|O distribution|O of|O these|O genetic|O alterations|O at|O an|O early|O stage|O remains|O poorly|O characterized|O .|O 
METHODS|O :|O 
The|O authors|O analyzed|O the|O immunoreactivity|O for|O p53|O protein|O (|O p53|O protein|O expression|O )|O ,|O which|O reflects|O the|O functionally|O altered|O p53|O gene|O ,|O and|O K-ras|O mutations|O at|O codons|variation-location 12|variation-location in|O 68|variation-location colorectal|O adenomas|O with|O both|O low|O -|O grade|O and|O high|O -|O grade|O dysplasia|O obtained|O from|O 62|O patients|O .|O 
RESULTS|O :|O 
The|O prevalence|O of|O p53|O positive|O immunostaining|O was|O significantly|O greater|O compared|O with|O the|O prevalence|O of|O K-ras|O mutations|O both|O in|O low|O -|O grade|O dysplasia|O and|O in|O high|O -|O grade|O dysplasia|O .|O 
Twenty-two|O adenomas|O (|O 32.3|O %|O )|O showed|O positive|O immunostaining|O for|O p53|O protein|O in|O high|O -|O grade|O dysplasia|O and|O also|O were|O positive|O for|O p53|O in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O 20|O adenomas|O (|O 29.4|O %|O )|O showed|O positive|O immunostaining|O for|O p53|O protein|O in|O high|O -|O grade|O dysplasia|O and|O were|O negative|O for|O p53|O in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O 8|O adenomas|O (|O 11.7|O %|O )|O showed|O negative|O immunostaining|O for|O p53|O protein|O in|O high|O -|O grade|O dysplasia|O and|O were|O positive|O for|O p53|O in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O ;|O and|O 18|O adenomas|O (|O 26.4|O %|O )|O showed|O negative|O immunostaining|O for|O p53|O protein|O in|O both|O high|O -|O grade|O dysplasia|O and|O in|O surrounding|O low|O -|O grade|O dysplastic|O tissues|O .|O 
On|O the|O whole|O ,|O a|O significant|O difference|O (|O P|O <|O 0.05|O )|O was|O seen|O in|O the|O frequency|O of|O p53|O positive|O immunostaining|O between|O low|O -|O grade|O dysplasia|O and|O high|O -|O grade|O dysplasia|O (|O 44.1|O %|O and|O 61.8|O %|O ,|O respectively|O )|O but|O not|O in|O that|O of|O K-ras|O mutations|O (|O 20.3|O %|O and|O 23.4|O %|O ,|O respectively|O )|O .|O 
CONCLUSIONS|O :|O 
The|O results|O of|O this|O study|O suggest|O that|O mutation|O of|O the|O p53|O suppressor|O gene|O occurs|O earlier|O in|O the|O adenoma|O -|O carcinoma|O sequence|O than|O K-ras|O mutation|O ,|O providing|O a|O clue|O for|O further|O understanding|O of|O the|O role|O of|O the|O p53|O gene|O in|O the|O early|O stage|O of|O colorectal|O tumorigenesis|O .|O 
Genetic|O profile|O of|O 22|O pancreatic|O carcinoma|O cell|O lines|O .|O 
Analysis|O of|O K-ras|O ,|O p53|O ,|O p16|O and|O DPC4|O /|O Smad4|O .|O 
The|O K-ras|O ,|O p53|O ,|O p16|O and|O DPC4|O genes|O are|O among|O those|O most|O frequently|O altered|O in|O pancreatic|O ductal|O carcinoma|O .|O 
We|O analyzed|O 22|O cell|O lines|O for|O alterations|O in|O these|O genes|O by|O direct|O sequence|O analysis|O and|O methylation|O -|O specific|O polymerase|O chain|O reaction|O .|O 
These|O cell|O lines|O showed|O mutations|O in|O K-ras|O and|O p53|O at|O frequencies|O of|O 91|O %|O and|O 95|O %|O ,|O respectively|O .|O 
Alterations|variation-event in|O p16INK4a|O were|O found|O in|O all|O cases|O and|O included|O nine|O homozygous|variation-type deletions|variation-type ,|O seven|O mutations|variation-event and|O promoter|O methylation|O in|O six|O cases|O .|O 
Eight|O cell|O lines|O (|O 36|O %|O )|O had|O an|O alteration|O of|O DPC4|O ,|O including|O one|O mutation|variation-event and|O seven|O homozygous|variation-type deletions|variation-type .|O 
The|O most|O typical|O mutational|O profile|O involved|O K-ras|O ,|O p53|O ,|O and|O p16INK4a|O ,|O concurrently|O aberrated|O in|O 20|O cases|O (|O 91|O %|O )|O .|O 
Eight|O cell|O lines|O had|O alterations|O in|O all|O four|O genes|O .|O 
Inactivation|O of|O DPC4|O was|O always|O accompanied|O by|O alteration|O of|O all|O of|O the|O other|O three|O genes|O .|O 
This|O comprehensive|O data|O regarding|O the|O cumulative|O genetic|O alterations|O in|O pancreatic|O carcinoma|O cell|O lines|O will|O be|O of|O great|O value|O for|O studies|O involving|O drug|O sensitivity|O or|O resistance|O that|O may|O be|O associated|O with|O inactivation|O of|O a|O particular|O gene|O or|O molecular|O pathway|O .|O 
Lack|O of|O association|O between|O N-ras|O gene|O mutations|O and|O clinical|O prognosis|O in|O Brazilian|O children|O with|O acute|O lymphoblastic|O leukemia|O .|O 
Point|variation-type mutations|variation-type in|O codons|variation-location 12|variation-location ,|O 13|variation-location and|O 61|variation-location of|O the|O N-ras|O proto|O -|O oncogene|O have|O been|O detected|O in|O several|O human|O malignancies|O .|O 
We|O studied|O 170|O patients|O with|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O ,|O treated|O from|O 1988|O to|O 1994|O according|O to|O a|O protocol|O derived|O from|O BFM-83|O studies|O ,|O in|O order|O to|O evaluate|O the|O incidence|O and|O prognostic|O significance|O of|O mutations|O in|O this|O gene|O in|O childhood|O ALL|O .|O 
DNA|O was|O extracted|O from|O bone|O marrow|O smears|O at|O diagnosis|O and|O amplified|O by|O polymerase|O chain|O reaction|O (|O PCR|O )|O .|O 
After|O screening|O with|O SSCP|O ,|O PCR|O products|O were|O hybridized|O with|O allele|O specific|O probes|O and|O ,|O in|O some|O cases|O ,|O cloned|O in|O a|O pMOS|O Blue|O T|O vector|O and|O sequenced|O .|O 
Exon|variation-location 2|variation-location was|O also|O studied|O in|O 101|O children|O .|O 
Our|O results|O showed|O 4|O %|O of|O mutations|variation-event in|O codons|variation-location 12|variation-location and|O 13|variation-location and|O 2|O %|O in|O exon|variation-location 2|variation-location .|O 
Similar|O to|O a|O previous|O report|O ,|O we|O identified|O 7|O %|O of|O mutations|O among|O children|O who|O were|O studied|O for|O both|O exons|O .|O 
A|O new|O mutation|variation-event in|O codon|variation-location 64|variation-location of|O the|O N-ras|O gene|O was|O detected|O in|O one|O patient|O .|O 
No|O significant|O clinical|O differences|O between|O patients|O with|O and|O without|O mutations|O were|O detected|O (|O sex|O ,|O age|O ,|O leukocyte|O counts|O at|O diagnosis|O ,|O nutritional|O status|O ,|O and|O risk|O factor|O according|O to|O the|O BFM|O protocol|O )|O .|O 
Children|O with|O mutations|O in|O codons|variation-location 12|variation-location and|O 13|variation-location showed|O significantly|O higher|O reactivity|O to|O PAS|O staining|O on|O blast|O cells|O than|O children|O with|O a|O wild|O type|O N-ras|O gene|O configuration|O .|O 
Comparison|O of|O overall|O -|O and|O recurrence|O -|O free|O survival|O did|O not|O show|O significant|O difference|O between|O groups|O with|O and|O without|O mutations|O .|O 
Our|O results|O suggest|O that|O mutations|O in|O the|O ras|O gene|O are|O infrequent|O in|O children|O with|O ALL|O at|O diagnosis|O and|O seem|O to|O be|O of|O low|O prognostic|O value|O .|O 
beta-Catenin|O mutation|O and|O overexpression|O in|O hepatocellular|O carcinoma|O :|O clinicopathologic|O and|O prognostic|O significance|O .|O 
BACKGROUND|O :|O 
beta-Catenin|O has|O been|O recognized|O as|O a|O critical|O member|O of|O the|O Wnt|O signaling|O pathway|O ,|O and|O inappropriate|O activation|O of|O this|O pathway|O has|O been|O implicated|O in|O carcinogenesis|O .|O 
METHODS|O :|O 
To|O determine|O the|O clinical|O significance|O of|O beta-catenin|O in|O hepatocellular|O carcinoma|O (|O HCC|O )|O ,|O we|O performed|O mutational|O analysis|O at|O exon|variation-location 3|variation-location of|O the|O gene|O ,|O investigated|O the|O subcellular|O protein|O expression|O ,|O and|O analyzed|O their|O clinicopathologic|O and|O prognostic|O significance|O in|O 60|O patients|O with|O resected|O primary|O HCC|O .|O 
RESULTS|O :|O 
By|O direct|O DNA|O sequencing|O ,|O somatic|O mutations|variation-event of|O the|O beta-catenin|O gene|O were|O detected|O in|O 7|O (|O 12|O %|O )|O HCCs|O .|O 
All|O the|O mutations|variation-event were|O found|O at|O the|O region|O (|O exon|variation-location 3|variation-location )|O responsible|O for|O phosphorylation|O and|O ubiquitination|O ,|O therefore|O likely|O to|O result|O in|O stabilization|O of|O free|O cytoplasmic|O beta-catenin|O .|O 
Nuclear|O accumulation|O of|O the|O beta-catenin|O protein|O ,|O similar|O to|O the|O response|O to|O the|O Wnt|O signal|O ,|O was|O found|O in|O 10|O (|O 17|O %|O )|O HCCs|O and|O was|O closely|O associated|O with|O gene|O mutation|O (|O P|O <|O 0.001|O )|O .|O 
In|O the|O remaining|O cases|O ,|O nonnuclear|O type|O overexpression|O ,|O that|O is|O ,|O overexpression|O in|O the|O cytoplasm|O and/or|O cytoplasmic|O membrane|O ,|O was|O observed|O in|O 31|O (|O 62|O %|O )|O HCCs|O ,|O thus|O suggesting|O that|O the|O mechanisms|O leading|O to|O beta-catenin|O overexpression|O may|O be|O heterogeneous|O .|O 
HCCs|O with|O a|O nonnuclear|O type|O of|O beta-catenin|O overexpression|O were|O more|O frequently|O larger|O than|O 5|O cm|O in|O diameter|O (|O P|O =|O 0.022|O )|O and|O had|O poorer|O cellular|O differentiation|O (|O P|O =|O 0.037|O )|O ,|O and|O the|O patients|O had|O significantly|O shorter|O disease|O -|O free|O survival|O lengths|O (|O P|O =|O 0.041|O )|O .|O 
Review|O of|O the|O data|O from|O previous|O studies|O in|O HCC|O showed|O that|O beta-catenin|O mutations|O were|O more|O frequent|O in|O HCV|O -|O associated|O HCC|O than|O in|O HBV|O -|O associated|O ones|O .|O 
CONCLUSIONS|O :|O 
beta-catenin|O mutation|O and|O deregulation|O may|O play|O an|O important|O role|O in|O hepatocarcinogenesis|O .|O 
Nonnuclear|O type|O beta-catenin|O overexpression|O appeared|O to|O have|O pathologic|O and|O prognostic|O significance|O .|O 
Rapid|O ,|O efficient|O genotyping|O of|O clinical|O tumor|O samples|O by|O laser|O -|O capture|O microdissection|O /|O PCR|O /|O SSCP|O .|O 
Background|O :|O 
Mutation|O analysis|O is|O becoming|O increasingly|O important|O in|O clinical|O practice|O ,|O since|O sporadic|O mutations|O in|O tumors|O often|O correlate|O with|O prognosis|O and/or|O therapeutic|O response|O .|O 
However|O ,|O the|O labor|O -|O intensive|O nature|O of|O the|O molecular|O analyses|O has|O limited|O the|O routine|O clinical|O use|O of|O tumor|O genotyping|O .|O 
Laser|O -|O capture|O microdissection|O (|O LCM|O )|O allows|O procurement|O of|O relatively|O pure|O tumor|O cell|O populations|O .|O 
We|O have|O investigated|O the|O possibility|O that|O the|O use|O of|O laser|O -|O capture|O microdissection|O would|O allow|O elimination|O of|O time|O -|O consuming|O intermediate|O steps|O in|O tumor|O genotyping|O .|O 
Design|O .|O 
Archival|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O tissues|O from|O seven|O cases|O of|O colorectal|O adenocarcinoma|O were|O laser|O -|O and|O hand|O -|O microdissected|O and|O subsequently|O evaluated|O by|O PCR|O /|O SSCP|O /|O sequencing|O for|O Ki-ras|O exon|variation-location 1|variation-location and|O p53|O exons|variation-location 5|variation-location ,|O 7|variation-location ,|O and|O 8|variation-location .|O 
Results|O .|O 
Mutations|variation-event in|O Ki-ras|O exon|variation-location 1|variation-location and/or|O p53|O exons|variation-location 5|variation-location and|O 7|variation-location were|O detected|O in|O five|O of|O the|O seven|O samples|O .|O 
In|O the|O hand|O -|O microdissected|O samples|O ,|O confident|O identification|O of|O mutations|O was|O possible|O in|O several|O cases|O only|O after|O band|O excision|O ,|O DNA|O elution|O ,|O reamplification|O ,|O and|O verification|O of|O mutant|O enrichment|O by|O a|O second|O SSCP|O analysis|O prior|O to|O sequencing|O .|O 
In|O the|O laser|O -|O microdissected|O samples|O ,|O confident|O mutation|O identification|O was|O possible|O in|O all|O cases|O with|O direct|O sequencing|O of|O the|O original|O PCR|O product|O ,|O reducing|O the|O time|O required|O for|O molecular|O analysis|O to|O 3|O days|O .|O 
Conclusion|O .|O 
Using|O laser|O -|O capture|O microdissection|O ,|O mutant|O signals|O are|O strong|O enough|O to|O sequence|O directly|O from|O original|O PCR|O products|O .|O 
With|O rapid|O ,|O efficient|O genotyping|O by|O LCM|O /|O PCR|O /|O SSCP|O ,|O results|O can|O be|O incorporated|O directly|O into|O the|O surgical|O pathology|O report|O .|O 
No|O major|O difference|O in|O K-ras|O and|O p53|O abnormalities|O in|O sporadic|O and|O hereditary|O nonpolyposis|O colorectal|O adenomas|O .|O 
K-ras|O and|O p53|O gene|O mutations|O are|O known|O to|O occur|O in|O high|O frequencies|O in|O sporadic|O colorectal|O cancers|O ,|O but|O findings|O are|O inconsistent|O in|O hereditary|O nonpolyposis|O colorectal|O cancer|O (|O HNPCC|O )|O .|O 
We|O compared|O K-ras|O codon|variation-location 12|variation-location and|O 13|variation-location gene|O mutations|variation-event and|O p53|O protein|O overexpression|O in|O 48|O HNPCC|O (|O positive|O for|O Amsterdam|O criteria|O )|O and|O 59|O sporadic|O colorectal|O adenomas|O ,|O to|O examine|O whether|O they|O may|O represent|O similar|O or|O different|O molecular|O pathways|O to|O cancer|O .|O 
In|O sporadic|O adenomas|O K-ras|O mutations|O were|O detected|O in|O 32|O %|O and|O p53|O overexpression|O in|O 31|O %|O of|O the|O cases|O .|O 
Similarly|O ,|O K-ras|O mutations|O and|O p53|O overexpression|O were|O both|O found|O in|O 25|O %|O of|O HNPCC|O adenomas|O .|O 
The|O frequencies|O of|O these|O abnormalities|O were|O not|O significantly|O different|O between|O HNPCC|O and|O sporadic|O adenomas|O .|O 
When|O taking|O differences|O in|O adenoma|O size|O into|O account|O ,|O the|O frequencies|O were|O even|O more|O similar|O .|O 
In|O conclusion|O ,|O these|O results|O suggest|O a|O similar|O molecular|O pathway|O to|O adenomas|O in|O HNPCC|O and|O sporadic|O carcinogenesis|O ,|O with|O respect|O to|O involvement|O of|O K-ras|O and|O p53|O .|O 
Combination|O analysis|O of|O genetic|O alterations|O and|O cell|O proliferation|O in|O small|O intestinal|O carcinomas|O .|O 
We|O analyzed|O K-ras|O and|O p53|O mutations|O ,|O microsatellite|O instability|O (|O MSI|O )|O ,|O and|O loss|variation-type of|variation-type heterozygosity|variation-type (|O LOH|variation-type )|O using|O the|O polymerase|O chain|O reaction|O (|O PCR|O )|O methods|O ,|O as|O well|O as|O p53|O expression|O and|O the|O Ki-67|O labeling|O index|O (|O LI|O )|O using|O immunohistochemistry|O in|O 10|O duodenal|O and|O 10|O jejunal|O /|O ileal|O carcinomas|O .|O 
K-ras|O mutations|O were|O detected|O in|O two|O duodenal|O (|O 20|O %|O )|O and|O three|O jejunal|O /|O ileal|O (|O 30|O %|O )|O carcinomas|O and|O p53|O mutations|O in|O one|O (|O 10|O %|O )|O and|O three|O (|O 30|O %|O )|O ,|O respectively|O .|O 
LOH|variation-type of|O 17p|variation-location was|O detected|O in|O two|O duodenal|O (|O 20|O %|O )|O and|O two|O jejunal|O /|O ileal|O (|O 20|O %|O )|O carcinomas|O and|O p53|O expression|O in|O four|O duodenal|O (|O 40|O %|O )|O and|O four|O jejunal|O /|O ileal|O (|O 40|O %|O )|O .|O 
One|O duodenal|O (|O 10|O %|O )|O and|O two|O jejunal|O /|O ileal|O (|O 20|O %|O )|O carcinomas|O demonstrated|O MSI|O .|O 
LOH|variation-type of|O APC|O was|O detected|O in|O three|O jejunal|O /|O ileal|O (|O 30|O %|O )|O ,|O but|O none|O of|O the|O duodenal|O carcinomas|O .|O 
The|O Ki-67|O LI|O was|O 44|O %|O in|O duodenal|O and|O 52.6|O %|O in|O jejunal|O /|O ileal|O carcinomas|O .|O 
A|O subset|O of|O small|O intestinal|O carcinomas|O showed|O involvement|O of|O K-ras|O and|O p53|O mutations|O ,|O LOH|variation-type of|O APC|O ,|O and|O MSI|O .|O 
A|O difference|O was|O also|O apparent|O for|O LOH|variation-type of|O APC|O between|O duodenal|O and|O jejunal|O /|O ileal|O carcinomas|O .|O 
Analysis|O of|O K-ras|O codon|variation-location 12|variation-location mutations|variation-event and|O p53|O overexpression|O in|O colorectal|O nodule|O -|O aggregating|O tumors|O .|O 
BACKGROUND|O AND|O AIMS|O :|O 
Morphologically|O ,|O colorectal|O nodule|O -|O aggregating|O tumors|O are|O quite|O different|O from|O polypoid|O -|O type|O colorectal|O tumors|O that|O develop|O via|O the|O adenoma|O -|O carcinoma|O sequence|O .|O 
Although|O polypoid|O -|O type|O colorectal|O tumors|O are|O well|O known|O to|O have|O a|O high|O incidence|O of|O K-ras|O gene|O mutation|O and|O p53|O overexpression|O ,|O colorectal|O nodule|O -|O aggregating|O tumors|O have|O not|O been|O examined|O in|O terms|O of|O genetic|O changes|O and|O clinicopathological|O features|O .|O 
In|O the|O present|O study|O ,|O therefore|O ,|O we|O analysed|O the|O clinicopathological|O features|O ,|O genetic|variation-event changes|variation-event in|O K-ras|O codon|variation-location 12|variation-location ,|O and|O p53|O overexpression|O in|O colorectal|O nodule|O -|O aggregating|O tumors|O .|O 
METHODS|O :|O 
A|O total|O of|O 18|O colorectal|O nodule|O -|O aggregating|O tumors|O were|O surgically|O resected|O and|O then|O analysed|O clinicopathologically|O .|O 
Immunohistochemistry|O and|O polymerase|O chain|O reaction|O -|O single|O stranded|O conformational|O polymorphism|O were|O performed|O to|O analyse|O p53|O abnormalities|O in|O the|O tumors|O .|O 
K-ras|O codon|variation-location 12|variation-location mutations|variation-event were|O screened|O out|O by|O the|O polymerase|O chain|O reaction|O -|O restriction|O fragment|O length|O polymorphism|O method|O and|O analysed|O by|O fluorescence|O direct|O sequencing|O .|O 
RESULTS|O :|O 
p53|O overexpression|O was|O observed|O in|O six|O lesions|O (|O 33|O %|O )|O .|O 
p53|O -|O overexpressing|O cells|O were|O observed|O in|O parts|O of|O carcinoma|O or|O adenoma|O showing|O high|O -|O grade|O atypia|O .|O 
Four|O of|O the|O 10|O (|O 40|O %|O )|O samples|O had|O a|O p53|O gene|O mutation|O .|O 
Nine|O of|O the|O 18|O (|O 50|O %|O )|O samples|O had|O a|O K-ras|O codon|variation-location 12|variation-location point|variation-type mutation|variation-type .|O 
In|O eight|O cases|O (|O 89|O %|O )|O ,|O the|O mutations|variation-event of|O the|O K-ras|O codon|variation-location 12|variation-location were|O of|O the|O same|O type|O :|O GGT|variation-state-original (|O glycine|variation-state-original )|O to|O GTT|variation-state-altered (|O valine|variation-state-altered )|O .|O 
CONCLUSIONS|O :|O 
The|O colorectal|O nodule|O -|O aggregating|O tumor|O has|O distinctive|O characteristics|O showing|O a|O morphological|O phenotype|O of|O the|O superficial|O -|O type|O tumors|O and|O genotype|O of|O the|O polypoid|O tumors|O in|O terms|O of|O K-ras|O gene|O mutation|O and|O p53|O overexpression|O .|O 
Impact|O of|O KRAS|O and|O TP53|O mutations|O on|O survival|O in|O patients|O with|O left|O -|O and|O right|O -|O sided|O Dukes|O '|O C|O colon|O cancer|O .|O 
OBJECTIVE|O :|O 
It|O has|O been|O suggested|O that|O KRAS|O and|O TP53|O mutated|O tumors|O might|O influence|O the|O phenotypic|O behavior|O of|O left|O -|O and|O right|O -|O sided|O colon|O tumors|O .|O 
We|O investigated|O the|O incidence|O of|O these|O mutations|O in|O left|O -|O and|O right|O -|O sided|O colon|O tumors|O and|O their|O possible|O influence|O on|O survival|O in|O a|O homogeneous|O group|O of|O patients|O with|O Dukes|O '|O C|O colon|O cancers|O .|O 
METHODS|O :|O 
The|O primary|O tumors|O of|O 55|O patients|O with|O a|O sporadic|O Dukes|O '|O C|O colon|O cancer|O ,|O all|O treated|O with|O adjuvant|O chemotherapy|O were|O analyzed|O for|O the|O presence|O of|O KRAS|O and|O TP53|O mutations|O .|O 
Mutation|O detection|O of|O the|O KRAS|O and|O TP53|O genes|O was|O performed|O on|O paraffin|O -|O embedded|O tumor|O material|O ,|O using|O denaturating|O gradient|O gel|O electrophoresis|O .|O 
The|O 5|O -|O yr|O survival|O rates|O of|O KRAS|O and|O TP53|O mutated|O tumors|O were|O analyzed|O regarding|O right|O -|O sided|O tumors|O (|O defined|O as|O tumors|O up|O to|O the|O splenic|O flexure|O )|O and|O left|O -|O sided|O tumors|O (|O defined|O as|O tumors|O from|O the|O splenic|O flexure|O to|O the|O rectosigmoid|O peritoneal|O reflection|O )|O .|O 
RESULTS|O :|O 
KRAS|O mutations|O occurred|O more|O frequently|O in|O the|O right|O colon|O compared|O to|O the|O left|O colon|O (|O R|O =|O 38|O %|O (|O 10|O /|O 26|O )|O ;|O L|O =|O 10|O %|O (|O 3|O /|O 29|O )|O ;|O chi2|O test|O :|O p|O =|O 0.014|O )|O .|O 
KRAS|O mutations|O did|O not|O influence|O survival|O in|O patients|O with|O right|O -|O sided|O colon|O tumors|O .|O 
Patients|O with|O KRAS|O mutation|O -|O negative|O tumors|O in|O the|O right|O colon|O ,|O however|O ,|O had|O a|O significantly|O worse|O survival|O than|O patients|O with|O left|O -|O sided|O KRAS|O mutation|O -|O negative|O tumors|O (|O 5|O -|O yr|O survival|O ;|O R|O :|O 34|O %|O vs|O L|O :|O 65|O %|O ,|O log|O -|O rank|O test|O :|O p|O =|O 0.007|O )|O .|O 
TP53|O mutations|O of|O a|O possible|O causative|O nature|O were|O found|O in|O 24|O tumors|O (|O 44|O %|O )|O .|O 
Neither|O the|O incidence|O (|O R|O =|O 42|O %|O (|O 11|O /|O 26|O )|O ;|O L|O =|O 45|O %|O (|O 13|O /|O 29|O )|O )|O nor|O the|O survival|O of|O TP53|O mutated|O tumors|O differed|O significantly|O between|O left|O -|O and|O right|O -|O sided|O tumors|O .|O 
Furthermore|O ,|O survival|O of|O patients|O with|O TP53|O mutation|O -|O negative|O tumors|O did|O not|O differ|O significantly|O between|O left|O -|O and|O right|O -|O sided|O tumors|O .|O 
CONCLUSIONS|O :|O 
There|O seems|O to|O be|O no|O difference|O in|O survival|O rate|O between|O patients|O with|O KRAS|O mutated|O and|O KRAS|O negative|O Dukes|O '|O C|O colon|O tumors|O ;|O however|O ,|O KRAS|O mutations|O are|O more|O frequently|O found|O in|O the|O right|O colon|O compared|O to|O the|O left|O colon|O .|O 
TP53|O mutations|O do|O not|O have|O predominance|O for|O either|O side|O of|O the|O colon|O ,|O and|O there|O are|O no|O differences|O in|O survival|O in|O patients|O with|O left|O -|O sided|O versus|O right|O -|O sided|O tumors|O .|O 
Patients|O with|O KRAS|O -|O nonmutated|O tumors|O in|O the|O right|O colon|O did|O have|O a|O worse|O survival|O compared|O to|O those|O with|O such|O tumors|O in|O the|O left|O colon|O .|O 
This|O suggests|O that|O other|O genetic|O factors|O may|O play|O a|O role|O in|O tumor|O genesis|O in|O this|O subgroup|O of|O patients|O .|O 
Mutational|O analysis|O of|O the|O CTNNB1|O and|O APC|O genes|O in|O uterine|O endometrioid|O carcinoma|O .|O 
Despite|O recent|O studies|O ,|O the|O molecular|O genetic|O events|O responsible|O for|O the|O development|O of|O uterine|O endometrioid|O carcinoma|O (|O UEC|O )|O remain|O incompletely|O characterized|O .|O 
Mutations|O in|O the|O beta-catenin|O (|O CTNNB1|O )|O gene|O have|O been|O recently|O reported|O in|O a|O small|O percentage|O of|O UECs|O and|O in|O the|O endometrioid|O variant|O of|O ovarian|O carcinoma|O suggesting|O that|O the|O Wnt|O signal|O transduction|O pathway|O is|O involved|O in|O the|O development|O of|O female|O genital|O tract|O tumors|O with|O endometrioid|O morphology|O .|O 
The|O Wnt|O pathway|O is|O a|O critical|O pathway|O in|O the|O development|O of|O colorectal|O cancer|O (|O CRC|O )|O with|O mutations|O occurring|O in|O the|O beta-catenin|O (|O CTNNB1|O )|O or|O adenomatous|O polyposis|O coli|O (|O APC|O )|O genes|O in|O 10|O to|O 15|O %|O and|O 85|O %|O of|O cases|O ,|O respectively|O .|O 
Because|O UEC|O and|O CRC|O share|O other|O molecular|O genetic|O alterations|O and|O histologic|O features|O and|O previous|O studies|O of|O UEC|O have|O not|O reported|O an|O analysis|O of|O the|O APC|O gene|O ,|O we|O chose|O to|O further|O elucidate|O the|O role|O of|O the|O Wnt|O pathway|O in|O UEC|O .|O 
To|O this|O end|O ,|O we|O analyzed|O 32|O cases|O of|O UEC|O for|O mutations|O of|O the|O CTNNB1|O and|O APC|O genes|O .|O 
Mutations|O of|O CTNNB1|O were|O present|O in|O six|O of|O 32|O (|O 18|O %|O )|O cases|O :|O four|O grade|O 1|O carcinomas|O ,|O one|O grade|O 2|O ,|O and|O one|O grade|O 3|O carcinoma|O .|O 
Five|O missense|variation-type mutations|variation-type were|O identified|O ,|O three|O involving|O Ser|O /|O Thr|O phosphorylation|O sites|O and|O two|O adjacent|O to|O a|O Ser|O phosphorylation|O site|O .|O 
One|O case|O contained|O a|O deletion|variation-type encompassing|O codons|variation-location 34|variation-location to|variation-location 37|variation-location ,|O which|O includes|O a|O Ser|O phosphorylation|O site|O .|O 
No|O mutations|variation-event resulting|O in|O truncation|O of|O the|O APC|O protein|O were|O found|O .|O 
Our|O results|O support|O a|O role|O for|O the|O Wnt|O signaling|O pathway|O via|O mutation|O of|O CTNNB1|O ,|O but|O not|O APC|O ,|O in|O the|O development|O of|O a|O subset|O of|O UECs|O .|O 
Ras|O oncogenes|O and|O p53|O tumor|O suppressor|O gene|O analysis|O in|O cardiac|O myxomas|O .|O 
Although|O ras|O oncogenes|O and|O p53|O tumor|O suppressor|O gene|O mutations|O are|O implicated|O in|O the|O development|O of|O several|O human|O tumors|O ,|O little|O is|O known|O about|O their|O role|O in|O the|O pathogenesis|O of|O primary|O cardiac|O tumors|O .|O 
Paraffin|O -|O embedded|O tissue|O from|O 19|O cardiac|O myxomas|O were|O investigated|O for|O the|O presence|O of|O ras|O oncogenes|O and|O p53|O tumor|O suppressor|O gene|O abnormalities|O .|O 
Immunohistochemical|O analysis|O was|O used|O to|O identify|O the|O accumulation|O of|O p21|O -|O ras|O and|O p53|O proteins|O .|O 
A|O polymerase|O chain|O reaction|O was|O used|O to|O amplify|O exons|variation-location 1|variation-location and|O 2|variation-location of|O the|O ras|O genes|O and|O exons|variation-location 5|variation-location to|variation-location 8|variation-location of|O the|O p53|O gene|O .|O 
The|O PCR|O products|O were|O analyzed|O by|O single|O strand|O conformation|O polymorphism|O analysis|O and|O by|O direct|O DNA|O sequencing|O .|O 
Three|O of|O 19|O myxomas|O showed|O strong|O positive|O staining|O for|O the|O ras|O p21|O protein|O .|O 
In|O contrast|O ,|O nuclear|O p53|O was|O not|O detectable|O in|O any|O of|O the|O myxomas|O .|O 
Among|O the|O ras|O p21|O immunopositive|O myxomas|O ,|O 2|O were|O heterozygous|O for|O a|O missense|variation-type point|variation-type mutation|variation-type of|O the|O K-ras|O ,|O Gly|variation-state-original 12|variation-location Asp|variation-state-altered .|O 
Further|O screening|O of|O the|O remaining|O myxomas|O showed|O no|O mutation|variation-event or|O even|O silent|O polymorphism|O in|O any|O exon|O of|O the|O ras|O and|O p53|O .|O 
The|O results|O suggest|O that|O although|O genetic|O alterations|O of|O ras|O oncogenes|O and|O p53|O are|O uncommon|O events|O in|O cardiac|O myxomas|O ,|O ras|O mutations|O may|O be|O involved|O in|O the|O pathogenesis|O of|O a|O subgroup|O of|O this|O type|O of|O tumor|O .|O 
ras|O gene|O mutations|O in|O salivary|O gland|O tumors|O .|O 
OBJECTIVE|O :|O 
To|O assess|O the|O prevalence|O of|O activating|O mutations|O in|O K-ras|O and|O H-ras|O genes|O in|O salivary|O gland|O tumors|O with|O ductal|O or|O acinar|O differentiation|O and|O to|O evaluate|O their|O potential|O correlation|O with|O clinical|O parameters|O .|O 
DESIGN|O :|O 
Paraffin|O -|O embedded|O tissue|O samples|O of|O salivary|O gland|O carcinomas|O were|O investigated|O by|O the|O application|O of|O a|O direct|O sequence|O analysis|O procedure|O with|O automated|O DNA|O sequencing|O of|O polymerase|O chain|O reaction|O -|O amplified|O ras|O sequences|O .|O 
SETTING|O :|O 
Tertiary|O care|O teaching|O hospital|O .|O 
PATIENTS|O :|O 
Twenty-four|O patients|O with|O salivary|O gland|O carcinoma|O were|O surgically|O treated|O .|O 
Nine|O had|O adenocarcinoma|O ,|O 1|O had|O adenosquamous|O carcinoma|O ,|O 11|O had|O mucoepidermoid|O carcinoma|O ,|O and|O 3|O had|O acinic|O cell|O carcinoma|O .|O 
RESULTS|O :|O 
Point|variation-type mutations|variation-type were|O detected|O in|O 7|O (|O 29|O %|O )|O of|O the|O 24|O carcinomas|O examined|O .|O 
The|O K-ras|O gene|O was|O mutated|O in|O only|O 2|O samples|O (|O 8|O %|O )|O :|O a|O GGC|variation-state-original -|O to|O -|O ATC|variation-state-altered mutation|variation-event at|O codon|variation-location 13|variation-location in|O an|O adenocarcinoma|O and|O a|O GGC|variation-state-original -|O to|O -|O GTC|variation-state-altered transversion|variation-type mutation|variation-event at|O codon|variation-location 13|variation-location in|O a|O mucoepidermoid|O carcinoma|O .|O 
Five|O (|O 21|O %|O )|O harbored|O H-ras|O mutations|O :|O 4|O contained|O a|O GGC|variation-state-original -|O to|O -|O GTC|variation-state-altered transversion|variation-type mutation|variation-event at|O codon|variation-location 12|variation-location and|O 1|O had|O 2|O distinct|O mutations|variation-event ,|O the|O same|O G|variation-state-original -|O to|O -|O T|variation-state-altered at|O codon|variation-location 12|variation-location as|O was|O shown|O in|O the|O other|O cases|O and|O a|O GGT|variation-state-original -|O to|O -|O GGA|variation-state-altered heterozygous|O mutation|O at|O codon|variation-location 13|variation-location .|O 
All|O the|O H-ras|O mutations|O were|O in|O the|O group|O of|O mucoepidermoid|O carcinoma|O lesions|O (|O 45|O %|O ;|O 5|O /|O 11|O )|O .|O 
CONCLUSION|O :|O 
Our|O data|O suggest|O that|O K-ras|O gene|O alteration|O is|O probably|O not|O an|O important|O factor|O in|O the|O oncogenesis|O of|O human|O salivary|O gland|O tumors|O .|O 
However|O ,|O mutational|O activation|O of|O the|O H-ras|O gene|O appears|O to|O play|O a|O role|O in|O the|O development|O and/or|O progression|O of|O salivary|O gland|O mucoepidermoid|O carcinomas|O .|O 
Relative|O reciprocity|O of|O NRAS|O and|O PTEN|O /|O MMAC1|O alterations|O in|O cutaneous|O melanoma|O cell|O lines|O .|O 
Both|O inactivation|O of|O the|O tumor|O suppressor|O gene|O ,|O PTEN|O /|O MMAC1|O ,|O and|O oncogenic|O activation|O of|O RAS|O have|O been|O described|O in|O human|O cutaneous|O melanoma|O .|O 
In|O mice|O ,|O activation|O of|O a|O RAS|O -|O containing|O pathway|O is|O a|O necessary|O step|O in|O the|O pathogenesis|O of|O murine|O melanomas|O .|O 
Because|O PTEN|O negatively|O regulates|O on|O the|O downstream|O effects|O of|O phosphatidylinositol-3-kinase|O (|O PI3-K|O )|O ,|O we|O hypothesized|O that|O the|O loss|variation-type of|O PTEN|O /|O MMAC1|O and|O the|O activation|O of|O RAS|O may|O be|O largely|O equivalent|O because|O RAS|O is|O a|O known|O positive|O upstream|O regulator|O of|O PI3-K|O .|O 
We|O expanded|O our|O previous|O survey|O of|O PTEN|O /|O MMAC1|O mutations|O and|O analyzed|O the|O RAS|O status|O of|O 53|O cutaneous|O melanoma|O cell|O lines|O ,|O 18|O glioma|O cell|O lines|O ,|O and|O 17|O uncultured|O cutaneous|O melanoma|O metastasis|O .|O 
Overall|O ,|O 51|O %|O of|O the|O cell|O lines|O had|O alterations|O in|O either|O PTEN|O /|O MMAC1|O or|O RAS|O .|O 
We|O found|O 16|O cell|O lines|O (|O 30|O %|O )|O with|O alterations|O in|O PTEN|O /|O MMAC1|O and|O 11|O cell|O lines|O (|O 21|O %|O )|O with|O activating|O NRAS|O mutations|O ;|O only|O 1|O cell|O line|O had|O concurrent|O alterations|O in|O both|O genes|O .|O 
Moreover|O ,|O glioma|O cell|O lines|O with|O a|O high|O frequency|O of|O PTEN|O /|O MMAC1|O inactivation|O had|O no|O identifiable|O RAS|O alterations|O .|O 
Ectopic|O expression|O of|O PTEN|O in|O several|O cutaneous|O melanoma|O cell|O lines|O suppressed|O colony|O formation|O irrespective|O of|O PTEN|O /|O MMAC1|O status|O ;|O furthermore|O ,|O PTEN|O expression|O in|O cell|O lines|O carrying|O activated|O RAS|O also|O suppressed|O colony|O formation|O .|O 
The|O relative|O reciprocity|O of|O PTEN|O /|O MMAC1|O abrogation|O and|O NRAS|O activation|O suggests|O that|O the|O two|O genetic|O changes|O ,|O in|O a|O subset|O of|O cutaneous|O melanomas|O ,|O are|O functionally|O overlapping|O .|O 
A|O relationship|O between|O K-ras|O gene|O mutations|O and|O some|O clinical|O and|O histologic|O variables|O in|O patients|O with|O primary|O colorectal|O carcinoma|O .|O 
Mutations|O in|O the|O Kirsten|O ras|O 2|O (|O K-ras|O )|O gene|O were|O described|O as|O early|O events|O in|O the|O process|O of|O colorectal|O carcinogenesis|O .|O 
The|O aim|O of|O this|O study|O was|O to|O find|O a|O possible|O relationship|O between|O the|O presence|O of|O K-ras|O mutation|O in|O samples|O of|O primary|O colorectal|O carcinomas|O and|O the|O clinico|O -|O pathological|O data|O of|O the|O investigated|O patients|O .|O 
Mutation|O in|O codon|variation-location 12|variation-location of|O the|O K-ras|O gene|O was|O determined|O in|O 18|O of|O 53|O colorectal|O carcinomas|O (|O 34|O %|O )|O in|O our|O group|O of|O patients|O .|O 
The|O presence|O of|O K-ras|O gene|O mutations|O was|O not|O related|O to|O gender|O ,|O age|O of|O subject|O at|O diagnosis|O ,|O staging|O or|O cancer|O location|O (|O p|O >|O 0.05|O )|O .|O 
Sixteen|O of|O the|O 42|O (|O 38|O %|O )|O moderately|O differentiated|O carcinomas|O ,|O and|O two|O of|O the|O eight|O (|O 25|O %|O )|O well|O differentiated|O carcinomas|O contained|O K-ras|O mutation|O in|O codon|variation-location 12|variation-location ,|O but|O none|O of|O the|O three|O poorly|O differentiated|O carcinomas|O contained|O the|O mutation|variation-event .|O 
Moderately|O differentiated|O tumours|O contained|O an|O aspartate|variation-state-generic code|O GAT|variation-state-generic (|O in|O eight|O cases|O )|O ,|O a|O valine|variation-state-generic code|O GTT|variation-state-generic (|O in|O six|O cases|O )|O ,|O an|O alanine|variation-state-generic code|O GCT|variation-state-generic (|O in|O one|O case|O )|O and|O a|O serine|variation-state-generic code|O AGT|variation-state-generic (|O in|O one|O case|O )|O in|O codon|variation-location 12|variation-location .|O 
Well|O differentiated|O tumours|O contained|O only|O the|O valine|variation-state-generic code|O GTT|variation-state-generic (|O two|O cases|O )|O .|O 
Our|O results|O show|O that|O the|O frequency|O of|O mutations|O in|O the|O K-ras|O gene|O in|O carcinomas|O in|O Central|O Europe|O is|O not|O different|O from|O the|O frequencies|O found|O in|O other|O parts|O of|O the|O world|O .|O 
The|O homogeneous|O incidence|O of|O K-ras|O mutation|O does|O not|O seem|O to|O be|O related|O to|O ethnic|O factors|O ,|O dietary|O habits|O ,|O or|O the|O composition|O of|O the|O diet|O .|O 
Frequent|O somatic|O mutations|O of|O the|O beta-catenin|O gene|O in|O intestinal|O -|O type|O gastric|O cancer|O .|O 
The|O increased|O level|O of|O cytoplasmic|O beta-catenin|O through|O the|O mutations|O to|O either|O beta-catenin|O or|O adenomatous|O polyposis|O coli|O (|O APC|O )|O has|O been|O proposed|O as|O an|O important|O oncogenic|O step|O in|O various|O tumors|O .|O 
Gastric|O cancer|O showed|O frequent|O genetic|O alterations|O of|O the|O APC|O gene|O ,|O and|O the|O risk|O for|O gastric|O cancer|O in|O familial|O adenomatosus|O polyposis|O patients|O is|O 10|O times|O higher|O than|O that|O in|O the|O general|O population|O .|O 
These|O findings|O raise|O the|O possibility|O that|O mutations|O of|O beta-catenin|O may|O also|O be|O associated|O with|O the|O development|O of|O gastric|O cancer|O .|O 
We|O detected|O seven|O somatic|O mutations|variation-event in|O a|O portion|O of|O exon|variation-location 3|variation-location encoding|O for|O the|O glycogen|O synthase|O kinase|O 3beta|O phosphorylation|O consensus|O region|O of|O the|O beta-catenin|O gene|O in|O 43|O gastric|O cancers|O .|O 
All|O of|O these|O mutations|variation-event were|O missense|variation-type mutations|variation-type ,|O of|O which|O five|O are|O in|O the|O highly|O conserved|O aspartic|variation-state-original acid|variation-state-original 32|variation-location and|O two|O are|O in|O serine|variation-state-original 29|variation-location ;|O all|O of|O these|O seven|O mutations|variation-event were|O detected|O exclusively|O in|O intestinal|O -|O type|O gastric|O cancers|O (|O 7|O of|O 26|O ;|O 26.9|O %|O )|O ,|O but|O not|O in|O the|O diffuse|O -|O type|O (|O 0|O of|O 17|O )|O .|O 
We|O concluded|O that|O disruption|O of|O the|O APC|O /|O beta-catenin|O /|O T|O cell|O factor|O -|O lymphoid|O enhancer|O binding|O factor|O pathway|O might|O play|O an|O important|O role|O especially|O in|O the|O development|O of|O intestinal|O -|O type|O gastric|O cancer|O .|O 
Sampling|O technique|O influences|O the|O detection|O of|O K-ras|O mutations|O in|O normal|O appearing|O mucosa|O of|O colorectal|O cancer|O patients|O .|O 
Based|O on|O three|O colorectal|O cancer|O cell|O lines|O with|O specified|O K-ras|O status|O ,|O a|O sensitive|O PCR|O -|O RFLP|O assay|O was|O established|O detecting|O one|O K-ras|O mutant|O among|O 106|O wild|O -|O type|O cells|O .|O 
Using|O this|O assay|O for|O tissues|O of|O 124|O colorectal|O cancer|O patients|O ,|O 59|O tumor|O (|O 46|O %|O )|O and|O 11|O mucosa|O samples|O (|O 9|O %|O )|O were|O found|O to|O harbor|O a|O K-ras|O mutation|O .|O 
When|O using|O the|O same|O scalpel|O for|O collecting|O tumor|O and|O mucosa|O tissues|O (|O group|O A|O )|O ,|O 18|O %|O of|O the|O patients|O had|O a|O matching|O K-ras|O mutation|O in|O both|O tissues|O ,|O but|O this|O coincidence|O was|O seen|O in|O 3|O %|O of|O patients|O only|O ,|O when|O separate|O scalpels|O were|O used|O (|O group|O B|O )|O .|O 
Thus|O we|O conclude|O that|O the|O sampling|O technique|O used|O for|O collecting|O specimens|O is|O a|O major|O contributor|O to|O the|O detection|O of|O K-ras|O mutations|O in|O normal|O appearing|O mucosa|O when|O a|O highly|O sensitive|O detection|O technique|O is|O used|O .|O 
Beta-catenin|O mutations|O are|O more|O frequent|O in|O small|O colorectal|O adenomas|O than|O in|O larger|O adenomas|O and|O invasive|O carcinomas|O .|O 
